Back

 

NAME OF THE HOSPITALSATHYA MEDICAL CENTRE &HOSPITAL
DISTRICTCOIMBATORE
ADDRESS58-63,TATABAD FIRST STREET, SIVANANDHACOLONY, COIMBATORE.
CONTACT NUMBER0422-2496989
AVAILABLE SPECIALITIESENT
OBSTETRICS AND GYNAECOLOGY
SURGICAL GASTROENTEROLOGY
VASCULAR SURGERY
ORTHOPEDICS
SPINE
MEDICAL ONCOLOGY
SURGICAL ONCOLOGY
PEDIATRICS SURGERGY
CARDIOLOGY
GENERAL SURGERY

Packages Rate
CM0076 : INGUINAL BLOCK DISSECTION ONE SIDE 8710
CM0077 : ABDOMNO PERINEAL RESECTION (APR) + SACRECTOMY 26926
CM0078-A : LAPROSCOPIC APR 30469
CM0078-B : EXTRALEVATOR APR 22793
CM0078-C : TRANS ABDOMINAL 22793
CM0078-D : TRANS ANAL 22793
CM0078-E : INTERSPHINCTERIC RESECTION 22793
CM0078-F : LOW ANTERIOR RESECTION 25745
CM0079 : ABDOMINAL WALL TUMORS RESECTION WITH RECONSTRUCTION 26277
CM0080 : ABDOMINAL WALL TUMORS RESECTION WITHOUT RECONSTRUCTION 18896
CM0081 : BILATERAL PELVIC LYMPH NODE DISSECTION(BPLND) ANY SITE 12991
CM0082-A : RADICAL VAGINECTOMY WITHOUT RECONSTRUCION a) WITH LND 16681
CM0082-B : RADICAL VAGINECTOMY WITHOUT RECONSTRUCION b) WITHout LND 15205
CM0083-A : RADICAL VAGINECTOMY WITH RECONSTRUCION a) WITH LND 24358
CM0083-B : RADICAL VAGINECTOMY WITH RECONSTRUCION b) WITHOUT LND 21405
CM0084-A : RADICAL HYSTERECOMY+BILATERAL PELVIC LYMPH NODE DISSECTION+BILATERAL SALPHINGO OOPHERECTOMY 21996
CM0084-B : OVARIAN TRANSPOSITION 26129
CM0085-A : ANTERIOR EXENTRATION - ANY SITE 34101
CM0085-B : POSTERIOR EXENTRATION- ANY SITE 24653
CM0086 : TOTAL PELVIC EXENTRATION - ANY SITE 41777
CM0087 : EXTRALEVATOR EXENTRATION - ANY SITE 23767
CM0088 : SUPRALEVATOR EXENTRATION - ANY SITE 23767
CM0089 : TOTAL ABDOMINAL HYSTERECTOMY+BILATERAL SALPHINGO OOPHERECTOMY+BILATERAL PELVIC LYMPH NODE DISSECTION+OMENTECTOMY 20490
CM0090-A : RETRO PERITONEAL LYMPH NODE DISSECTION(RPLND) (FOR RESIDUAL DISEASES /STAGING 12548
CM0090-B : RETRO PERITONEAL LYMPH NODE DISSECTION(RPLND) (FOR RESIDUAL DISEASES /WITH VASCULAR RECONSTRUCTION 18600
CM0091-A : OESOPHAGECTOMY WITH TWO FIELD LYMPADENECTOMY 35577
CM0091-B : OESOPHAGECTOMY WITH THREE FIELD LYMPADENECTOMY 42958
CM0092-A : VERMILIONECTOMY WITHOUT WEDGE EXCISION 9891
CM0092-B : VERMILIONECTOMY WITH WEDGE EXCISION 11072
CM0093 : EMASCULATION 14585
CM0094 : PALATECTOMY ANY TYPE 14910
CM0095 : RADICAL TRACHELECTOMY 20224
CM0096 : SUBSTERNAL BYPASS 16091
CM0097 : ABBE OPERATION 11072
CM0098 : CYTOREDUCTIVE SURGERY 13729
CM0099 : VULVECTOMY 9005
CM0100 : BREAST CANCER 0
CM0100-a : BREAST CANCER - combined regimen AC & T 0
CM0100-a-I : BREAST CANCER - Dose Dense AC (Adriamycin/Cyclophosphamide) ; (Day 1: Doxorubicin 60mg/m2 IV, Cyclophosphamide 600mg/m2 IV) ; Repeat cycle - every 14 days for 4 cycles; Followed by Paclitaxel for 4 cycles 3000
CM0100-a-II : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 175mg/m2) Repeat cycle - every 14 days for 4 cycles 7000
CM0100-b : BREAST CANCER - TC (Doectaxel & Cyclophosphamide) ; Day 1: Docetaxel 75mg/m2 IV, Cyclophosphamide 600mg/m2 IV ; Repeat cycle - every 21 days for 4 cycles 6000
CM0100-c : BREAST CANCER - CMF (Cyclophosphamide/Methotrexate/Fluorouracil) - (includes day 1 & day 8) ; Days 1-14: Cyclophosphamide 100mg/m2 orally ; Days 1 and 8: Methotrexate 40mg/m2 IV ; Days 1 and 8: 5-fluorouracil 600mg/m2 IV. ; Repeat cycle - every 28 days for 6 cycles 2700
CM0100-d : BREAST CANCER - EC (Epirubicin/Cyclophosphamide) ; Day 1: Epirubicin 100mg/m2 IV ; Day 1: Cyclophosphamide 830mg/m2 IV. ; Repeat cycle - every 21 days for 8 cycles 5100
CM0100-e : BREAST CANCER - FEC + T 0
CM0100-e-I : BREAST CANCER - FEC/CEF followed by T (Fluorouracil/Epirubicin/Cyclophosphamide) - followed by Docetaxel or followed by weekly Paclitaxel) ; Day 1: 5-fluorouracil 500mg/m2 IV ; Day 1: Epirubicin 100mg/m2 IV ; Day 1: Cyclophosphamide 500mg/m2 IV. ; Repeat cycle every 21 days for 3 cycles 5100
CM0100-e-II : BREAST CANCER - Docetaxel - (Preceeded by FEC/CEF ) ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle - every 21 days for 3 cycles 5500
CM0100-e-III : BREAST CANCER - Paclitaxel - weekly - (Preceeded by FEC/CEF ) ; Paclitaxel 100mg/m2 IV ; Repeat cycle - once weekly for 8 weeks 3500
CM0100-f : BREAST CANCER - FAC + T 0
CM0100-f-I : BREAST CANCER - FAC followed by T (Fluorouracil/Adriamycin/Cyclophosphamide) - followed by weekly Paclitaxel ; 5-fluorouracil 500mg/m2 IV Days 1 and 8 OR 1 and 4: ; Day 1: Doxorubicin 50mg/m2 IV ; Day 1: Cyclophosphamide 500mg/m2 IV. ; Repeat cycle - every 21 days for 6 cycles 3200
CM0100-f-II : BREAST CANCER - Paclitaxel - weekly - Preceeded by FAC ; Paclitaxel 80mg/m2 IV ; Repeat Cycle weekly for 12 weeks. 3500
CM0100-g : BREAST CANCER - TAC (Docetaxel/Adriamycin/Cyclophosphamide) ; Day 1: Doxorubicin 60mg/m2 IV ; Day 1: Cyclophosphamide 600mg/m2 IV. ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, 5600
CM0100-h : BREAST CANCER - AC followed by T + Trastuzumab 0
CM0100-h-I : BREAST CANCER - AC - followed by Paclitaxel + Trastuzumab +/- Pertuzumab ; Day 1: Doxorubicin 60mg/m2 IV ; Day 1: Cyclophosphamide 600mg/m2 IV. ; Repeat cycle - every 21 days for 4 cycle 3000
CM0100-h-II : BREAST CANCER - Paclitaxel (Preceeded by AC) ; (To be choosen along with Trastuzumab package - CM0100-h-III or CM0100-h-IV or CM0100-h-V) ; Paclitaxel 80mg/m2 IV. ; Repeat Cycle weekly for 12 weeks. 3500
CM0100-h-III : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 6mg/kg IV ; Repeat cycle every 21 days to complete 1 year. ; (to be approved with Paclitaxel Cycle 1, 4, 7, 10 and standalone for the upto 1 year every 21 days) 30500
CM0100-h-IV : BREAST CANCER - Trastuzumab 4mg (Followed by Trastuzumab 2mg subsequent weeks) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 4mg/kg IV with first dose of paclitaxel. ; (First dose - only to be approved with Paclitaxel Cycle 1. Subsequent cycles - 2mg package only) 30500
CM0100-h-V : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 2mg/kg IV weekly Till one year from Day 1 of AC. ; (to be approved with Paclitaxel Cycles 2 - 12 and standalone for the upto 1 year every week) 11500
CM0100-i : BREAST CANCER - TCH 0
CM0100-i-I : BREAST CANCER - TC (Docetaxel/Carboplatin) ; (To be choosen along with Trastuzumab package - CM0100-i-II or CM0100-i-III or CM0100-i-IV) ; Day 1: Docetaxel 75mg/m2 IV; Carboplatin AUC 6mg per min/mL IV. ; every 21 days for 6 cycles 7100
CM0100-i-II : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with TC package CM0100-i-I) ; Trastuzumab 6mg/kg IV ; Repeat cycle every 21 days to complete 1 year. ; (to be approved with TC Cycle 1 to 6 and standalone for the upto 1 year every 21 days (or) after completion of weekly trastuzumab for 18 weeks as standalone for the upto 1 year every 21 days) 30500
CM0100-i-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with TC package CM0100-i-I) ; Day 1: Trastuzumab 4mg/kg IV ; (First dose - only to be approved with TC Cycle 1. Subsequent cycles - 2mg package only) 30500
CM0100-i-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses - Weekly) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 17 weeeks may overlap with TC Cycles 2 - 6. To be followed by Trastuzumab (6mg) package upto 1 year 11500
CM0100-j : BREAST CANCER - AC followed by Docetaxel + Trastuzumab 0
CM0100-j-I : BREAST CANCER - AC - followed by Docetaxel + Trastuzumab ; Day 1: Doxorubicin 60mg/m2 IV; Day 1: Cyclophosphamide 600mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, 3000
CM0100-j-II : BREAST CANCER - Docetaxel (preceeded by AC) + Trastuzumab ; (To be choosen along with Trastuzumab package - CM0100-j-III or CM0100-j-IV or CM0100-j-V) ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles 5400
CM0100-j-III : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Docetaxel package CM0100-j-II) ; Day 1: Trastuzumab 6mg/kg IV ; Repeat every 21 days till 1 year ; (to be approved with Docetaxel Cycle 1 to 4 and standalone for the upto 1 year every 21 days (or) or from 13 th week after completion of 12 weeks of weekly Trastuzumab - upto 1 year every 21 days) 30500
CM0100-j-IV : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Docetaxel package CM0100-j-II) ; Trastuzumab 4mg/kg IV ; (First dose - only to be approved with Docetaxel Cycle 1. Subsequent cycles - 2mg package only) 30500
CM0100-j-V : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 11 weeeks may overlap with Docetaxel Cycles 2 - 4. To be followed by Trastuzumab (6mg) package upto 1 year) 11500
CM0100-k : BREAST CANCER - Docetaxel + Cyclophosphamide + Trastuzumab 0
CM0100-k-I : BREAST CANCER - Docetaxel + Cyclophosphamide - with Trastuzumab ; (To be choosen along with Trastuzumab package - CM0100-k-II or CM0100-k-III or CM0100-k-IV) ; Day 1: Docetaxel 75mg/m2 IV; Cyclophosphamide 600mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, 5000
CM0100-k-II : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Docetaxel + Cyclophosphamide package CM0100-k-I) ; Day 1: Trastuzumab 6mg/kg IV ; (to be approved with Docetaxel + Cyclophosphamide Cycle 1 to 4 and standalone for the upto 1 year every 21 days (or) after completion of weekly trastuzumab for 12 weeks as standalone for the upto 1 year every 21 days) 30500
CM0100-k-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Docetaxel + Cyclophosphamide package CM0100-k-I) ; Trastuzumab 4mg/kg IV ; (First dose - only to be approved with Docetaxel + Cyclophosphamide Cycle 1. Subsequent cycles - 2mg package only) 30500
CM0100-k-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 11 weeeks may overlap with Docetaxel + Cyclophosphamide Cycles 2 - 4. To be followed by Trastuzumab (6mg) package upto 1 year) 11500
CM0100-L : BREAST CANCER - Paclitaxel + Trastuzumab 0
CM0100-L-I : BREAST CANCER - Paclitaxel - (with Trastuzumab) ; (To be choosen along with Trastuzumab package - CM0100-L-III or CM0100-L-IV) ; Paclitaxel 80mg/m2 IV. ; Repeat Cycle weekly for 12 weeks. 3000
CM0100-L-II : BREAST CANCER - Trastuzumab (6mg) ; trastuzumab 6mg/kg IV ; Repeat every 21 days ; (to be approved after completion of weekly trastuzumab for 12 weeks as standalone for the upto 1 year every 21 days) 30500
CM0100-L-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Paclitaxel package CM0100-L-I) ; Trastuzumab 4mg/kg IV with first dose of paclitaxel. ; (First dose - only to be approved with Paclitaxel Cycle 1. Subsequent cycles - 2mg package only) 30500
CM0100-L-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; (to be choosen along with Paclitaxel package CM0100-L-I) ; Day 1: Trastuzumab 2mg/kg IV weekly ; (to be approved with Paclitaxel Cycles 2 - 12. May be approved as standalone for the upto 1 year every week or Trastuzumab 6mg Package may be used once every 21 days upto 1 year) 11500
CM0100-M : BREAST CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0101 : BLADDER CANCER 0
CM0101-a-I : BLADDER CANCER - DDMVAC ; Day 1: Methotrexate 30mg/m2 IV; Day 2: Vinblastine 3mg/m2 IV, doxorubicin 30mg/m2 IV, cisplatin 70mg/m2 IV; ; Repeat every 2 weeks for 3-4 cycles 3800
CM0101-a-II : BLADDER CANCER - Gemcitabine + cisplatin ; Days 1, 8, and 15: Gemcitabine 1,000mg/m2 IV; Day 2: Cisplatin 70mg/m2. ; Repeat every 4 weeks for 4 cycles. 6400
CM0101-a-III : BLADDER CANCER - Cisplatin + methotrexate + vinblastine (CMV) ; Day 1: Methotrexate 30mg/m2 IV, vinblastine 4mg/m2 IV; Day 2: Cisplatin 100mg/m2 IV, leucovorin 15mg oral or IV every 6 hours for 4 doses; Day 8: Methotrexate 30mg/m2 IV, vinblastine 4mg/m2 IV Day 9: Leucovorin 15mg oral every 6 hours for 4 doses ; Repeat every 3 weeks for 3 cycles. 4800
CM0101-b : BLADDER CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0102 : LUNG CANCER 0
CM0102-i : LUNG CANCER - Mesothelioma 0
CM0102-i-a : LUNG CANCER - Mesothelioma - Pemetrexed + cisplatin ; Day 1: Pemetrexed 500mg/m2 IV, cisplatin 75mg/m2 ; Repeat every 21 days up to 12 cycles. 14500
CM0102-i-b : LUNG CANCER - Mesothelioma - Pemetrexed + carboplatin ; Day 1: Pemetrexed 500mg/m2 IV, carboplatin AUC 5mg/min/mL IV. ; Repeat every 21 days for a max of 9 cycles. 16500
CM0102-i-c : LUNG CANCER - Mesothelioma - Cisplatin & Gemcitabine ; Day 1: Cisplatin 80-100mg/m2 IV ; Days 1, 8, and 15: Gemcitabine 1000-1250mg/m2 IV ; Repeat every 21 - 28 days for 6 cycles. 7600
CM0102-i-d : LUNG CANCER - Mesothelioma - Vinorelbine ; Vinorelbine 25-30mg/m2 (max 60mg) IV ; Repeat every week for 12 weeks. 9000
CM0102-i-e : LUNG CANCER - Mesothelioma - Pemetrexed ; Day 1: Pemetrexed 500mg/m2 IV. ; Repeat every 21 days for 4 cycles (If First line) or Repeat every 21 days for 8 cycles (If Second line) 14500
CM0102-i-f : LUNG CANCER - Mesothelioma - Gemcitabine ; Days 1, 8, and 15: Gemcitabine 1250mg/m2 IV. ; Repeat every 28 days for a max of 10 cycles. 7600
CM0102-i-g : LUNG CANCER - Mesothelioma - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0102-ii : LUNG CANCER - NSCLC 0
CM0102-ii-a : LUNG CANCER - NSCLC - Cisplatin & Vinorelbine - (i) ; Days 1 and 8: Cisplatin 50mg/m2 IV and Days 1, 8, 15 and 22: Vinorelbine 25mg/m2 IV ; (or) ; Day 1: Cisplatin 100mg/m2 IV and Days 1, 8, 15 and 22: Vinorelbine 30mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles. 33600
CM0102-ii-b : LUNG CANCER - NSCLC - Cisplatin & Vinorelbine - (ii) ; Day 1: Cisplatin 75-80mg/m2 ; Days 1 and 8: Vinorelbine 25-30mg/m2. ; Repeat every 3 weeks for 4 cycles 17900
CM0102-ii-c : LUNG CANCER - NSCLC - Cisplatin & Etoposide ; Day 1: Cisplatin 100mg/m2 IV ; Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles 4900
CM0102-ii-d : LUNG CANCER - NSCLC - Cisplatin & Docetaxel ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV. ; Repeat every 3 weeks for 4 cycles. 6300
CM0102-ii-e : LUNG CANCER - NSCLC - Cisplatin & Gemcitabine ; Day 1: Cisplatin 75mg/m2 IV ; Days 1 and 8: Gemcitabine 1,250mg/m2 IV. ; Repeat every 3 weeks for 4 cycles 6100
CM0102-ii-f : LUNG CANCER - NSCLC - Pemetrexed + cisplatin (for Non Squamous Cell CA) ; Day 1: Cisplatin 75mg/m2 IV, pemetrexed 500mg/m2 IV. ; Repeat every - 21 days for 4 cycles. 14500
CM0102-ii-g : LUNG CANCER - NSCLC - Paclitaxel/Carboplatin ; Day 1: Paclitaxel 200mg/m2 IV, carboplatin AUC 6mg per min/mL IV. ; Repeat cycle every 3 weeks for 4 cycles. 8100
CM0102-ii-h : LUNG CANCER - NSCLC - Cisplatin & Etoposide ; Days 1, 8, 29 and 36: Cisplatin 50mg/m2 IV ; Days 1-5 and 29-33: Etoposide 50mg/m2 IV ; Concurrent thoracic radiotherapy 1.8Gy/day for 5 days/week (total dose, 61Gy). 8500
CM0102-ii-i : LUNG CANCER - NSCLC - Cisplatin & Vinblastine ; Days 1 and 29: Cisplatin 100mg/m2 IV ; Days 1, 8, 15, 22 and 29: Vinblastine 5mg/m2 IV ; concurrent thoracic radiotherapy (total dose, 60Gy). 8200
CM0102-ii-j : LUNG CANCER - NSCLC - Carboplatin + Pemetrexed ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Day 1: Pemetrexed 500 mg/m2 IV ; with concurrent thoracic radiotherapy. ; Repeat every 3 weeks for 4 cycles. 16500
CM0102-ii-k : LUNG CANCER - NSCLC - Cisplatin + Pemetrexed ; Day 1: Cisplatin 75 mg/m2 IV. ; Day 1: Pemetrexed 500 mg/m2 IV ; with concurrent thoracic radiotherapy. ; Repeat every 3 weeks for 3 cycles. 14900
CM0102-ii-l : LUNG CANCER - NSCLC - Paclitaxel + Carboplatin ; Paclitaxel 45mg/m2 IV + carboplatin AUC 2mg per min/mL IV ; with concurrent thoracic radiotherapy (total dose, 60Gy) ; Repeat weekly for 6 weeks 3300
CM0102-ii-m : LUNG CANCER - NSCLC - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0102-iii : LUNG CANCER - SCLC 0
CM0102-iii-a : LUNG CANCER - SCLC - Cisplatin & Etoposide ; Day 1: Cisplatin 60mg/m2 IV, Days 1-3: Etoposide 120mg/m2 IV. ; Repeat cycle every 3 weeks for at least 4 cycles. ;(OR) ; Day 1: Cisplatin 80mg/m2 IV, Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 4 weeks for 4-6 cycles. 4900
CM0102-iii-b : LUNG CANCER - SCLC - Carboplatin & Etoposide ; Day 1: Carboplatin AUC 5-6mg per min/mL IV ; Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 21 days or 28 days for 4 - 6 cycles 6500
CM0102-iii-c : LUNG CANCER - SCLC - Cisplatin + Irinotecan ; Day 1: Cisplatin 60mg/m2 IV. ; Days 1, 8, and 15: Irinotecan 60mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles. 5800
CM0102-iii-d : LUNG CANCER - SCLC - Cisplatin + Irinotecan ; Day 1 and 8: Cisplatin 30mg/m2 IV, irinotecan 65mg/m2 IV. ; Repeat cycle every 3 weeks for 4-6 cycles. 5700
CM0102-iii-e : LUNG CANCER - SCLC - Carboplatin & Irinotecan ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Days 1, 8, and 15: Irinotecan 50mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles 7700
CM0102-iii-f : LUNG CANCER - SCLC - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0103-i : ESOPHAGEAL CANCER - Neo Adjuvant 0
CM0103-i-a : ESOPHAGEAL CANCER - Neo Adjuvant - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV + carboplatin AUC 2mg/min/mL IV. ; Repeat weekly for 5 weeks 3300
CM0103-i-b : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Cisplatin ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV. 12000
CM0103-i-c : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Cisplatin ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5 and Days 22-26: 5-FU 800 mg/m2 IV ; Repeat every 21 days for 2 cycles 7100
CM0103-i-d : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil + Oxaliplatin + Leucovorin ; Day 1: Oxaliplatin 85mg/m2, leucovorin 200mg/m2 and 5-FU 400mg/m2 bolus, with 1,600mg/m2 infusion; ; Repeat every 14 days for 6 cycles 4600
CM0103-i-e : ESOPHAGEAL CANCER - Neo Adjuvant - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily ; Repeat cycle weekly for 5 weeks 2500
CM0103-i-f : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Oxaliplatin ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day IV 25800
CM0103-i-g : ESOPHAGEAL CANCER - Neo Adjuvant - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks. 8900
CM0103-i-h : ESOPHAGEAL CANCER - Neo Adjuvant - Irinotecan & Cisplatin ; Days 1, 8, 22, and 29: Irinotecan 65mg/m2 IV, cisplatin 30mg/m2 IV. 9700
CM0103-i-i : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45mg/m2 IV ; Days 1-5: 5-FU 300mg/m2/day IV infusion. ; Repeat cycle weekly for 5 weeks. 5500
CM0103-i-j : ESOPHAGEAL CANCER - Neo Adjuvant - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks. 12200
CM0103-i-k : ESOPHAGEAL CANCER - Neo Adjuvant - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0103-ii : ESOPHAGEAL CANCER - Peri-Operative 0
CM0103-ii-a : ESOPHAGEAL CANCER - Peri-Operative - ECF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; cisplatin 60mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV continuous infusion once daily; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively 16700
CM0103-ii-b : ESOPHAGEAL CANCER - Peri-Operative - EOF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. 18700
CM0103-ii-c : ESOPHAGEAL CANCER - Peri-Operative - EOC (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. 7800
CM0103-ii-d : ESOPHAGEAL CANCER - Peri-Operative - Fluorouracil & Cisplatin ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV ; Repeat cycle every 28 days for 2-4 cycles 12000
CM0103-ii-e : ESOPHAGEAL CANCER - Peri-Operative - Fluorouracil & Cisplatin ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5: 5-FU 800 mg/m2 IV continuous infusion over 24 hours. ; Cycled every 21 days for 2 cyclesCycled every 21 days for 2 cycles 7100
CM0103-ii-f : ESOPHAGEAL CANCER - Peri-Operative - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0103-iii : ESOPHAGEAL CANCER - Post-Operative 0
CM0103-iii-a : ESOPHAGEAL CANCER - Post-Operative - Fluorouracil + Leucovorin (i) ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV, followed by 4 weeks break and CCRT ; RT Days 1-4 and 23-25: 5-FU 400mg/m2/day IV and leucovorin 20mg/m2/day IV followed by one month Break and ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV followed by one month Break and ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV. 25400
CM0103-iii-b : ESOPHAGEAL CANCER - Post-Operative - Fluorouracil + Leucovorin (ii) ; Days 1, 2, 15, and 16: Leucovorin 200mg/m2 IV, 5-FU 400mg/m2 IV push and 5-FU 600mg/m2 infusion 9000
CM0103-iii-c : ESOPHAGEAL CANCER - Post-Operative - Capecitabine (i) ; Days 1-14: Capecitabine 750-1000mg/m2 orally twice daily; ; Repeat every 28 days; 1 cycle before and 2 cycles after chemoradiation 3100
CM0103-iii-d : ESOPHAGEAL CANCER - Post-Operative - Capecitabine (ii) ; Days 1-5 OR Days 1-7: Capecitabine 625-825mg/m2 orally twice daily, ; once weekly for 5 weeks. 1600
CM0103-iii-e : ESOPHAGEAL CANCER - Post-Operative - FluorouracilDays 1-5 OR Days 1-7: 5-FU 200-250mg/m2 IV continuous infusion over 24 hours daily, ; once weekly for 5 weeks.once weekly for 5 weeks. 6500
CM0103-iii-f : ESOPHAGEAL CANCER - Post-Operative - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0103-iv : ESOPHAGEAL CANCER - Definitive 0
CM0103-iv-a : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Cisplatin (i) ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV 12000
CM0103-iv-b : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Cisplatin (ii) ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5: 5-FU 800 mg/m2 IV continuous infusion over 24 hours. ; Cycled every 21 days for 2 cycles 7100
CM0103-iv-c : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Oxaliplatin ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day continuous IV infusion. 25800
CM0103-iv-d : ESOPHAGEAL CANCER - Definitive - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily ; Repeat cycle weekly for 5 weeks 2000
CM0103-iv-e : ESOPHAGEAL CANCER - Definitive - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks 8900
CM0103-iv-f : ESOPHAGEAL CANCER - Definitive - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV and carboplatin 2mg/min/mL IV ; Repeat weekly for 5 weeks. 3300
CM0103-iv-g : ESOPHAGEAL CANCER - Definitive - Cisplatin with Docetaxel (i) ; Days 1 and 22: Docetaxel 60mg/m2 IV ; Days 1 and 22: Cisplatin 60-80mg/m2 IV given for 1 cycle 8900
CM0103-iv-h : ESOPHAGEAL CANCER - Definitive - Cisplatin with Docetaxel (ii) ; Day 1: Docetaxel 20-30mg/m2 IV ; Day 1: Cisplatin 20-30mg/m2 IV ; Repeat weekly for 5 weeks 3000
CM0103-iv-i : ESOPHAGEAL CANCER - Definitive - Cisplatin with Paclitaxel ; Days 1, 8, 15, and 22: Paclitaxel 60mg/m2 IV ; Day 1: Cisplatin 75mg/m2 IV given for 1 cycle. 13100
CM0103-iv-j : ESOPHAGEAL CANCER - Definitive - Irinotecan & Cisplatin ; Days 1, 8, 22, and 29: Irinotecan 65mg/m2 IV ; Days 1, 8, 22, and 29: Cisplatin 30mg/m2 IV. 9700
CM0103-iv-k : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45mg/m2 IV ; Days 1-5: 5-FU 300mg/m2/day IV ; Repeat cycle weekly for 5 weeks. 5500
CM0103-iv-l : ESOPHAGEAL CANCER - Definitive - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 PO twice daily. ; Repeat cycle weekly for 5 weeks. 12200
CM0103-iv-m : ESOPHAGEAL CANCER - Definitive - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0104 : GASTRIC CANCER 0
CM0104-i : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) 0
CM0104-i-a : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV, carboplatin AUC 2mg/min/mL IV. ; Repeat cycle weekly for 5 weeks. 3300
CM0104-i-b : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Cisplatin (i) ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1000mg/m2/day IV 12000
CM0104-i-c : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Cisplatin (ii) ; Days 1-5: Cisplatin 15mg/m2 IV once daily, 5-FU 800mg/m2/day IV ; Repeat cycle every 21 days for 2 cycles. 7100
CM0104-i-d : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Oxaliplatin (i)Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day IV. 25800
CM0104-i-e : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Oxaliplatin (ii)Day 1: Oxaliplatin 85mg/m2 and leucovorin 400mg/m2 followed by 5-FU 400mg/m2 bolus, then 800mg/m2 24-hour continuous infusion over days 1 and 2; the first 3 cycles were delivered during radiotherapy (RT), the other 3 after RT; 6 bimonthly (14 days) cycles. 6100
CM0104-i-f : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks. 2000
CM0104-i-g : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks 8900
CM0104-i-h : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45-50mg/m2 IV weekly ; Days 1-5: 5-FU 300mg/m2 IV ; Repeat cycle weekly for 5 weeks 5500
CM0104-i-i : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks. 3100
CM0104-i-j : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0104-ii : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) 0
CM0104-ii-a : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - ECF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV, cisplatin 60mg/m2 IV ; Days 1-21: 5-FU 200mg/m2/day IV ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively 16700
CM0104-ii-b : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - EOF (Epirubicin/ oxaliplatin /Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. 18700
CM0104-ii-c : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - epirubicin + cisplatin + capecitabine ; Day 1: Epirubicin 50mg/m2 IV + cisplatin 60mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. 5900
CM0104-ii-d : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - ECF modification (epirubicin + oxaliplatin + capecitabine) ; Day 1: Epirubicin 50mg/m2 IV + oxaliplatin 130mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperativelyRepeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively 7800
CM0104-ii-e : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - Fluorouracil & Cisplatin ; Day 1: Cisplatin 75-80mg/m2 IV ; Days 1-5: 5-FU 800mg/m2 IV ; Repeat cycle every 28 days for 2-3 cycles preoperatively and 3-4 cycles postoperatively for a total of 6 cycles. 6900
CM0104-ii-f : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0104-iii : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) 0
CM0104-iii-a : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil + Leucovorin (i) ; Cycles 1, 3, and 4 (before and after radiation) Days 1-5: Leucovorin 20mg/m2 IV, 5-FU 425mg/m2/day IV ; Repeat cycle every 28 days. ; Cycle 2 (with radiation) Days 1-4 and 31-33: Leucovorin 20mg/m2 IVP ; Days 1-4: 5-FU 400mg/m2/day IVP. ; Repeat cycle every 35 days 25400
CM0104-iii-b : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil + Leucovorin (ii) ; Days 1, 2, 15, and 16: Leucovorin 400mg/m2 IV, 5-FU 400mg/m2 IV and 5-FU 1200mg/m2 infusion; ; 1 cycle before and 2 cycles after chemoradiation. ; Repeat cycle every 28 daysRepeat cycle every 28 days 14900
CM0104-iii-c : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Capecitabine (i) ; Days 1-14: Capecitabine 750-1000mg/m2 orally twice daily. ; Repeat cycle every 28 days; 1 cycle before and 2 cycles after chemoradiation. 3100
CM0104-iii-d : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Capecitabine (ii) ; Days 1-5 OR Days 1-7: Capecitabine 625-825mg/m2 orally twice daily; weekly for 5 weeks. 1600
CM0104-iii-e : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil ; Days 1-5 OR Days 1-7: 5-FU 200-250mg/m2 IV; ; weekly for 5 weeks. 6500
CM0104-iii-f : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Cisplatin + capecitabine ; Day 1: Cisplatin 60mg/m2 IV. ; Days 1-14: Capecitabine 1000mg/m2 orally twice daily ; Repeat cycle every 21 days for 6 cycles. 4000
CM0104-iii-h : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Oxaliplatin + capecitabine ; Day 1: Oxaliplatin 130mg/m2 IV. ; Days 1-14: Capecitabine 1000mg/m2 orally twice daily ; Repeat cycle every 21 days for 8 cycles.Repeat cycle every 21 days for 8 cycles. 6000
CM0104-iii-i : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0105-i : COLORECTAL CARCINOMA 0
CM0105-i-a : COLORECTAL CARCINOMA - FOLFOX (Stage - III) - (Oxaliplatin, Leucovorin, 5-FU) ; Day 1: Oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV , 5-FU 400mg/m2 IV, followed by 5-FU 1,200mg/m2/day IV x 2 days (total 2,400mg/m2) over 46-48-hour continuous infusion. ; Repeat cycle every 2 weeks- upto 12 cycles 8000
CM0105-i-b : COLORECTAL CARCINOMA - CAPEOX (Stage - III) (Oxaliplatin, Capecitabine) ; Day 1: Oxaliplatin 130mg/m2 IV over 2 hours ; Days 1-14: Capecitabine 1,000mg/m2 orally twice daily. ; Repeat cycle every 3 weeks for 6 months 6500
CM0105-i-c : COLORECTAL CARCINOMA - FLOX (Stage - III) (5-FU, leucovorin, oxaliplatin) ; 5-FU 500mg/m2 IV bolus weekly x 6, leucovorin 500mg/m2 IV weekly x 6, each ; oxaliplatin 85mg/m2 IV on weeks 1, 3, and 5 ; 8-week cycle x 3 cycles ; 30000
CM0105-i-d : COLORECTAL CARCINOMA - Capecitabine ; Capecitabine 1,250mg/m2 - BD / TDS D 1-14 ; every 3 weeks * 24 weeks 4300
CM0105-i-e : COLORECTAL CARCINOMA - Fluorouracil + Leucovorin (i) ; Leucovorin 500mg/m2 weekly x 6 weeks, ; 5-FU 500mg/m2 weekly x 6 weeks. ; Repeat cycle every 8 weeks for 4 cycles. 23700
CM0105-i-f : COLORECTAL CARCINOMA - Fluorouracil + Leucovorin (ii)Simplified biweekly infusion. ; Leucovorin 400mg/m2 IV, 5-FU bolus 400mg/m2 and then 1,200mg/m2/day x 2 days (total 2,400mg/m2 over 46-48 hours) ; Repeat cycle every 2 weeks for 6 cycles. 5200
CM0105-i-g : COLORECTAL CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0105-ii : COLORECTAL CARCINOMA - Concurrent 0
CM0105-ii-a : COLORECTAL CARCINOMA - Concurrent - 5FU - with XRT ; Days 1-5 OR 1-7: 5-FU 225mg/m2 IV ; with External beam radiotherapy 3800
CM0105-ii-b : COLORECTAL CARCINOMA - Concurrent - Fluorouracil + Leucovorin - with XRT ; Days 1-4: 5-FU 400mg/m2 IV + leucovorin 20mg/m2 IV. ; Repeat cycle during weeks 1 and 5 of XRT. 6100
CM0105-ii-c : COLORECTAL CARCINOMA - Concurrent - Capecitabine - with XRT ; Capecitabine Tablet 825mg / m2 twice daily on Days 1-5 ; Repeat cycle weekly for 5 weeks. 1300
CM0105-ii-d : COLORECTAL CARCINOMA - Concurrent - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0106-106 : OSTEOSARCOMA/ BONE TUMORS 0
CM0106-i-a : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - Cisplatin + doxorubicin ; Days 1-3: Doxorubicin 25mg/m2/day IV, ; Day 1: Cisplatin 100mg/m2 IV ; Repeat cycle every 3 weeks for 6 cycles 5600
CM0106-i-b-1 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - PRE OPERATIVE ; Days 1 and 28: Methotrexate 8g/m2 IV ; Days 7-9 and 34-36: Cisplatin 120mg/m2 by infusion for 72 hours. ; Days 9 and 36: Doxorubicin 60mg/m2 IV 24200
CM0106-i-b-2 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - POST OPERATIVE NECROSIS < 90% ; Days 1, 48, 96, and 144: Doxorubicin 45mg/m2/day for 2 consecutive days ; Days 21, 69, and 117: Methotrexate 8g/m2 IV ; Days 27, 75, and 123: Cisplatin 120mg/m2 by infusion for 72 hours. 40100
CM0106-i-b-3 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - POST OPERATIVE NECROSIS > 90%Postoperative Chemotherapy (Necrosis 59100
CM0106-i-c : Doxorubicin + cisplatin + ifosfamide + high-dose methotrexate (surgery to be done also) 111505
CM0106-i-d : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - Ifosfamide + cisplatin + epirubicin ; Day 1: Epirubicin 90mg/m2 IV, cisplatin 100mg/m2 IV ; Days 2-4: Ifosfamide 2.0g/m2 with mesna ; Repeat cycle every 21 days. (3 cycles preoperatively and 3 cycles postoperatively). 8300
CM0106-ii : Other bone tumors - Chordroma 0
CM0106-ii-a : Other bone tumors - Chordroma - Imatinib ; Imatinib 800 mg once daily 4500
CM0106-ii-b : Other bone tumors - Chordroma - Imatinib + cisplatin ; Imatinib 400mg OD + cisplatin 25mg/m2 weekly. 4500
CM0106-ii-c : Other bone tumors - Chordroma - Imatinib + sirolimus ; Imatinib 400mg OD + sirolimus 2mg OD 6000
CM0106-ii-d : Other bone tumors - Chordroma - Erlotinib ; Erlotinib 150mg OD 2200
CM0106-ii-e : Other bone tumors - Chordroma - Sunitinib ; Sunitinib 37.5mg OD 28500
CM0106-iii :Other bone tumors - Giant Cell Tumor of Bone 0
CM0106-iii-a :Other bone tumors - Giant Cell Tumor of Bone - Denosumab ; Denosumab 120mg subcutaneous on Week 1,2 and 3 of a 4 week cycle 56000
CM0106-iii-b :Other bone tumors - Giant Cell Tumor of Bone - Interferon alfa ; interferon alfa- 2a thrice weekly 4600
CM0106-iii-c :Other bone tumors - Giant Cell Tumor of Bone - Peginterferon ; Peginterferon alfa-2a 1.0mcg/kg SQ injection weekly. 3500
CM0106-iv : Other bone tumors - Mesenchymal Chordosarcoma 0
CM0106-iv-a : VAC and IE cycles 6420
CM0106-iv-b : Other bone tumors - Mesenchymal Chordosarcoma VAIA ; Day 1: Vincristine 1.5mg/m2 IV ; Days 1-3: Ifosfamide 2,000mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 3 weeks. 7600
CM0106-v : Other bone tumors - Mesenchymal Chordosarcoma Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0107 : WILMS TUMOR 0
CM0107-a : WILMS TUMOR - Vincristine & Actinomycin D ; Dactinomycin 45mcg/kg - week - 0, 3, 6,9,12,15,18 ; Vincristine 1.5 mg/m2 - week - 1,2,3,4,5,6,7,8,9,10,12,15,18 19400
CM0107-b : WILMS TUMOR - Dactinomycin, Vincristine & Adriamycin ; Dactinomycin 1.35 mg /m2 - week - 0, 6, 12, 18,24 ; Adriyamycin 30-45 mg /m2- week - 3, 9, 15, 21 ; Vincristine 2mg max- week - 1,2,3,4,5,6,7,8,9,10,12,15,18,21,24 23200
CM0107-c : WILMS TUMOR - Adriamycin, Cyclophosphamide, Etoposide, Vincristine ; Cyclophosphamide 440mg/m2/day - week 3, 9, 15, 21 for 5 days, week - 6,12,18,24 for 3 days ; Adriyamycin 30-45mg /m2- week -0, 6, 12, 18,24 ; Vincristine 2mg (max)- week - 1,2,4,5,6,7,8,10,11, 12,13,18,24 ; Etoposide 100mg /m2- week - 3,9,15,21 53700
CM0107-d : WILMS TUMOR - Cyclophosphamide, Etoposide, Carboplatin ; Cyclophosphamide 440mg/m2/day - week 6,15,24 *5 days / week ; Carboplatin 500mg/m2 - week - 0,3,9,12,18,21 *2 days / week ; Etoposide 100mg/m2 - week - 0,3,9,12,18,21 *5 days / week 84500
CM0107-e : WILMS TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0108 : HEPATOBLASTOMA- OPERABLEHEPATOBLASTOMA- OPERABLE 0
CM0108-a : HEPATOBLASTOMA- OPERABLE - PLADO - Cisplatin + Doxorubicin ; cisplatin (PLA) (80mg/m2 / iv), doxorubicin (DO) (30 mg/m2 IV ; Every 21 days for 6 cycles 2800
CM0108-b : HEPATOBLASTOMA- OPERABLE - Cisplatin + Vincristine +5FU ; cisplatin (90 mg/m2), vincristine (1.5mg/m2), 5-FU(5-Flurouracil- 600 mg/m2) ; Every 21 days for 6 cycles 2400
CM0108-c : HEPATOBLASTOMA- OPERABLE - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0109 : HEPATOCELLULAR CARCINOMA 0
CM0109-a : HEPATOCELLULAR CARCINOMA - Sorafenib ; Sorafenib 400 mg PO BID 5800
CM0109-b : HEPATOCELLULAR CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0110A : Neuroblastoma ALL STAGES - VINCRISTINE/CISPLATIN/ETOPOSIDE/CYCLOPHOSPHAMIDE/CARBOPLATIN 8000
CM0110B : Neuroblastoma ALL STAGES - CYCLOPHOSPHAMIDE/ADRIAMYCIN/VINCRISTINE ; D1-D5 - CYCLOPHOSPHAMIDE 300mg/m2 ; ADRIAMYCIN 60mg/m2 ; VINCRISTINE 1.5mg/m2 7100
CM0110C : Neuroblastoma ALL STAGES - Cisplatin & Etoposide ; Days 1-5 : Cisplatin - 20mg/m2 ; Days 1-5 : Etoposide - 70 mg/m2 4900
CM0110D : Neuroblastoma ALL STAGES - Carboplatin & Etoposide ; Days 1-2 : Carboplatin - 500mg/m2 ; Days 1-5: Etoposide 100mg/m2 6500
CM0110E : Neuroblastoma ALL STAGES - For Stage IV Palliative Chemotherapy only 10000
CM0110F : Neuroblastoma ALL STAGES - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0111 : RETINOBLASTOMA 0
CM0111-a : RETINOBLASTOMA - Melphalan - Intra-arterial ; Melphalan - 3-7.5mg - Intra-arterial 9700
CM0111-b : RETINOBLASTOMA - Carboplatin - Intra-arterial ; Carboplatin 15-30 mg - Intra-arterial 8900
CM0111-c : RETINOBLASTOMA - Topotecan - Intra-arterial ; Topotecan 0.15-1.5 mg - Intra-arterial 9900
CM0111-d : RETINOBLASTOMA - Methotrexate - Intra-arterial ; Methotrexate 6-12 mg - Intra-arterial 8600
CM0111-e : RETINOBLASTOMA - Carboplatin - Peri Ocular ; Carboplatin 20mg/m2 - Peri Ocular 1900
CM0111-f : RETINOBLASTOMA - Topotecan - Peri Ocular ; Topotecan 0.09 - 0.27 - Peri Ocular 4300
CM0111-g : RETINOBLASTOMA - Melphalan - Intra-vitreal ; Melphalan 20-30 mcg / 0.1cc - Intra-vitreal 270
CM0111-h : RETINOBLASTOMA - Carboplatin - Intra-vitreal ; Carboplatin 3-6mcg / 0.05cc - Intra-vitreal 1900
CM0111-i : RETINOBLASTOMA - Methotrexate - Intra-vitreal ; Methotrexate 400mcg/0.1cc - Intra-vitreal 1600
CM0111-j : RETINOBLASTOMA - Carboplatin + Etoposide + Vincristine ; Carboplatin 560mg/m2 ; Etoposide 150mg/m2 ; Vincristine 1.5mg/m2 6800
CM0111-k : RETINOBLASTOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0112 : HISTIOCYTOSIS 0
CM0112-a : HISTIOCYTOSIS - Prednisolone and Vinblastine - 1; Prednisolone and Vinblastine - 1 ; Prednisolone - 6 weeks oral ; Vinblastine 1,2,3,4,5,6 6100
CM0112-b : HISTIOCYTOSIS - Prednisolone and Vinblastine - 2; Prednisolone and Vinblastine - 1 ; Prednisolone - 6 weeks oral ; Vinblastine 1,2,3,4,5,6 6800
CM0112-c : HISTIOCYTOSIS - Prednisolone and Vinblastine - continuation; Prednisolone and Vinblastine - continuation after either course 1 or both 1 & 2 ; Prednisolone - 5 days a week oral ; Vinblastine -IV ; repeat every 3 weeks till 1 year 1800
CM0112-d : HISTIOCYTOSIS - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0113 : RHABDOMYOSARCOMA 0
CM0113-a : RHABDOMYOSARCOMA - VAC (Vincristine + Dactinomycin + Cyclophosphamide + Mesna ) ; Day -1 - Vincristine 1.5 mg /m2 IV (2 mg max), Doxorubicin 75 mg /m2 IV , cyclophosphamide 1200 mg /m2 IV + mesna ; Repeat at 21 day intervals for 4-6 cycles 3800
CM0113-b : RHABDOMYOSARCOMA - IVA (Vincristine + Dactinomycin + Ifosfamide + Mesna ) ; Day 1,2 - Ifosfamide IV 3 g/m2 + mesna ; Day 1 - Vincristine IV 1.5 mg/m2 (max 2 mg), Actinomycin-D IV 1.5 mg/m2 (max 2 mg) ; Repeat at 21 day intervals for 6 cycles 5600
CM0113-c : RHABDOMYOSARCOMA - IVAD (Vincristine + Doxorubicin + Ifosfamide + Mesna ) ; Days 1 and 2 - Ifosfamide 3 g/m2 + Mesna, Doxorubicin 30mg/m2 ; Day 1 - vincristine 1.5 mg/m2, Actinomycin-D 1.5 mg/m2 ; Repeat at 21 day intervals for 6 cycles 5500
CM0113-d : RHABDOMYOSARCOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0114 : EWINGS SARCOMA 0
CM0114-i : EWINGS SARCOMA - Induction Treatment I 0
CM0114-i-a : EWINGS SARCOMA - Induction Treatment - VIDE ; Day 1:Vincristine 1.5mg/m2(max 2mg) IV ; Days 1-3:Doxorubicin 20mg/m2 IV, ifosfamide 3g/m2IV, mesna continuous IV, etoposide 150mg/m2 IV ; Repeat cycle every 3 weeks for up to 6 cycles 8300
CM0114-i-b : EWINGS SARCOMA - Induction Treatment - VAC/IE ; 0
CM0114-i-c : EWINGS SARCOMA - Induction Treatment - VAIA - 4 day Regimen ; Day 1:Vincristine 1.5mg/m2IV ; Days 1-3: Ifosfamide 2,000mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, then local therapy, followed by 10 additional cycles of VAIA for High risk and ; 10 additional cycles of VAIA or 10 cycles of VACA for standard-risk patients 7600
CM0114-i-d : EWINGS SARCOMA - Induction Treatment - VAIA - 24 day Regimen ; Days 1, 8, 15, and 22: Vincristine 1.5mg/m2 IV ; Days 1, 2, 22, 23, 43, and 44 : Ifosfamide 3,000mg/m2 IV + mesna ; Days 1, 2, 43, and 44 : Doxorubicin 30mg/m2 IV ; Days 22, 23, and 24: Dactinomycin 0.5mg/m2 IV ; After completion of one 9-week cycle, local therapy followed by 3 additional cycles. 17700
CM0114-ii : EWINGS SARCOMA - Maintenance Treatment 0
CM0114-ii-a : EWINGS SARCOMA - Maintenance Treatment - Etoposide/Ifosfamide ; Days 1-5: Ifosfamide 1,800mg/m2/day IV + mesna ; Days 1-5: Etoposide 100mg/m2/day IV. 8200
CM0114-iii : EWINGS SARCOMA - Maintenance Treatment - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0115 : PALLIATIVE CHEMOTHERAPY (Any Regimen)- Maximum Payable 10000
CM0116 : CERVICAL CANCER 0
CM0116-a : CERVICAL CANCER - CISPLATIN ; Cisplatin 40mg/m2 IV once weekly for up to 6 cycles 1800
CM0116-b : CERVICAL CANCER - Cisplatin & 5FU with RT ; Days 1-5 of radiotherapy: Cisplatin 75mg/m2 IV, 5-FU 4,000mg/m2 IV over 96 hours ; Repeat cycle every 3 weeks for 3 9200
CM0116-c : CERVICAL CANCER - Cisplatin & 5FU ; Days 1 and 29: Cisplatin 50mg/m2 IV ; Days 2-5, and 30-33: 5-FU 1,000mg/m2 IV 8900
CM0116-d : CERVICAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0117 : VULVAL CANCER 0
CM0117-a : VULVAL CANCER - Cisplatin ; Day 1 : 40 mg/m 2 IV 1800
CM0117-b : VULVAL CANCER - Cisplatin + 5FU ; Days 1-5 of radiotherapy: Cisplatin 75mg/m2 IV, 5-FU 4,000mg/m2 ; Repeat cycle every 3 weeks - total 3 cycles 4700
CM0117-c : VULVAL CANCER - 5-FU + Mitomycin ; 5-FU + Mitomycin ; Days 1-4 and 29-32: 5-FU 1,000mg/m2/day continuous IV infusion ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus (maximum 20mg per course), 11400
CM0117-d : VULVAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0118 : VAGINAL CANCER 0
CM0118-a : VAGINAL CANCER - Cisplatin ; Cisplatin 75mg/m2 ; once weekly for up to 6 doses 1800
CM0118-b : VAGINAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0119 : OVARIAN CANCER 0
CM0119-a : OVARIAN CANCER - Paclitaxel + Cisplatin ; Day 1: Paclitaxel 135mg/m2 continuous IV ; Day 2: Cisplatin 75-100mg/m2 ; Day 8: Paclitaxel 60mg/m2 ; Repeat every 3 weeks for 6 cycles. 8800
CM0119-b : OVARIAN CANCER - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 175mg/m2 IV, Carboplatin AUC 5-6 mg/min/mL IV ; Repeat every 3 weeks for 6 cycles 7000
CM0119-c : OVARIAN CANCER - Docetaxel + Carboplatin ; Day 1: Docetaxel 60-75mg/m2 IV, Carboplatin AUC 5-6 mg/min/mL ; Repeat every 3 weeks for 6 cycles 8700
CM0119-d : OVARIAN CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0120 : ENDOMETRIAL CANCER (Palliative Chemotherapy only) 10000
CM0121 : OVARY- GERM CELL TUMOR 0
CM0121-a : OVARY- GERM CELL TUMOR - BEP (Bleomycin + Etoposide + Cisplatin) ; Days 1,8,15 : Bleomycin 30 units/wk IV, Etoposide 100 mg/m 2/day IV ; Days 1-5 : Cisplatin 20 mg/m 2/day IV ; Repeat every 21 days 3-4 cycles 10800
CM0121-b : OVARY- GERM CELL TUMOR - EP ( Etoposide + Carboplatin) ; Day 1 : Carboplatin 400 mg/m 2 IV on days 1-3 ; Repeat every 28 days for three cycles 6500
CM0121-c : OVARY- GERM CELL TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0122 : GESTATIONAL TROPHOBLAST DISEASES 0
CM0122-a : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate (5 days regimen) ; Days 1-5: MTX 0.4 mg/kg/day IV or IM for 5 days, not to exceed 25 mg/day ; Repeat cycle every 14 days 2100
CM0122-b : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate (8-day alternating regimen) ; Days 1, 3, 5, and 7 : MTX 1 mg/kg IM, ; Days 2, 4, 6, and 8 : Folinic acid 15 mg ; Repeat cycle every 14 days 2900
CM0122-c : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate + Folinic Acid ; Day 1 : MTX 100 mg/m 2 IVP, then 200 mg/m 2 infusion ; Day 2 : Folinic acid 15 mg IM/PO q12h for 4 doses ; Repeat cycle every 18 days 2000
CM0122-d : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate - Weekly ; MTX 30-50 mg/m 2 IM weekly 1300
CM0122-e : GESTATIONAL TROPHOBLAST DISEASES - Act-D ; Act-D 10-13 mcg/kg or 0.5-mg flat dose IV qd for 5d ; Repeat cycle every 14 days 7800
CM0122-f : GESTATIONAL TROPHOBLAST DISEASES - Actinomycin ; Actinomycin 1.25 mg/m 2 IV ; Repeat every 2 weeks 2200
CM0122-g : GESTATIONAL TROPHOBLAST DISEASES - EMA-CO (complete) ; Day 1 : Act-D - 0.5 mg IV, Etoposide - 100 mg/m2 IV, MTX - 300 mg/m2 IV ; Day 2 : Act-D - 0.5 mg IV, Etoposide - 100 mg/m2 IV, Leucovorin - 15 mg PO/IM q12h 4 doses ; Day 8 : Vincristine - 0.8 mg/m2 IV, Cyclophosphamide - 600 mg/m2 IV ; Repeat cycle every 14 days 6400
CM0122-h : GESTATIONAL TROPHOBLAST DISEASES - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0123 : TESTICULAR CANCER 0
CM0123-a : TESTICULAR CANCER - EP ; Days 1-5: Etoposide 100mg/m2, cisplatin 20mg/m2 ; Repeat cycle every 3 weeks for 4 cycles. 5400
CM0123-b : TESTICULAR CANCER - BEP ; Days 1-5: Cisplatin 20mg/m2, etoposide 100mg/m2 ; Days 1, 8, and 15 OR Days 2, 9, or 16: Bleomycin 30 units IV ; Repeat cycle every 3 weeks for 3 cycles. 10000
CM0123-c : TESTICULAR CANCER - VIP ; Day 1 (before ifosfamide): Mesna 120mg/m2 IV ; Days 1-5: Etoposide 75mg/m2 IV, mesna 1,200mg/m2 IV, ifosfamide 1,200mg/m2 IV + cisplatin 20mg/m2. ; Repeat cycle every 3 weeks for 4 cycles. 6300
CM0123-d : TESTICULAR CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0124 : PROSTATE CANCERPROSTATE CANCER 0
CM0124-a : PROSTATE CANCER - Docetaxel + prednisone ; Day 1: Docetaxel 75mg/m2 IV, prednisone 5mg orally twice daily. ; once every 3 weeks, Repeat for up to 10 cycles if tolerated 3600
CM0124-b : PROSTATE CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0125 : FEBRILE NEUTROPENIA 0
CM0125-a : FEBRILE NEUTROPENIA - First-line monotherapy ; Piperacillin-tazobactam 4.5 g ; Cefepime 2 g ; Meropenem 1 g ; Imipenem-cilastatin 500 mg 13500
CM0125-b : FEBRILE NEUTROPENIA - Second-line dual therapy ; Piperacillin-tazobactam 4.5 g IV plus an aminoglycoside ; Meropenem 1 g IV plus an aminoglycoside ; Imipenem-cilastatin 500 mg IV plus an aminoglycoside 19500
CM0125-c : Other Regimen 10000
CM0126 : THYROID CANCER 0
CM0126-a : THYROID CANCER - sorafenib ; sorafenib 400 mg PO BID 2900
CM0126-b : THYROID CANCER - sunitinib ; sunitinib 50 mg 28500
CM0126-c : THYROID CANCER - pazopanib 9500
CM0126-d : THYROID CANCER - Doxorubicin ; Doxorubicin 60 mg/m2 as monotherapy or in combination with cisplatin 40 mg/m2 4400
CM0126-e : THYROID CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0127 : THYMOMA 0
CM0127-a : THYMOMA - CAP ; Day 1: Cisplatin 50mg/m2 IV, doxorubicin 50mg/m2 IV, cyclophosphamide 500mg/m2 IV. ; Repeat every 21 days for a max of 8 cycles. 4600
CM0127-b : THYMOMA - CAPP ; Day 1: Cyclophosphamide 500mg/m2 IV ; Days 1-3: Cisplatin 30mg/m2 IV ; Days 1-3: Doxorubicin 20mg/m2 ; Days 1-5: Prednisone 100mg. ; Repeat every 3 weeks for 3 cycles. 6800
CM0127-c : THYMOMA - ADOC ; Day 1: Cisplatin 50mg/m2 IV, doxorubicin 40mg/m2 IV ; Day 3: Vincristine 0.6mg/m2 IV ; Day 4: Cyclophosphamide 700mg/m2 IV. ; Repeat every 3 weeks for 5 cycles. 5900
CM0127-d : THYMOMA - PE ; Day 1: Cisplatin 60mg/m2 IV ; Days 1-3: Etoposide 120mg/m2 IV ; Repeat every 3 weeks for a max of 8 cycles. 5100
CM0127-e : THYMOMA - VIP ; Days 1-4: Etoposide 75mg/m2 IV, ifosfamide 1.2g/m2 IV, cisplatin 20mg/m2 IV. ; Repeat every 3 weeks for 4 cycles 7600
CM0127-f : THYMOMA - Carboplatin+paclitaxel ; Day 1: Paclitaxel 225mg/m2 IV, carboplatin AUC = 6 IV ; Repeat every 3 weeks for a max of 6 cycles. 9300
CM0127-g : THYMOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0128 : BRAIN CARCINOMA 0
CM0128-i : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma 0
CM0128-i-a : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Combination PCV (lomustine + procarbazine + vincristine) ; Day 1: Lomustine 110mg/m2 orally. ; Days 8-21: Procarbazine 60mg/m2 orally once daily. ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks. 3800
CM0128-i-b : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide (7 weeks) ; Days 1-49: Temozolomide 75mg/m2 orally. ; Repeat cycle every 11 weeks (7 weeks on/4 weeks off) for 6 cycles. 6500
CM0128-i-c : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide monthly 5-day course ; Temozolomide monthly 5-day courses at doses of 180 - 200mg/m2/day 2100
CM0128-i-d : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide (3 weeks) ; Days 1-21: Temozolomide 75mg/m2/day orally. ; Repeat cycle every 28 days. 3400
CM0128-ii : BRAIN CARCINOMA - Systemic Therapy for Anaplastic GliomasSystemic Therapy for Anaplastic Gliomas 0
CM0128-ii-a : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - Temozolomide monthly 5-day course ; Days 1-5: Temozolomide 200mg/m2/day orally. ; Repeat cycle every 4 weeks until disease progression or for up to 24 cycles. 2100
CM0128-ii-b : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - PCV with deferred RT (lomustine + procarbazine + vincristine) ; Day 1: Lomustine 110mg/m2 orally ; Days 8-21: Procarbazine 60mg/m2 orally once daily ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks 3800
CM0128-ii-c : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide ; 0
CM0128-ii-d : Adjuvant Temozolomide 2100
CM0128-ii-e : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - PCV for 1p19q co-deleted (with Radiotherapy) ; Day 1: Lomustine 110mg/m2 orally ; Days 8-21: Procarbazine 60mg/m2 orally once daily ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks. for 6 cycles 3800
CM0128-iii : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma 0
CM0128-iii-a : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide ; Daily oral temozolomide (75mg/m2/day, 7 days per week from the first to the last day of radiotherapy) 7200
CM0128-iii-b : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Adjuvant Temozolomide (preceeded by Concurrent temozolzmide) ; Days 1-5: Temozolomide 150-200mg/m2/day orally for 5 days. ; Repeat cycle every 28 days for 6 cycles. 2100
CM0128-iii-c : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Temozolomide (post RT) ; Days 1-5: Temozolomide 150-200mg/m2/day orally for 5 days. ; Repeat cycle every 28 days 2100
CM0128-iii-d : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Temozolomide (200mg) with standard RT ; Days 1-5: Temozolomide 200mg/m2, orally 2100
CM0128-iv : BRAIN CARCINOMA - Systemic Therapy for Adult Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor (PNET) 0
CM0128-iv-a : BRAIN CARCINOMA - Systemic Therapy for Adult Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor (PNET) - Vincristine + cisplatin + lomustine ; Day 1: Lomustine 75mg/m2 orally ; Day 2: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus; ; During Cranio-spinal RT 4400
CM0128-iv-b : BRAIN CARCINOMA - Systemic Therapy for Adult Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor (PNET) - Vincristine + cisplatin + cyclophosphamide ; Day 1: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus ; Days 22, 23: Cyclophosphamide 1,000mg/m2 IV. 5500
CM0128-v : BRAIN CARCINOMA - Primary CNS LymphomaPrimary CNS Lymphoma 0
CM0128-v-a : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate combined with the following plus radiation therapyHigh dose methotrexate combined with the following plus radiation therapy 0
CM0128-v-a-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose Methotrexate + Cytarabine ; Day 1: MTX 3.5g/m2 ; Days 2-3: Cytarabine 2g/m2 IV twice a day. 6600
CM0128-v-a-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose Methotrexate + leucovorin + Ifosfamide + mesna ; Day 1: MTX 4gm/m2 IV, ; Days 2-5: leucovorin 20-25mg IV (upto 40mg) ; Days 3-5: Ifosfamide 1.5gm/m2 IV + mesna 400mg IV 9500
CM0128-v-b : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate combined with the following plus radiation therapy High dose methotrexate (MTX 2.5-4.0mg/m2) + chemotherapy monoclonal antibody 0
CM0128-v-b-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + MTX + vincristine +procarbazine ; Day 1: Rituximab 500mg/m2 IV ; Day 2: MTX 3.5mg/m2 IV plus vincristine 1.4mg/m2 ; Procarbazine 100mg/m2/day administered for 7 days with odd-numbered cycles 41900
CM0128-v-c : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate (MTX 8.0mg/m2) + chemotherapy +/- monoclonal antibody High dose methotrexate (MTX 8.0mg/m2) + chemotherapy monoclonal antibody 0
CM0128-v-c-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Induction ; MTX 8g/m2 IV ; Repeat every 2 weeks until complete response achieved or max of 8 cycles reached. ; 7900
CM0128-v-c-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Consolidation ; MTX 8g/m2 IV administered ; Repeat every 2 weeks for 2 cycles. 7900
CM0128-v-c-3-i : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Maintanance (Cycles 1-4) ; Day 1: MTX 8g/m2 IV, Rituximab 375mg/m2 IV. ; Repeat every 4 weeks for 4 cycles 32400
CM0128-v-c-3-ii : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Maintanance (cycles 5-11) ; MTX 8g/m2 IV administered every 4 weeks for 11 cycles. ; Repeat cycle every 4 weeks for 4 cycles 7900
CM0128-v-d : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + Temozolomide regimen 0
CM0128-v-d-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + Temozolomide regimen - Induction ; Day 1: Rituximab 375mg/m2 IV, followed by ; Days 1-5: Temozolomide 150-200mg/m2 orally daily, after rituximab infusion. ; Repeat cycle every 4 weeks for 4 cycles. 26600
CM0128-v-d-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + Temozolomide regimen - MaintananceDays 1-5: Temozolomide 150-200mg/m2 orally daily. ; Repeat cycle every 4 weeks for 8 cycles. 1600
CM0128-v-e : BRAIN CARCINOMA - Meningioma 0
CM0128-v-e-1 : BRAIN CARCINOMA - Meningioma - Interferon-alfaInterferon-alfa ; alpha-IFN 106 units/m2 SC every other day for 4 weeks. ; Repeat cycle every 4 weeks. ; 6000
CM0128-v-e-2 : BRAIN CARCINOMA - Meningioma -Somatostatin analog ; Sandostatin LAR Depot 10-30mg IM ; Repeat every 4 weeks. ; 5400
CM0128-v-e-3 : BRAIN CARCINOMA - Meningioma - Sunitinib ; Days 1-28: Sunitinib 50mg orally daily. ; Repeat cycle every 42 days. 2900
CM0129 : HEAD AND NECK CANCER 0
CM0129-i : HEAD AND NECK CANCER - Squamous Cell Cancers 0
CM0129-i-a : HEAD AND NECK CANCER - HIgh Dose Cisplatin ; Cisplatin 100mg/m2 IV + concurrent radiotherapy; Repeat cycle every 3 weeks for 3 cycles 2000
CM0129-i-b : HEAD AND NECK CANCER - Carboplatin + infusional 5-FU ; Days 1-4: 5-FU 600mg/m2/day as continuous IV I, carboplatin 70mg/m2/day IV ; Repeat every 3 weeks for 3 cycles (given concurrently with radiotherapy). 4700
CM0129-i-c : HEAD AND NECK CANCER - 5-FU + hydroxyurea ; Day 1: Hydroxyurea 1,000mg orally every 12 hours (11 doses/cycle), 5-FU 800mg/m2/day ; Repeat every other week for 7 cycles. with Concurrent radiotherapy 2300
CM0129-i-d : HEAD AND NECK CANCER - Cisplatin + paclitaxel ; Day 1: Paclitaxel 30mg/m2 IV (every Monday), ; Day 2: Cisplatin 20mg/m2 IV (every Tuesday). ; Repeat cycle every week for 7 cycles, with Concurrent radiotherapy 3400
CM0129-i-e : HEAD AND NECK CANCER - Cisplatin + infusional 5-FU ; Day 1: Cisplatin 60mg/m2 over ; Days 1-5: 5-FU 800mg/m2/day ; Repeat every other week for 7 cycles. with Concurrent radiotherapy 5300
CM0129-i-f : HEAD AND NECK CANCER - Carboplatin + paclitaxel ; Day 1: Paclitaxel 40-45mg/m2, carboplatin 100mg/m2 ; Repeat cycle every week for 8 cycles, with Concurrent radiotherapy 3500
CM0129-i-g : HEAD AND NECK CANCER - Weekly cisplatin ; Cisplatin 40mg/m2 IV per week 1800
CM0129-i-h : HEAD AND NECK CANCER - Cisplatin (For high risk oropharyngeal carcinoma) ; Days 1, 22, and 43: Cisplatin 100mg/m2 IV + radiotherapy. 5300
CM0129-i-i : HEAD AND NECK CANCER - Docetaxel + cisplatin + 5-FU ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV, ; Days 1-5: 5-FU 750mg/m2/day IV. ; Repeat every 3 weeks for up to 4 cycles. 6700
CM0129-i-j : HEAD AND NECK CANCER - Paclitaxel + cisplatin+ infusional 5-FU ; Day 1: Paclitaxel 175mg/m2 ; Day 2: Cisplatin 100mg/m2 ; Day 2-6: 5-FU 500mg/m2/day IV ; Repeat every 3 weeks for 3 cycles. 7900
CM0129-ii : HEAD AND NECK CANCER - Nasopharynx Cancer 0
CM0129-ii-a : Nasopharynx Cancer - Concurrent Cisplatin followed by concurrent Cisplatin +5FUC ; 0
CM0129-ii-a-1 : Nasopharynx Cancer - Concurrent Cisplatin (followed by concurrent Cisplatin +5FU) ; Day 1: Cisplatin 100mg/m2 IV; plus radiotherapy. ; Repeat cycle every 3 weeks for 3 cycles; followed by concurrent Cisplatin +5FU 2000
CM0129-ii-a-2 : Nasopharynx Cancer - concurrent Cisplatin +5FU - Preceeded by (Concurrent Cisplatin 3 cycles) ; Days 1-4: Cisplatin 80mg/m2/day, 5-FU 1,000mg/m2/day IV ; Repeat cycle every 4 weeks for 3 cycles 6700
CM0129-ii-b : Nasopharynx Cancer - Concurrent Carboplatin followed by concurrent Carboplatin +5FU 0
CM0129-ii-b-1 : Nasopharynx Cancer - Concurrent Carboplatin - (followed by concurrent Carboplatin +5FU) ; Day 1: Carboplatin AUC 6mg/min/mL IV. ; Repeat cycle every 3 weeks for 3 cycles; 4300
CM0129-ii-b-2 : Nasopharynx Cancer - concurrent Carboplatin +5FU - Preceeded by (Concurrent Carboplatin ) ; Day 1: Carboplatin AUC 5mg/min/mL IV ; Days 1-4: 5-FU 1,000mg/m2/day IV ; Repeat cycle every 3 weeks for 3 cycles. 13500
CM0129-ii-c : Nasopharynx Cancer - Concurrent Cisplatin ; Cisplatin 40mg/m2 ; Repeat weekly for 7 cycles 1800
CM0129-ii-d : Nasopharynx Cancer - Docetaxel + cisplatin + 5-FU followed by Cisplatin ; 0
CM0129-ii-d-1 : Nasopharynx Cancer - Docetaxel + cisplatin + 5-FU - followed by Cisplatin after 3 cycles ; Day 1: Docetaxel 70mg/m2 IV, cisplatin 75mg/m2 IV ; Days 1-4: 5-FU 1,000mg/m2/day IV ; Repeat every week for 3 cycles 6200
CM0129-ii-d-2 : Nasopharynx Cancer - Cisplatin - weekly - Preceded by 3 cycles of Docetaxel + 5-FU ; Day 1: Cisplatin 100mg/m2; ; Repeat every 3 weeks, Till radiation 2800
CM0129-ii-e : Nasopharynx Cancer - Docetaxel + cisplatin 0
CM0129-ii-e-1 : Nasopharynx Cancer - Docetaxel + cisplatin - followed by Cisplatin after 2 cycles ; Day 1: Docetaxel 75mg/m2 IV + cisplatin 75mg/m2 IV ; Repeat every 3 weeks for two cycles 3900
CM0129-ii-e-2 : Nasopharynx Cancer - Cisplatin - weekly - Preceded by 2 cycles of Docetaxel + cisplatin ; Cisplatin 40mg/m2 IV ; weekly concurrent with radiotherapy. 2300
CM0129-ii-f : Nasopharynx Cancer - Cisplatin + 5-FU ; Day 1: Cisplatin 100mg/m2/day IV. ; Days 1-4: 5-FU 1,000mg/m2/day continuous IV infusion for 4 days. ; Repeat cycle every 3 weeks for a minimum of 6 cycles 5100
CM0129-iii : HEAD AND NECK CANCER (or) Nasopharynx Cancer - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0130 : RENAL CELL CARCINOMARENAL CELL CARCINOMA 0
CM0130-a : Pazopanib 19000
CM0130-b : Sunitinib 29000
CM0130-c : Sorafenib 5800
CM0130-d : Other Regimen 10000
CM0131 : UNKNOWN PRIMARYUNKNOWN PRIMARY 0
CM0131-i : UNKNOWN PRIMARY - Adenocarcinoma 0
CM0131-i-a : UNKNOWN PRIMARY - Adenocarcinoma - Paclitaxel + carboplatin + etoposide ; Day 1: Paclitaxel 200 mg/m 2 IV, carboplatin AUC 6 ; Days 1-10: etoposide 50 mg PO alternating with 100 mg daily ; Repeat every 21days for 2-3 cycles; restage, can be treated upto 8 cycles 8000
CM0131-i-b : UNKNOWN PRIMARY - Adenocarcinoma - Paclitaxel + carboplatin ; Day 1: Paclitaxel 200 mg/m 2, carboplatin AUC 6 ; Repeat cycle every 3 weeks, Maximum 8 cycles 7200
CM0131-i-c : UNKNOWN PRIMARY - Adenocarcinoma - Docetaxel + carboplatin ; Day 1: Docetaxel 65mg/m2 IV, carboplatin AUC 6 ; Repeat cycle every 3 weeks, Maximum 8 cycles. 3800
CM0131-i-d : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + cisplatin ; Day 1: Cisplatin 100mg/m2 IV ; Day 1 and 8: Gemcitabine 1250mg/m2 IV. ; Repeat cycle every 3 weeks for 4 cycles. 5300
CM0131-i-e : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + docetaxel ; Day 1 and 8: Gemcitabine 1000mg/m2 IV over 30 minutes ; Day 8: Docetaxel 75mg/m2 IV ; Repeat cycle every 3 weeks for a maximum of 6 cycles 5800
CM0131-i-f : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + irinotecan ; Days 1 and 8: Irinotecan 100mg/m2 IV, gemcitabine 1000mg/m2 IV. ; Repeat cycle every 3 weeks for 6 cycles.restage every 2-3 cycles 5600
CM0131-ii : UNKNOWN PRIMARY - Squamous cell carcinoma 0
CM0131-ii-a : UNKNOWN PRIMARY - Squamous cell carcinoma - Paclitaxel + cisplatin + 5-FU ; Paclitaxel 175 mg/m 2 IV, ; Day 2: cisplatin 100 mg/m 2 IV, ; Day 5-FU (5-fluorouracil) 500 mg/m 2/day IV ; Repeat every 21d 6200
CM0131-ii-b : UNKNOWN PRIMARY - Squamous cell carcinoma - Docetaxel + cisplatin + 5-FU ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV. ; Days 1-5: 5-FU 750mg/m2/day IV ; Repeat cycle every 3 weeks for 3 cycles. 6800
CM0131-iii : UNKNOWN PRIMARY - Neuroendocrine tumors 0
CM0131-iii-b : UNKNOWN PRIMARY - Neuroendocrine tumors - Etoposide + cisplatin ; Days 1-3: Etoposide 100 mg/m 2 ; Days 2-3: cisplatin 45 mg/m 2 IV ; Repeat every 28 days 5000
CM0131-iv : UNKNOWN PRIMARY - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0132 : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMACA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA 0
CM0132-a : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Gemcitabine + cisplatin ; Days 1 and 8: Cisplatin 25mg/m2 IV, gemcitabine 1,000mg/m2 IV ; Repeat every 21 days for 4 cycles, re-evaluate and continue an additional 4 cycles if warranted 3700
CM0132-b : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - 5-FU ; 5 - FU IV 4100
CM0132-c : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Capecitabine ; Capecitabine oral ; Repeat every 21 days 3600
CM0132-d : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0133 : PANCREAS CARCINOMAPANCREAS CARCINOMA - 0
CM0133-i : PANCREAS CARCINOMA - Patients with resectable pancreatic cancer - Locally Advanced ; 0
CM0133-i-a : PANCREAS CARCINOMA - Patients with resectable pancreatic cancer - Locally Advanced Gemcitabine ; Days 1, 8, and 15: Gemcitabine 1,000mg/m2 IV ; Repeat every 4 weeks for six cycles 6600
CM0133-ii : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation 0
CM0133-ii-a : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - 5-FU + Leucovorin ; Days 1-5: Leucovorin 20mg/m2 IV, 5-FU 425mg/m2 IV ; Repeat cycle every 4 weeks 5000
CM0133-ii-b : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - Gemcitabine & 5FU ; Prior to chemoradiation: ; Days 1, 8 and 15: Gemcitabine 1,000mg/m2 IV; initiate 1-2 weeks prior to chemoradiation (50.4Gy + 5-FU 250mg/m2/day). ; After chemoradiation: ; Days 1, 8 and 15: Gemcitabine 1,000mg/m2 IV; initiate 3-5 weeks following chemoradiation. ; Repeat cycle every 4 weeks for 3 months. 6700
CM0133-ii-c : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - Continuous infusion 5-FU (with Radiation) ; Prior to chemoradiation: ; Days 1-21: 5-FU 250mg/m2/day continuous IV infusion; initiate 1-2 weeks prior to chemoradiation (50.4Gy + 5-FU 250mg/m2/day). ; After chemoradiation: ; Days 1-28: 5-FU 250mg/m2/day continuous IV infusion; initiate 3-5 weeks following chemoradiation. ; Repeat cycle every 6 weeks for 3 months. 20700
CM0133-iii : PANCREAS CARCINOMA - Neoadjuvant therapy - Neoadjuvant therapy 0
CM0133-iii-a : PANCREAS CARCINOMA - Neoadjuvant therapy - CapecitabineCapecitabine ; Capecitabine ; Repeat cycle every 3 weeks for up to 52 weeks. 3600
CM0133-iv : PANCREAS CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0134 : PERI AMPULLARY CARCINOMA 0
CM0134-a : PERI AMPULLARY CARCINOMA - 5-FU ; Fluorouracil 425 mg/m2 administered on days 1 to 5 and 29-33 5300
CM0134-b : PERI AMPULLARY CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0135 : NEURO ENDOCRINE CARCINOMA 0
CM0135-a : NEURO ENDOCRINE CARCINOMA - All NECs are covered under Organ Cancers. If uncovered - Unlisted only. 0
CM0135-b : NEURO ENDOCRINE CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0136 : SARCOMA 0
CM0136-i : SARCOMA - Gastrointestinal Stromal Tumor - GIST 0
CM0136-i-a : SARCOMA - Gastrointestinal Stromal Tumor - GIST - Imatinib ; Imatinib 400mg orally once daily to twice daily 3000
CM0136-ii : SARCOMA - SOFT TISSUE SARCOMA 0
CM0136-ii-a : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin + dacarbazine (AD) ; Days 1-4: Doxorubicin 60mg/m2 + dacarbazine 750mg/m2 ; Repeat cycle every 3 weeks 11500
CM0136-ii-b : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin + ifosfamide + mesna ; Days 1 and 2: Doxorubicin 30mg/m2/day IV, ifosfamide 3,750mg/m2/day IV, mesna 750mg/m2 IV ; Repeat cycle every 3 weeks 9200
CM0136-ii-c : SARCOMA - SOFT TISSUE SARCOMA - Mesna + doxorubicin + ifosfamide + dacarbazine (MAID) ; Days 1-3: Doxorubicin 20mg/m2/day, ifosfamide 2,500mg/m2/day, dacarbazine 300mg/m2/day IV ; Days 1-4: Mesna 2,500mg/m2/day IV for 84 to 96 hours. ; Repeat cycle every 3 weeks. 10700
CM0136-ii-d : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide + epirubicin + mesna ; Days 1 and 2: Epirubicin 60mg/m2/day IV ; Days 1-5: Ifosfamide 1.8g/m2/day IV + mesna. ; Repeat cycle every 3 weeks for 5 cycles. 12800
CM0136-ii-e : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + docetaxel ; Days 1 and 8: Gemcitabine 900mg/m2 IV ; Day 8: Docetaxel 100mg/m2 IV. ; Repeat cycle every 3 weeks 5100
CM0136-ii-f : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + vinorelbine ; Days 1 and 8: Vinorelbine 25mg/m2 IV, gemcitabine 800mg/m2 IV ; Repeat cycle every 3 weeks 14700
CM0136-ii-g : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + dacarbazine ; Day 1: Gemcitabine 1,800mg/m2 IV + dacarbazine 500mg/m2 IV. ; Repeat cycle ever 2 weeks for a total of 12 cycles; 3300
CM0136-ii-h : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin ; Doxorubicin 60-75mg/m2 IV ; once every 3 weeks 2900
CM0136-ii-i : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide ; Days 1-3: Ifosfamide 2,000-3,000mg/m2/day IV for 3 to 4 days + mesna ; Repeat every 3 weeks. 10000
CM0136-ii-j : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide ; Day 1: Ifosfamide 5,000mg/m2 + mesna 5,000mg/m2 IV ; Day 2: mesna 400-600mg/m2 IV ; Ifosfamide, mesna ; Repeat every 3 weeks 1900
CM0136-ii-k : SARCOMA - SOFT TISSUE SARCOMA - Epirubicin ; Epirubicin 160mg/m2 IV ; Repeat every 3 weeks 5900
CM0136-ii-l : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine ; Days 1 and 8: Gemcitabine 1,200mg/m2 IV ; Repeat cycle every 3 weeks. 3600
CM0136-ii-m : SARCOMA - SOFT TISSUE SARCOMA - Dacarbazine (i) ; Dacarbazine 250mg/m2/day IV for 5 days ; Repeat every 3 weeks. 6200
CM0136-ii-n : SARCOMA - SOFT TISSUE SARCOMA - Dacarbazine (ii) ; Dacarbazine 800-1,000mg/m2 IV ; Repeat every 3 weeks. 2400
CM0136-ii-o : SARCOMA - SOFT TISSUE SARCOMA - Liposomal doxorubicin ; Liposomal doxorubicin 30-50mg/m2 IV ; Repeat every 4 weeks. 7900
CM0136-ii-p : SARCOMA - SOFT TISSUE SARCOMA - Temozolomide ; Temozolomide 200mg/m2 orally twice daily for 5 days, followed by 9 doses of 90mg/m2 orally ; Repeat every 4 weeks 4200
CM0136-iii : SARCOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0137 : PRIMITIVE NEURO ECTODERMAL TUMOR 0
CM0137-a : PRIMITIVE NEURO ECTODERMAL TUMOR - Weekly vincristine ; vincristine 1.5mg/m2 IV, max 2mg ; for 5 to 6 weeks 1700
CM0137-b : PRIMITIVE NEURO ECTODERMAL TUMOR - Vincristine + cisplatin + lomustine ; During craniospinal radiotherapy (RT) ; Day 1: Lomustine 75mg/m2 orally ; Day 2: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus; up to max 8 doses 4400
CM0137-c : PRIMITIVE NEURO ECTODERMAL TUMOR - Vincristine + cisplatin + cyclophosphamide ; Day 1: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV, max 2mg ; Days 22, 23: Cyclophosphamide 1,000mg/m2 IV 7600
CM0137-d : PRIMITIVE NEURO ECTODERMAL TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0137-vi : Other Regimen 10000
CM0138 : MELANOMA - No primary regimens only RT. For advanced unresectable and metastatic disease - Pallitive Chemotherapy 10000
CM0139 : ANAL CANAL CANCER 0
CM0139-a : ANAL CANAL CANCER - 5-FU + Mitomycin ; Days 1-4 and 29-32: 5-FU 1,000mg/m2/day IV ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus (maximum 20mg per course), with Concurrent radiotherapy 11400
CM0139-b : ANAL CANAL CANCER - Capecitabine + Mitomycin (i) ; Days 1-5: Capecitabine 825mg/m2 orally twice daily weekly for 6 weeks, ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus, with Concurrent radiotherapy. 8100
CM0139-c : ANAL CANAL CANCER - Capecitabine + Mitomycin (ii) ; Days 1-5: Capecitabine 825mg/m2 orally twice daily weekly for 6 weeks, ; Day 1: Mitomycin 12mg/m2 IV bolus, with Concurrent radiotherapy 6800
CM0139-d : ANAL CANAL CANCER - Cisplatin + 5-FU ; Days 1-5: 5-FU 1,000mg/m2/day IV ; Day 2: Cisplatin 100mg/m2 IV ; Repeat cycle every 4 weeks, with Concurrent radiotherapy 6700
CM0139-e : ANAL CANAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0183 : SURGICAL CORRECTION OF LONGBONE FRACTURE-FRACTURE NECK/ SHAFT OF FEMUR/FRACTURE SHAFT OF OTHER LONG BONES (HUMERUS,BOTH BONES OF FOREARM, BOTH BONES OF LEG) 13138
CM0184 : CORRECTION OF NON-UNION FRACTURES - NON-UNION OF FRACTURE OF FEMUR/BOTH BONE OF LEG/ NON-UNION OF OTHER LONG BONES -HUMERUS/ BOTH BONES OF FOREARM WITH OR WITHOUT BONE GRAFTING 13138
CM0185 : SKELETAL SKULL TRACTION 17921
CM0186A : IMPLANT EXIT- K-WIRES /SCREWS/OTHER MINOR IMPLANTS 4576
CM0186B : IMPLANT EXIT- PLATES (SPINE IMPLANTS/OTHER MAJOR IMPLANT) 12105
CM0187 : ARTHRODESIS OF JOINTS -SHOULDER/ HIP / KNEE /ELBOW/ ANKLE / WRIST / HAND / FOOT 15943
CM0192 : ILIZAROV RING FIXATOR APPLICATION-FEMUR - DEFORMITY CORRECTION / LIMB LENGTHENING/TIBIA - DEFORMITY CORRECTION / LIMB LENGTHENING /PLATING/EXTERNAL FIXATOR/K WIRES 23472
CM0193 : SURGERY FOR NEGLECTED CTEV/RECURRENT CTEV-CTEV CORRECTIVE SURGERY /CTEV PONSETTI CORRECTION (FOLLOW UP PROCEDURES)/CTEV ILIZAROV 26424
CM0195 : KNEE LIGAMENT RECONSTRUCTION-ACL RECONSTRUCTION/PCL RECONSTRUCTION/MPFL RECONSTRUCTION 17715
CM0203 : SURGICAL CORRECTION FOR PELVIC BONE FRACTURES 19043
CM0204 : CORRECTION SACRO ILLIAC JOINT / ACETABULAR FRACTURES 17419
CM0248 : OESOPHAGEAL ATRESIA/INTESTINAL ATRESIA WITHOUT OBSTRUCTION 29525
CM0249 : OESOPHAGEAL ATRESIA/INTESTINAL ATRESIA WITH OBSTRUCTION 29525
CM0250 : BILIARY ATRESIA & CHOLEDOCHAL CYST (INCLUDES OPERATIVE CHOLANGIOGRAM) 29525
CM0251 : ANORECTAL MALFORMATIONS - STAGE 1 /COLOSTOMY 17715
CM0252 : ANORECTAL MALFORMATIONS - STAGE 2/PULLTHROUGH 23620
CM0253 : ANORECTAL MALFORMATION - STAGE 3/CLOSURE 17715
CM0254 A : HIRSCHPRUNGS DISEASE - STAGE 1 24801
CM0254 B : HIRSCHPRUNGS DISEASE - STAGE 2 29525
CM0255 : CONGENITAL HYDRONEPHROSIS 29525
CM0256 : EXSTROPHY BLADDER - STAGE 1/2 32477
CM0257 : POSTERIOR URETHRAL VALVES (VESICOSTOMY / URETEROSTOMY) 17715
CM0258 : POSTERIOR URETHRAL VALVES (CYSTOSCOPIC FULGRATION) 20667
CM0259 : POSTERIOR URETHRAL VALVES (VESICOSTOMY / URETEROSTOMY CLOSURE) 17715
CM0260 : HAMARTOMA EXCISION 11810
CM0261 : HEMANGIOMA EXCISION(INCLUDING MEDICAL MANAGEMENT) 14762
CM0262 : LYMPHANGIOMA EXCISION 23620
CM0263 : NEUROBLASTOMA 26572
CM0264 A : PAEDIATRIC OESOPHAGEAL OBSTRUCTIONS-SURGICAL CORRECTION 17715
CM0264 B : PAEDIATRIC OESOPHAGEAL OBSTRUCTIONS-OESOPHAGEAL SUBSTITUTIONS 35429
CM0266 : THORACOSCOPIC CYST EXCISION 26572
CM0267 : THORACIC DUPLICATION 26572
CM0268 : LAPAROSCOPIC PULL THROUGH FOR ANO RECTAL ANOMALIES 31296
CM0269 : LAPAROSCOPIC PULL THROUGH FOR HD 31296
CM0270 : GASTRIC OUTLET OBSTRUCTIONS 20667
CM0271 : INTERSEX 24801
CM0272 A : SURGICAL CORRECTION FOR URACHAL ANOMALY 23620
CM0272 B : SURGICAL CORRECTION FOR CLOACAL ANOMALY 26572
CM0273 : CONGENITAL UROGENITAL ANOMALY STAGED CORRECTION 26572
CM0274 : BLADDER AUGMENTATION AND SUBSTITUTION 32477
CM0275 A : URETEROSTOMY 23620
CM0275 B : URETEROSTOMY CLOSURE 17715
CM0276 : CONGENITAL LUNG LESIONS (CLE, CCAM) 90000
CM0277 : SURGICAL CORRECTION FOR ANY CONGENITAL ANOMALY 29525
CM0278 : PATENT VITELLO INTESTINAL DUCT 23620
CM0279 A : VUR - CYSTOSCOPY/STING PROCEDURE (INSTILLATION OF HYALURONIC ACID) - UNILATERAL 26572
CM0279 B : VUR - CYSTOSCOPY/STING PROCEDURE (INSTILLATION OF HYALURONIC ACID) - BILATERAL 47239
CM0280 : RECTAL POLYP - POLYPECTOMY 20667
CM0281 : INTESTINAL POLYPOSIS SURGICAL CORRECTION 29525
CM0282 : ENCEPHALOCELE 23620
CM0283 : SCROTAL TRANSPOSITION REPAIR 17715
CM0284 : OPEN CYSTECTOMY 20667
CM0285 : LAP CYSTECTOMY 20667
CM0286 A : NECROTISING ENTEROCOLITIS - FLANK DRAINAGE 14762
CM0286 B : NECROTISING ENTEROCOLITIS - /LAPAROTOMY 23620
CM0287 : CONGENITAL HYDROCELE REPAIR 14762
CM0288 : VULVAL SYNECHIAE 8857
CM0289 : THORACIC/ABDOMINAL WALL DEFECTS -CORRECTION 29525
CM0290 : TUMORS (NEONATES/PAEDIATRICS) 29525
CM0336 : D V T - IVC FILTER 42722
CM0337 : PERIPHERAL EMBOLECTOMY WITHOUT GRAFT 16238
CM0338 : EXCISION OF ARTERIO VENOUS MALFORMATION - SMALL 23472
CM0339 : EXCISION OF ARTERIO VENOUS MALFORMATION - LARGE 43696
CM0340 : ARTERIAL EMBOLECTOMY 16681
CM0341 : VASCULAR TUMORS 23354
CM0342 : SMALL ARTERIAL ANEURYSMS - REPAIR 11219
CM0343 : MEDIUM SIZE ARTERIAL ANEURYSMS - REPAIR 27458
CM0344 : MEDIUM SIZE ARTERIAL ANEURYSMS WITH SYNTHETIC GRAFT 43401
CM0345 : THORACO ABDOMINAL ANEURYSM REPAIR WITH RENO / MESENTRIC REVASCULARISATION 40891
CM0346 : VISCERAL ARTERY ANEURSYM REPAIR / RENAL ARTERY ANEURYSM REPAIR 27015
CM0347A : AORTO - BILLIAC - BIFEMORAL BYPASS WITH VEIN 46796
CM0347B : AORTO - BILLIAC - BIFEMORAL BYPASS WITH SYNTHETIC GRAFT 54768
CM0348 : AXILLO BIFEMORAL BYPASS WITH SYNTHETIC GRAFT 55654
CM0349 : FEMORO DISTAL BYPASS WITH VEIN GRAFT 33215
CM0350 : FEMORO DISTAL BYPASS WITH SYNTHETIC GRAFT 46501
CM0351 : AXILLO BRACHIAL BYPASS USING SYNTHETIC GRAFT 36758
CM0352 : BRACHIO - RADIAL BYPASS WITH SYNTHETIC GRAFT 28196
CM0353 : FEMORO- POPLITEAL BYPASS WITH GRAFT 32920
CM0354 : FEMORO- POPLITEAL BYPASS WITHOUT GRAFT 17862
CM0355 : FEMORO ILEAL BYPASS WITH GRAFT 26720
CM0356 : FEMORO ILEAL BYPASS WITHOUT GRAFT 13729
CM0357 : FEMORO FEMORAL BYPASS WITH GRAFT 26424
CM0358 : FEMORO FEMORAL BYPASS WITHOUT GRAFT 14319
CM0359 : AORTO RENAL BYPASS 29377
CM0360 : AORTO MESENTRIC BYPASS 29377
CM0361 : CAROTID SUBCLAVIAN ARTERY BYPASS WITH SYNTHETIC GRAFT 43844
CM0362 : AXILLO AXILLARY BYPASS WITH SYNTHETIC GRAFT 30263
CM0363 : SUBCLAVIAN SUBCLAVIAN BYPASS WITH SYNTHETIC GRAFT 30853
CM0364 : CAROTID BODY TUMOR - EXCISION 25568
CM0365 : CAROTID ARTERY BYPASS WITH SYNTHETIC GRAFT 54473
CM0366 : SURGERY WITHOUT GRAFT FOR ARTERIAL INJURIES OR VENOUS INJURIES 6348
CM0367 : VASCULAR INJURY IN UPPER LIMBS - AXILLARY, BRANCHIAL, RADIAL AND ULNAR - REPAIR WITH VEIN GRAFT 20077
CM0368 : MAJOR VASCULAR INJURY -REPAIR - LOWER LIMBS(INCLUDING FOOT) 24653
CM0369 : MINOR VASCULAR INJURY REPAIR -LOWER LIMBS (INCLUDING FOOT) 10776
CM0370 : SURGERY WITH VEIN GRAFT 9743
CM0371 : WITH PROSTHETIC GRAFT 23620
CM0372 : NECK VASCULAR INJURY - CAROTID VESSELS 53587
CM0373 : ABDOMINAL VASCULAR INJURIES - AORTA, ILLAC ARTERIES, IVC, ILIAC VEINS 53587
CM0374 : THORACIC VASCULAR INJURIES 53587
CM0375 : VARICOSE VEINS RFA FOR B/L 22143
CM0376 : COVERED STENT PLACEMENT FOR ANEURSYM / MURAL THROMBOSIS- Aorto-illiac 84883
CM0377 : THROMBOLYSIS FOR DEEP VEIN THROMBOSIS (CATHETER DIRECTED THROMBOLYSIS) 0
CM0377A : THROMBOLYSIS FOR DEEP VEIN THROMBOSIS (CATHETER DIRECTED THROMBOLYSIS) - STK 29377
CM0377B : THROMBOLYSIS FOR DEEP VEIN THROMBOSIS (CATHETER DIRECTED THROMBOLYSIS) - RTPA 42958
CM0378 : BRACHIO - BASILIC TRANSPOSITION FOR HEMODIALYSIS ACCESS 12991
CM0379 : VERTEBRAL ARTERY STENTING WITH EMBOLIC PROTECTION DEVICE 41777
CM0380 : END ARTERECTOMY FOR PERIPHERAL ARTERIES / PATCH CLOSURE 0
CM0380A : END ARTERECTOMY FOR PERIPHERAL ARTERIES 20667
CM0380B : END ARTERECTOMY FOR PERIPHERAL ARTERIES / PATCH CLOSURE 23620
CM0381 : END ARTERECTOMY FOR LARGE ARTERIES 29377
CM0382 : THROMBIN INJECTION UNDER DUPLEX GUIDANCE FOR PSEUDOANEURYSM 11219
CM0383 : PSEUDOANEURYSM MANAGEMENT WITH USG COMPRESSION THERAPY 5757
CM0384 : PSEUDOANEURYSM LIGATION 20520
CM0385 : PROFUNDA PLASTY 17862
CM0388 : SYSTEMIC THROMBOLYSIS IN PERIPHERAL ARTERY DISEASE 8857
CM0389 : REDO BYPASS AFTER GRAFT THROMBOSIS 0
CM0389A : REDO BYPASS AFTER GRAFT THROMBOSIS - VEIN GRAFT 29377
CM0389B : REDO BYPASS AFTER GRAFT THROMBOSIS - SYNTHETIC GRAFT 33510
CM0390 : ENDOVASCULAR AORTIC REPAIR 0
CM0390A : ENDOVASCULAR AORTIC REPAIR - WITHOUT PATCH 37201
CM0390B : ENDOVASCULAR AORTIC REPAIR - WITH PATCH 58016
CM0391 : THORACIC ENDOVASCULAR AORTIC REPAIR 0
CM0391A : THORACIC ENDOVASCULAR AORTIC REPAIR - WITHOUT PATCH 54177
CM0391B : THORACIC ENDOVASCULAR AORTIC REPAIR - WITH PATCH 70416
CM0392 : HYBRID / OPEN INCLUDING COVERED STENT PLACEMENT - UNILATERAL 90345
CM0393 : HYBRID / OPEN INCLUDING COVERED STENT PLACEMENT - BILATERAL 115441
CM0394 : TUMOR RESECTION WITH VASCULAR RECONSTRUCTION 39592
CM0395 : GRAFT THROMBECTOMY BYPASS / AV ACCESS SURGERY 12548
CM0396 : SARTORIUS/ GRACILIS MUSCLE FLAP COVER FOR VASCULAR COVER 17272
CM0412 : EXPANSION SPHINTERO PLASTY 10422
CM0413 : ZETA PLASTY 11603
CM0415 : EXISION OF TUMOR IN PHARYNX / PARAPHARYNX (BENIGN) 11987
CM0416 : EXCISION OF TUMOR IN PHARYNX / PARAPHARYNX ( MALIGNANT) 14644
CM0417 : EXCISION OF TUMOR NASAL CAVITY (BENIGN /ANGIOFIBROMA NOSE) 11987
CM0424 : LABYRINTHECTOMY 13138
CM0427 : NASAL BONE FRACTURE REDUCTION 4635
CM0428A : MICRO DEBRIDER 15176
CM0428B : CO-ABLATION TURBINOPASTY 9743
CM0429 : CUT THROAT INJURY NECK - EXPLORATION & REPAIR WITHOUT VASCULAR INTERVENTION 7056
CM0430 : CUT THROAT INJURY NECK - EXPLORATION & REPAIR WITH VASCULAR INTERVENTION 9182
CM0431 : TRANS ORAL LASER EXCISION OF LARYNGEAL TUMOR (TOLMS) - BENIGN 17154
CM0432 : TRANS ORAL LASER EXCISION OF LARYNGEAL TUMOR (TOLMS) - MALIGNANT 19220
CM0433 : EXTERNAL ETHMOIDECTOMY 8887
CM0434 : FRACTURE ZYGOMA OPEN REDUCTION 8887
CM0435 : RADIO FREQUENCY ABLATION OF TONGUE 12016
CM0471 : ECLAMPSIA WITH COMPLICATIONS REQUIRING VENTILATORY SUPPORT 16386
CM0472 : ECLAMPSIA WITH COMPLICATIONS & HELLP SYNDROME 13729
CM0473 : ABRUPTIO-PLACENTA WITH OUT COAGULATION DEFECTS (DIC) 11544
CM0474 : ABRUPTIO-PLACENTA WITH COAGULATION DEFECTS (DIC) 15087
CM0477 : SLINGS WITH MESH REPAIR FOR PROLAPSE 10658
CM0478A : VAULT PROLAPSE ABDOMINAL REPAIR WITHOUT MESH 9477
CM0478B : VAULT PROLAPSE ABDOMINAL REPAIR WITH MESH 10068
CM0480 : LAPAROSCOPIC MYOMECTOMY 12430
CM0481 A : RECANALISATION ANY TYPE- open 8592
CM0481 B : RECANALISATION ANY TYPE- lap 11249
CM0482 : STAGING LAPROTOMY FOR OVARIAN AND UTERINE CA 15943
CM0484 : LAPAROSCOPIC SLING OPERATIONS 13906
CM0485A : PPH SURGICAL MANAGEMENT - HYSTERECTOMY 11249
CM0485B : PPH SURGICAL MANAGEMENT -LIGATION/ EMBOLIZATION 9477
CM0487 : ACUTE MI (CONSERVATIVE MANAGEMENT WITHOUT ANGIOGRAM) 18000
CM0488 : ACUTE MI (CONSERVATIVE MANAGEMENT WITH ANGIOGRAM) 27000
CM0489 : ACUTE MI WITH CARDIOGENIC SHOCK 32400
CM0490 : ACUTE MI REQUIRING IABP PUMP 48600
CM0491 : CONGESTIVE CARDIAC FAILURE 45000
CM0492 : INFECTIVE ENDOCARDITIS 27000
CM0493 : PULMONARY EMBOLISM 36000
CM0494 : ARRYTHMIAS (SUPRAVENTRICULLAR / VENTRICULAR) - INVASIVE MANAGEMENT 90000
CM0496 : PERICARDIAL EFFUSION/TAMPONADE 27000
CM0497 : CARDIAC CATHETERISATION AND RIGHT & LEFT HEART STUDY 13500
CM0498A : PROSTHETIC VALVE THROMBOSIS- THROMBOLYSIS - FOR SK 21600
CM0498B : PROSTHETIC VALVE THROMBOSIS- THROMBOLYSIS - FOR RTPAS 52200
CM0498-A : PROSTHETIC VALVE THROMBOSIS- THROMBOLYSIS - FOR SK 9300
CM0498-B : PROSTHETIC VALVE THROMBOSIS- THROMBOLYSIS - FOR RTPAS 28934
CM0499 : TENECTEPLASE/TPA ADDITIONAL FOR MI MANAGEMENT 31500
CM0547A : RT. HEPATECTOMY. 37496
CM0547B : NON ANATOMICAL RESECTION OF LIVER 23620
CM0548A : LT. HEPATECTOMY 37496
CM0548B : NON ANATOMICAL RESECTION OF LIVER 23620
CM0549 : SPLENORENAL ANASTOMOSIS 35429
CM0550 : SURGERY FOR BLEEDING ULCERS 23620
CM0551 : I STAGE-SUB TOTAL COLECTOMY + ILEOSTOMY 35429
CM0552 : II STAGE - J-POUCH 20667
CM0553 : III STAGE-ILEOSTOMY CLOSURE 12991
CM0554 A : HEPATICO JEJUNOSTOMY - BILIARY STRICTURE 44287
CM0554 B : HEPATICO JEJUNOSTOMY - INJURY / EXTERNAL BILIARY FISTULA MANAGEMENT 26572
CM0555A : BILIARY PANCREATITIS - CBD CALCULI - OTHER STENTS 12991
CM0555B : BILIARY PANCREATITIS - CBD CALCULI - SEMS 20667
CM0556 : REPAIR SURGERY FOR INJURIES DUE TO FB 29525
CM0557A : SURGICAL REMOVAL OF FOREIGN BODY FROM GIT (INVASIVE) 29525
CM0557B : SURGICAL REMOVAL OF FOREIGN BODY FROM GIT (NON INVASIVE ) 11810
CM0558 : GASTRO STUDY FOLLOWED BY THORACOTOMY & SURGICAL MANAGEMENT FOR OESOPHAGEAL INJURY FOR CORROSIVE INJURIES/FB 32772
CM0559 : HAEMANGIOMA SOL LIVER HEPATECTOMY + WEDGE RESECTION 23620
CM0560 : LIENORENAL SHUNT 35429
CM0563A : ANAL SPHINCTER RECONSTRUCTION 20667
CM0563B : LEVATOROPLASTY 23620
CM0564 : GRACILOPLASTY 23620
CM0565 : BILIARY PERITONITIS -EMERGENCY LAPAROTOMY 23620
CM0566 : SPLEEN SPARING DEVASCULARISATION 23620
CM0567 : LIVER SEGMENTECTOMY 26572
CM0568 : PORTOCAVAL ANASTOMOSIS 47239
CM0569 : DEVASCULARISATION WITH OESOPHAGEAL TRANSECTION 47239
CM0570 : WARREN SHUNT 35429
CM0571 : PANCREAS DIVISUM 17715
CM0615-II : CAROTID EMBOLECTOMY 28845
CM0616-II : PULMONARY EMBOLECTOMY WITH IVC FILTER 43401
CM0617-II : RENAL ANGIOPLASTY 33510
CM0618-II : VERTERBRAL ANGIOPLASTY 37053
CM0619 : EXISION OF TUMORS IN NASOPHARYNX (BENIGN ) 12341
CM0620-I : EXCISION OF TUMOR IN NASOPHARYNX( MALIGNANT) 12341
CM0620-II : EXCISION OF TUMOR IN NASOPHARYNX( MALIGNANT) 12341
CM0621-I : ENDOSCOPIC DCR 9123
CM0624-I : WERTHEIMS / RADICAL HYSTERECTOMY 16858
CM0624-II : WERTHEIMS / RADICAL HYSTERECTOMY 16858
CM0625-I : AMPUTATIONS - FORE QUARTER / HIND QUARTER WITH OR WITHOUT HEMIPELVECTOMY 23620
CM0625-II : AMPUTATIONS - FORE QUARTER / HIND QUARTER WITH OR WITHOUT HEMIPELVECTOMY 23620
CM0628-II : NEPHROSTOMY 4724
CM0629-I : OBSCURE/ NON VARICEAL BLEED- CLIPPING / ARGON PLASMA COAGULATION/ INJECTION/CONSERVATIVE 27251
CM0629-II : OBSCURE/ NON VARICEAL BLEED- CLIPPING / ARGON PLASMA COAGULATION/ INJECTION/CONSERVATIVE 27251
CM0632-I : FULL THICKNESS BUCCAL MUCOSAL RESECTION & RECONSTRUCTION 24712
CM0633-I : ORBITAL EXENTERATION/ EVISCERATION WITH IMPLANT 13965
CM0635-I : OPEN PROSTATECTOMY 17715
CM0636-I : RADICAL PROSTATECTOMY 29525
CM0640 : USG GUIDED MAJOR PROCEDURES ( EG. LIVER ABSCESS,POST OP COLLECTIONS)DRAINAGE PIGTAIL INSERTION 5610
CM0641A-I : USG GUIDED MAJOR PROCEDURES (RF ABLATION Solid organs) 17124
CM0641B-I : USG GUIDED MAJOR PROCEDURES (RF ABLATION other organs ) 14762
CM0641C-I : USG GUIDED MAJOR PROCEDURES (ETHANOL ABLATION Solid organs) 12696
CM0641D-I : USG GUIDED MAJOR PROCEDURES (ETHANOL ABLATION other organs) 23029
CM0642 : USG GUIDED MINOR PROCEDURES (FNAC, BIPOSY, SINOGRAPHY,TAPPING) 0
CM0642A-I : USG GUIDED MINOR PROCEDURES (FNAC & BIPOSY) 886
CM0642B-I : USG GUIDED MINOR PROCEDURES (SINOGRAPHY) 1181
CM0642C-I : USG GUIDED MINOR PROCEDURES (TAPPING) 886
CM0643-II : RENAL ARTERY EMBOLIZATION WITH MULTIPLE COILS AND MICRO CATHETER 56244
CM0644-II : EMBOLIZATION OF AV MALFORMATION OF PERIPHERAL EXTREMITY, CRANIOFACIAL AND VISCERAL PER SITTING 39415
CM0645-II : GASTROINTESTINAL VISCERAL ARTERIAL EMBOLIZATION IN UPPER AND LOWER GASTROINTESTINAL BLEEDING WITH MICROCATHETER 45025
CM0645-III : GASTROINTESTINAL VISCERAL ARTERIAL EMBOLIZATION IN UPPER AND LOWER GASTROINTESTINAL BLEEDING WITH MICROCATHETER 45025
CM0646-II : BRONCHIAL ARTERY EMBOLIZATION IN HEMOPTYSIS USING PVA AND MICRO CATHETER 32920
CM0647-II : EMBOLIZATION OF POSTOPERATIVE/ POST TRAUMATIC BLEEDING 48273
CM0648-II : UTERINE ARTERY EMBOLIZATION IN SEVERE MENORRHAGIA SECONDARY TO PPH/UTERINE FIBROIDS / AVM 31148
CM0649-II : PREOPERATIVE PORTAL VEIN EMBOLIZATION FOR LIVER TUMORS 41482
CM0649-III : PREOPERATIVE PORTAL VEIN EMBOLIZATION FOR LIVER TUMORS 41482
CM0650-II : EMBOLIZATION OF PULMONARY AV MALFORMATION 43253
CM0652-II : EMBOLIZATION OF CARATICO-CAVERNOUS FISTULA 54768
CM0653-II : PLAIN SIMPLE COILING OF ANEURYSM 28196
CM0654-II : BRAIN AVM EMBOLIZATION 57720
CM0655-II : TUMOR EMBOLIZATION 49454
CM0656-II : PERIPHERAL AVM EMBOLIZATION 45320
CM0657-II : TRANS ARTERIAL CHEMOEMBOLIZATION 54177
CM0658-II : HEAD AND NECK TUMOR EMBOLIZATION 43549
CM0659-II : PSEUDOANEURYSM EMBOLIZATION 27015
CM0660-II : PROSTATIC ARTERY EMBOLIZATION 25539
CM0661-A-III : SPINAL AVM EMBOLIZATION 28786
CM0661-B-III : SPINAL AVM EMBOLIZATION 34691
CM0662-III : SPINAL DURAL FISTULA EMBOLIZATION 36463
CM0663 : BALLOON RETERO GRADE VARICEAL EMBOLIZATION 33510
CM0664-II : LIVER HEMANGIOMA EMBOLIZATION 47682
CM0668-II : SUPERFICIAL FEMORAL ARTERY ANGIOPLASTY ANY STENTING 63330
CM0669-II : FISTULA SALVAGE ANGIOPLASTY 43253
CM0670-II : CAROTID ARTERY STENTING WITH EMBOLIC PROTECTION DEVICE 78388
CM0671-II : ILIAC / IVC STENTING / HIGH END VASCULAR REVASCULARISATION PROCEDURE 65102
CM0672-II : VENOUS / POLY TETRA FLUORO ETHYLENE PATCH ANGIOPLASTY 33806
CM0673-II : SUBCLAVIAN, ILIAC, SUPERFICIAL FEMORAL ARTERY STENTING EACH WITH ONE STENT 61854
CM0674-II : TIBIAL ANGIOPLASTY IN CRITICAL LIMB ISCHEMIA 55063
CM0675-II : MESENTERIC ARTERY ANGIOPLASTY & STENTING IN ACUTE & CHRONIC MESENTERIC ISCHEMIA - SINGLE STENT 55063
CM0676-II : CENTRAL VENOUS STENTING FOR CENTRAL VENOUS OCCLUSION (BRACHIOCEPHALIC, SUBCLAVIAN VEIN AND SUP VENA CAVA) SINGLE METALLIC STENT 58016
CM0679-II : PERIPHERAL STENT GRAFT FOR PERIPHERAL ANEURYSMS AND AV FISTULA 72778
CM0680-II : PERIPHERAL ANGIOPLASTY 34396
CM0681-II : PERIPHERAL ANGIOPLASTY AND STENTING 37348
CM0682-II : SVC ANGIOPLASTY AND STENTING 62297
CM0683-II : IVC ANGIOPLASTY 37496
CM0684-II : IVC ANGIOPLASTY AND STENTING 64659
CM0685-II : BELOW KNEE ANGIOPLASTY 31444
CM0686-II : SUBCLAVIAN ANGIOPLASTY STENTING 64216
CM0687-II : RENAL ANGIOPLASTY STENTING 35282
CM0689-I : HEPATIC VEIN ANGIOPLASTY AND STENTING 31148
CM0689-III : HEPATIC VEIN ANGIOPLASTY AND STENTING 31148
CM0690-II : CENTRAL VEIN STENOSIS ANGIOPLASTY 62001
CM0692-II : ACUTE STROKE THROMBOLYSIS (R TPA ) 44434
CM0693-II : INFERIOR VENA CAVA FILTER PLACEMENT 46353
CM0694-I : BILIARY DRAINAGE PROCEDURES/ERCP - EXTERNAL DRAINAGE AND STENT PLACEMENT - METALLIC BILIARY STENT / POST OP BILIARY STRICTURE/LEAK/CHOLANGITIS/BILIARY PANCREATITIS/CHOLEDOCHAL CYST/BILE DUCT STONES 55181
CM0695-II : CAROTID STENTING SINGLE STENT WITH EMBOLIC PROTECTION DEVICE 66578
CM0706-I : EXCISION OF LINGUAL THYROID 12135
CM0709 A-I : LAP NEPHRECTOMY SIMPLE/HEMI/PARTIAL. 26572
CM0709 A-II : LAP NEPHRECTOMY SIMPLE/HEMI/PARTIAL. 26572
CM0709 B-I : LAP NEPHRECTOMY-RADICAL 26572
CM0709 B-II : LAP NEPHRECTOMY-RADICAL 26572
CM0710 A-II : NEPHROURETERECTOMY OPEN 23620
CM0710 B-II : NEPHROURETERECTOMY LAP 23620
CM0713-I : TRACHEOSTOMY 2982
CM0714-I : THOROCOSTOMY 25627
CM0722-II : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MANDIBLE, MAXILLA 11839
CM0723-I : HEAD & NECK CANCER COMPOSITE RESECTION 22055
CM0724-I : HEAD & NECK CANCER COMPOSITE RESECTION WITH RECONSTRUCTION 27664
CM0725-I : SKIN TUMOR/SOFT TISSUE/BONE TUMORS - EXCISION / AMPUTATION/RESECTION WITH RECONSTRUCTION 14556
CM0725-III : SKIN TUMOR/SOFT TISSUE/BONE TUMORS - EXCISION / AMPUTATION/RESECTION WITH RECONSTRUCTION 14556
CM0725-IV : SKIN TUMOR/SOFT TISSUE/BONE TUMORS - EXCISION / AMPUTATION/RESECTION WITH RECONSTRUCTION 14556
CM0729-II : DIAPHRAGMATIC HERNIA 23620
CM0730 A-II : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - U/L OPEN 23620
CM0730 B-II : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - U/L LAP 23620
CM0730 C-II : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - B/L OPEN 32477
CM0730 D-II : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - B/L LAP 32477
CM0731-I : HYPOSPADIAS 17715
CM0732-I : EPISPADIAS 24801
CM0733-I : TORSION TESTIS 14762
CM0734-I : URETEROCELE SURGERY 17715
CM0734-II : URETEROCELE SURGERY 17715
CM0735 A-I : OPEN CHOLECYSTECTOMY- RADICAL WITH OR WITHOUT CBD EXPLORATION 29525
CM0735 A-II : OPEN CHOLECYSTECTOMY- RADICAL WITH OR WITHOUT CBD EXPLORATION 29525
CM0735 B-I : OPEN CHOLECYSTECTOMY- ANY TYPE/ CBD EXPLORATION 12991
CM0735 B-II : OPEN CHOLECYSTECTOMY- ANY TYPE/ CBD EXPLORATION 12991
CM0736 A-I : LAP CHOLECYSTECTOMY- RADICAL WITH /WITHOUT CBD EXPLORATION 29525
CM0736 A-II : LAP CHOLECYSTECTOMY- RADICAL WITH /WITHOUT CBD EXPLORATION 29525
CM0736 B-I : LAP CHOLECYSTECTOMY- ANY TYPE/ CBD EXPLORATION 12991
CM0736 B-II : LAP CHOLECYSTECTOMY- ANY TYPE/ CBD EXPLORATION 12991
CM0737-I : LAP CHOLECYSTOSTOMY WITH /WITHOUT EXPLORATION CBD 12991
CM0737-II : LAP CHOLECYSTOSTOMY WITH /WITHOUT EXPLORATION CBD 12991
CM0738-I : OPEN CHOLECYSTOSTOMY 11810
CM0738-II : OPEN CHOLECYSTOSTOMY 11810
CM0739-I : GASTRECTOMY ANY TYPE - ANY CAUSE 23531
CM0739-II : GASTRECTOMY ANY TYPE - ANY CAUSE 23531
CM0739-III : GASTRECTOMY ANY TYPE - ANY CAUSE 23531
CM0740-I : GASTRECTOMY ANY TYPE - ANY CAUSE WITH LYMPHADENECTOMY 28845
CM0740-II : GASTRECTOMY ANY TYPE - ANY CAUSE WITH LYMPHADENECTOMY 28845
CM0740-III : GASTRECTOMY ANY TYPE - ANY CAUSE WITH LYMPHADENECTOMY 28845
CM0741-A : PENECTOMY- PARTIAL WITHOUT PERINEAL URETHEROSTOMY -CA 9212
CM0741-B : PENECTOMY- Total WITHOUT PERINEAL URETHEROSTOMY -CA 14378
CM0742A : PENECTOMY- PARTIAL WITH PERINEAL URETHEROSTOMY -CA 17449
CM0742B : PENECTOMY- TOTAL WITH PERINEAL URETHEROSTOMY -CA 23531
CM0743-I : ANTERIOR RESECTION 30026
CM0743-II : ANTERIOR RESECTION 30026
CM0743-III : ANTERIOR RESECTION 30026
CM0744-A-I : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH 14497
CM0744-A-II : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH 14497
CM0744-A-III : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH 14497
CM0744-B-I : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH /ILEOSTOMY 28964
CM0744-B-II : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH /ILEOSTOMY 28964
CM0744-B-III : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH /ILEOSTOMY 28964
CM0744-C-I : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH/ WITH STAPLED ANASTOMOSIS 44021
CM0744-C-II : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH/ WITH STAPLED ANASTOMOSIS 44021
CM0744-C-III : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH/ WITH STAPLED ANASTOMOSIS 44021
CM0745-I : ABDOMINOPERINIAL RESECTION 23236
CM0745-II : ABDOMINOPERINIAL RESECTION 23236
CM0745-III : ABDOMINOPERINIAL RESECTION 23236
CM0746A-I : SPLENECTOMY WITHOUT DEVASCULARISATION -TRAUMATIC 20667
CM0746A-II : SPLENECTOMY WITHOUT DEVASCULARISATION -TRAUMATIC 20667
CM0749A-I : NECK DISSECTION ANY TYPE - WITH WIDE EXCISION (INCLUDING MALIGNANCY) 17921
CM0749B-I : NECK DISSECTION ANY TYPE - WITHOUT WIDE EXCISION (INCLUDING MALIGNANCY) 12016
CM0750-A-I : NECK DISSECTION ANY TYPE - WITHOUT RECONSTRUCTION (INCLUDING MALIGNANCY) 15264
CM0750-B-I : NECK DISSECTION ANY TYPE - WITH RECONSTRUCTION (INCLUDING MALIGNANCY) 20579
CM0751-I : HEMIMANDIBULECTOMY 14851
CM0751-IV : HEMIMANDIBULECTOMY 14851
CM0752-I : MARGINAL MANDIBULECTOMY 13257
CM0752-IV : MARGINAL MANDIBULECTOMY 13257
CM0753-I : SEGMENTAL MANDIBULECTOMY 13257
CM0753-IV : SEGMENTAL MANDIBULECTOMY 13257
CM0754 : LEIOMYOMA EXCISION 7086
CM0755 : MULTI ORGAN RESECTION FOR ANY GI CANCERS 39710
CM0756 : SURGERIES FOR ENTERO CUTANEOUS FISTULA 23620
CM0757 : INCISIONAL HERNIA REPAIR WITHOUT MESH 11810
CM0758 : INCISIONAL HERNIA REPAIR WITH MESH 14762
CM0760-I : LIVER ABSCESS - OPEN DRAINAGE 10629
CM0760-II : LIVER ABSCESS - OPEN DRAINAGE 10629
CM0763A-I : RECTAL PROLAPSE - THEIRSCH WIRING 8857
CM0763A-II : RECTAL PROLAPSE - THEIRSCH WIRING 8857
CM0763B-I : RECTAL PROLAPSE - DEBULKING 15353
CM0763B-II : RECTAL PROLAPSE - DEBULKING 15353
CM0763C-I : RECTAL PROLAPSE - LAPAROSCOPIC RECTOPEXY 15353
CM0763C-II : RECTAL PROLAPSE - LAPAROSCOPIC RECTOPEXY 15353
CM0764B : SPLENECTOMY WITH DEVASCULARISATION -TRAUMATIC 22439
CM0764 : GLOSSECTOMY (TOTAL/HEMI/PARTIAL) FOR CANCER 11515
CM0765 : GLOSSECTOMY (TOTAL/HEMI/PARTIAL) WITH RECONSTRUCTION- FOR CANCER 23531
CM0766 : MAXILLECTOMY ANY TYPE -FOR CA 14762
CM0767 : PAROTIDECTOMY ANY TYPE- FOR CA 11515
CM0768 : LARYNGECTOMY ANY TYPE -FOR CA 21405
CM0769-I : LARYNGO PHARYNGO OESOPHAGECTOMY 43696
CM0770 A-I : TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE 24801
CM0770 A-II : TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE 24801
CM0770 A-III : TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE 24801
CM0770 B-I : SUB TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE 19486
CM0770 B-II : SUB TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE 19486
CM0770 B-III : SUB TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE 19486
CM0771-I : WHIPPLES ANY TYPE 48715
CM0771-II : WHIPPLES ANY TYPE 48715
CM0771-III : WHIPPLES ANY TYPE 48715
CM0772A-I : OPEN CYSTECTOMY(/PARTIAL/ COMPLETE) WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 20667
CM0772A-II : OPEN CYSTECTOMY(/PARTIAL/ COMPLETE) WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 20667
CM0772B-I : OPEN CYSTECTOMY(RADICAL )WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 26572
CM0772B-II : OPEN CYSTECTOMY(RADICAL )WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 26572
CM0773 A-I : LAPAROSCOPIC CYSTECTOMY [PARTIAL / COMPLETE] WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 20667
CM0773 A-II : LAPAROSCOPIC CYSTECTOMY [PARTIAL / COMPLETE] WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 20667
CM0773 B-I : LAPAROSCOPIC CYSTECTOMY [RADICAL ]WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 26572
CM0773 B-II : LAPAROSCOPIC CYSTECTOMY [RADICAL ]WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 26572
CM0774 : LAPROSCOPIC ASSISTED VAGINAL HYSTERECTOMY 11839
CM0775-I : SALPINGO OOPHORECTOMY U/L OR B/L- FOR CA 14969
CM0775-II : SALPINGO OOPHORECTOMY U/L OR B/L- FOR CA 14969
CM0776-I : MASTECTOMY ANY TYPE 11810
CM0776-II : MASTECTOMY ANY TYPE 11810
CM0777-I : MASTECTOMY ANY TYPE WITH AXILLARY DISSECTION / SENTINAL NODE EXPLORATION 0
CM0777-II : MASTECTOMY ANY TYPE WITH AXILLARY DISSECTION / SENTINAL NODE EXPLORATION 0
CM0777-A-I : MASTECTOMY ANY TYPE WITH AXILLARY DISSECTION 14762
CM0777-A-II : MASTECTOMY ANY TYPE WITH AXILLARY DISSECTION 14762
CM0777-B-I : MASTECTOMY ANY TYPE WITH SENTINAL NODE EXPLORATION 14762
CM0777-B-II : MASTECTOMY ANY TYPE WITH SENTINAL NODE EXPLORATION 14762
CM0778-I : WIDE EXICISION/ LUMPECTOMY - TUMORS OF BREAST (BENIGN /MALIGNANT) 0
CM0778-II : WIDE EXICISION/ LUMPECTOMY - TUMORS OF BREAST (BENIGN /MALIGNANT) 0
CM0778-A-I : WIDE EXICISION/ LUMPECTOMY - TUMORS OF BREAST -BENIGN 2893
CM0778-A-II : WIDE EXICISION/ LUMPECTOMY - TUMORS OF BREAST -BENIGN 2893
CM0778-B-I : WIDE EXICISION/ LUMPECTOMY - TUMORS OF BREAST (MALIGNANT) 3838
CM0778-B-II : WIDE EXICISION/ LUMPECTOMY - TUMORS OF BREAST (MALIGNANT) 3838
CM0785-I : METASTATECTOMY SOLITARY OR MULTIPLE - ANY CAUSE 22055
CM0785-II : METASTATECTOMY SOLITARY OR MULTIPLE - ANY CAUSE 22055
CM0786-A-I : OPERATIONS OF ADRENAL GLAND - U/L( ANY CAUSE) 14733
CM0786-A-II : OPERATIONS OF ADRENAL GLAND - U/L( ANY CAUSE) 14733
CM0786-B-I : OPERATIONS OF ADRENAL GLAND - B/L ( ANY CAUSE) 26661
CM0786-B-II : OPERATIONS OF ADRENAL GLAND - B/L ( ANY CAUSE) 26661
CM0789-I : STERNOTOMY + MEDIASTINAL DISSECTION - CA / SOL 24535
CM0795-I : PARATHYROIDECTOMY - ANY TYPE 14762
CM0796-I : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - SMALL INTESTINE- ANY CAUSE 23620
CM0796-II : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - SMALL INTESTINE- ANY CAUSE 23620
CM0796-III : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - SMALL INTESTINE- ANY CAUSE 23620
CM0797-I : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - LARGE INTESTINE- ANY CAUSE 26572
CM0797-II : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - LARGE INTESTINE- ANY CAUSE 26572
CM0797-III : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - LARGE INTESTINE- ANY CAUSE 26572
CM0798-I : GASTROSTOMY/FEEDING GASTROSTOMY/PERCUTANEOUS ENDOSCOPIC GASTROSTOMY 11810
CM0798-II : GASTROSTOMY/FEEDING GASTROSTOMY/PERCUTANEOUS ENDOSCOPIC GASTROSTOMY 11810
CM0798-III : GASTROSTOMY/FEEDING GASTROSTOMY/PERCUTANEOUS ENDOSCOPIC GASTROSTOMY 11810
CM0799-I : OESOPHAGOSTOMY 14762
CM0799-II : OESOPHAGOSTOMY 14762
CM0800-I : JEJUNOSTOMY / FEEDING JEJUNOSTOMY 11810
CM0800-II : JEJUNOSTOMY / FEEDING JEJUNOSTOMY 11810
CM0801-I : GASTROJEJUNOSTOMY 14762
CM0801-II : GASTROJEJUNOSTOMY 14762
CM0802-I : ILEOSTOMY 11810
CM0802-II : ILEOSTOMY 11810
CM0803 A-I : ILEOTRANSVERSE COLOSTOMY 14762
CM0803 A-II : ILEOTRANSVERSE COLOSTOMY 14762
CM0803 A-III : ILEOTRANSVERSE COLOSTOMY 14762
CM0803 B-I : COLOSTOMY 11810
CM0803 B-II : COLOSTOMY 11810
CM0803 B-III : COLOSTOMY 11810
CM0804-I : HARTMANNS PROCEDURE WITH COLOSTOMY- ANY CAUSE 26572
CM0804-II : HARTMANNS PROCEDURE WITH COLOSTOMY- ANY CAUSE 26572
CM0805-I : CLOSURE OF GASTROSTOMY/ILEOSTOMY/COLOSTOMY / JEJUNOSTOMY / GASTROJEJUNOSTOMY / ILEOTRANSVERSE COLOSTOMY / OESOPHAGOSTOMY 11810
CM0805-II : CLOSURE OF GASTROSTOMY/ILEOSTOMY/COLOSTOMY / JEJUNOSTOMY / GASTROJEJUNOSTOMY / ILEOTRANSVERSE COLOSTOMY / OESOPHAGOSTOMY 11810
CM0805-III : CLOSURE OF GASTROSTOMY/ILEOSTOMY/COLOSTOMY / JEJUNOSTOMY / GASTROJEJUNOSTOMY / ILEOTRANSVERSE COLOSTOMY / OESOPHAGOSTOMY 11810
CM0806-I : RESECTION OF RETRO PERITONEAL TUMORS 26306
CM0806-II : RESECTION OF RETRO PERITONEAL TUMORS 26306
CM0807 : BONE RESECTION / CURRETTAGE/ CEMENTING- ANY CAUSE 17715
CM0809 : SUPRA PUBIC CYSTOSTOMY 4724
CM0810-II : INTERCOSTAL DRAINAGE 2421
CM0811 : CRYOTHERAPY FOR ALL LESIONS 13434
CM0814-I : VASCULAR MALFORMATIONS- (INCLUDING SCLEROTHERAPY/ REDUCTION SURGERY) 15500
CM0820-I : AMPUTATION OF ANY SITE / ANY CAUSE WITHOUT PROSTHESIS (except fingers, toes and small joints) 14762
CM0820-II : AMPUTATION OF ANY SITE / ANY CAUSE WITHOUT PROSTHESIS (except fingers, toes and small joints) 14762
CM0820-III : AMPUTATION OF ANY SITE / ANY CAUSE WITHOUT PROSTHESIS (fingers, toes and small joints) 5905
CM0821-I : AMPUTATION OF ANY SITE / ANY CAUSE WITH CUSTOM MADE PROSTHESIS (except fingers, toes and small joints) 100000
CM0821-II : AMPUTATION OF ANY SITE / ANY CAUSE WITH CUSTOM MADE PROSTHESIS (except fingers, toes and small joints) 100000
CM0821-III : AMPUTATION OF ANY SITE / ANY CAUSE WITH CUSTOM MADE PROSTHESIS (fingers, toes and small joints) 50000
CM0822 A-I : SOFT TISSUE INJURY - LACERATION (SUTURING) /WOUND DEBRIDEMENT 354
CM0822 B-I : SOFT TISSUE INJURY - DEEP WOUND [NERVE/TENDON REPAIR] 2952
CM0827-II : SEVERE MYOCARDITIS/CONGENITAL HEART DISEASE PRESENTING WITH OR WITHOUT / INFECTION / FAILURE / CARDIOGENIC SHOCK / SEPTIC SHOCK / INFECTIVE ENDOCARDITIS/ CYANOTIC SPELL - NON VENTILATED 23620
CM0828-II : SEVERE MYOCARDITIS/CONGENITAL HEART DISEASE PRESENTING WITH OR WITHOUT / INFECTION / FAILURE / CARDIOGENIC SHOCK / SEPTIC SHOCK / INFECTIVE ENDOCARDITIS/ CYANOTIC SPELL - VENTILATED 29525
CM0851A-II : CHEST WALL RESECTION WITHOUT RECONSTRUCTION 23531
CM0851B-II : CHEST WALL RESECTION WITH RECONSTRUCTION 30912
CM0854 A-I : ORCHIDECTOMY /HIGH ORCHIDECTOMY U/L 7086
CM0854 A-III : ORCHIDECTOMY /HIGH ORCHIDECTOMY U/L 7086
CM0855 B-I : ORCHIDECTOMY /HIGH ORCHIDECTOMY B/L 8857
CM0855 C : LAPAROSCOPIC VARICOCELE LIGATION (PAEDIATRIC) 14762
CM0857 : SURGERY OF CORD TUMORS - INTRA MEDULLARY TUMORS 34703
CM0858 : SURGERY OF CORD TUMORS -INTRADURAL EXTRAMEDULLARY TUMOR 27027
CM0859 : SURGERY OF CORD TUMORS - EXTRADURAL TUMOR 27027
CM0860 : SPILT CORD MALFORMATIONS - ANY TYPE(INCLUDES SPINA BIFIDA MAJOR/MINOR) 15382
CM0861-I : POSTERIOR DISCECTOMY WITH OR WITHOUT BONE GRAFT/SPACER/IMPLANT/VERTEBROPLASTY ( FOR CERVICAL COMPRESSIVE MYELOPATHY/ AT ANY LEVELS) 25480
CM0861-II : POSTERIOR DISCECTOMY WITH OR WITHOUT BONE GRAFT/SPACER/IMPLANT/VERTEBROPLASTY ( FOR CERVICAL COMPRESSIVE MYELOPATHY/ AT ANY LEVELS) 25480
CM0862 : ANTERIOR DISCECTOMY (WITH OR WITHOUT BONE GRAFTING/SPACER/IMPLANT/VETEBROPLASTY ) ANY LEVEL 25480
CM0863 : ANTERIOR CERVICAL SPINE SURGERY WITH FUSION 23649
CM0864 : ANTERIOR LATERAL DECOMPRESSION/STABILSIATION 14201
CM0865-I : LAMINECTOMY AT ANY LEVEL - (INCLUDING LUMBAR LAMINECTOMY FOR LUMBAR CANAL STENOSIS)- MICROLUMBAR 20697
CM0865-II : LAMINECTOMY AT ANY LEVEL - (INCLUDING LUMBAR LAMINECTOMY FOR LUMBAR CANAL STENOSIS)- MICROLUMBAR 20697
CM0866-I : LAMINECTOMY AT ANY LEVEL - (INCLUDING LUMBAR LAMINECTOMY FOR LUMBAR CANAL STENOSIS)- CONVENTIONAL 14792
CM0866-II : LAMINECTOMY AT ANY LEVEL - (INCLUDING LUMBAR LAMINECTOMY FOR LUMBAR CANAL STENOSIS)- CONVENTIONAL 14792
CM0867 : SPINAL FUSION PROCEDURE 25125
CM0871 : SYRINGOMYELIA 35872
CM0872 : CORPECTOMY (ANTERIOR /ANTEROLATERAL) AT ALL SPINAL LEVELS 26602
CM0873 : SPINAL FIXATION RODS ,SCREWS,PLATES, ARTIFICIAL DISCS 35459
CM0877 : CAROTID ENDARTERECTOMY 33215
CM0878-I : PELVIC FLOOR RECONSTRUCTION WITH MESH 18158
CM0878-II : PELVIC FLOOR RECONSTRUCTION WITH MESH 18158
CM0879-I : LAPAROSCOPIC / LAPROTOMY - ECTOPIC RESECTION 12607
CM0879-II : LAPAROSCOPIC / LAPROTOMY - ECTOPIC RESECTION 12607
CM0880 : LAPAROSCOPIC ADHESOLYSIS 11839
CM0884-I : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - SCLEROTHERAPY 4488
CM0884-II : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - SCLEROTHERAPY 4488
CM0885-I : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - DEVASCULARISATION 23620
CM0885-II : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - DEVASCULARISATION 23620
CM0886-I : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - GLUE INJECTION 4488
CM0886-II : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - GLUE INJECTION 4488
CM0896 : OPERATION FOR HYDATID CYST OF LIVER 20667
CM0898 : COLONIC PULL THOROUGH /COLOPLASTY/ ABDOMINAL RESECTION 29525
CM0899-I : OESOPHAGECTOMY ANY TYPE INCLUDING (TRANS HIATAL / TRANS THORACIC WITH GASTRIC PULL UP) 38382
CM0899-II : OESOPHAGECTOMY ANY TYPE INCLUDING (TRANS HIATAL / TRANS THORACIC WITH GASTRIC PULL UP) 38382
CM0900 : OESOPHAGO- GASTRECTOMY 47239
CM0901 : ACHALASIA CARDIA -SURGICAL CORRECTION 17715
CM0902-I : ACHALASIA CARDIA - LAP SURGICAL CORRECTION ( INCLUDING HELLERS MYOTOMY) 17715
CM0902-II : ACHALASIA CARDIA - LAP SURGICAL CORRECTION ( INCLUDING HELLERS MYOTOMY) 17715
CM0903 : ACHALASIA CARDIA -PNEUMATIC DILATATION 6171
CM0904 : LAP FUNDOPLICATIONS 26572
CM0905-I : CYST EXCISION WITH OR WITHOUT HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE 26572
CM0905-II : CYST EXCISION WITH OR WITHOUT HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE 26572
CM0907 : ENUCLEATION OF CYST 23620
CM0908A-I : OTHER BYPASS PANCREAS 23620
CM0908A-II : OTHER BYPASS PANCREAS 23620
CM0908B-I : TRIPLE BYPASS 23620
CM0908B-II : TRIPLE BYPASS 23620
CM0910 : PANCREATIC NECROSECTOMY OPEN 24801
CM0911 : PANCREATIC NECROSECTOMY LAP 24801
CM0916 : AV FISTULA ( INCLUDING PRE TRANSPLANTATION ) 5610
CM0917 : COMPLEX AV ACCESS WITH GRAFT FOR HEMODIALYSIS 16829
CM0921A : EPIGASTRIC HERNIA / ABDOMINAL /UMBILICAL / FEMORAL HERNIA-WITHOUT MESH - OPEN 8857
CM0921B : HIATUS HERNIA REPAIR ABDOMINAL - WITHOUT MESH - OPEN 20667
CM0921C : VENTRAL AND SCAR /SPIGELIAN/OBTURATOR/SCIATIC- WITHOUT MESH - OPEN 9448
CM0921D : EPIGASTRIC HERNIA/UMBILICAL HERNIA - WITH MESH - OPEN 11810
CM0921E : HIATUS HERNIA REPAIR ABDOMINAL - WITH MESH - OPEN 23620
CM0921F : VENTRAL AND SCAR / FEMORAL /SPIGELIAN/OBTURATOR/SCIATIC WITH MESH - OPEN 11810
CM0922A : EPIGASTRIC HERNIA / ABDOMINAL /UMBILICAL / FEMORAL HERNIA-WITHOUT MESH - LAP 8857
CM0922B : HIATUS HERNIA REPAIR ABDOMINAL - WITHOUT MESH - LAP 20667
CM0922C : VENTRAL AND SCAR /SPIGELIAN/OBTURATOR/SCIATIC- WITHOUT MESH - LAP 9448
CM0922D : EPIGASTRIC HERNIA/UMBILICAL HERNIA - WITH MESH - LAP 11810
CM0922E : HIATUS HERNIA REPAIR ABDOMINAL - WITH MESH - LAP 23620
CM0922F : VENTRAL AND SCAR / FEMORAL /SPIGELIAN/OBTURATOR/SCIATIC WITH MESH - LAP 11810
CM0924 : APPENDICULAR PERFORATION 8857
CM0925A : VAGOTOMY ANY TYPE WITHOUT DRAINAGE PROCEDURES 14762
CM0925B : VAGOTOMY ANY TYPE WITH DRAINAGE PROCEDURES 23620
CM0926 : OPERATION FOR BLEEDING PEPTIC ULCER 23620
CM0927 : PYLOROMYOTOMY 12991
CM0928 : OPERATIONS FOR RECURRENT INTESTINAL OBSTRUCTION (NOBLE PLICATION /OTHER) 20667
CM0929 : OPERATION FOR ACUTE INTESTINAL PERFORATION / PERFORATION PERITONITIS (INTESTINAL/GASTRIC/BILIARY)/ DUODENAL PERFORATION 17715
CM0930 : OPERATION FOR ACUTE INTESTINAL OBSTRUCTION (INCLUDING VOLVULUS / MALROTATION/INTUSUSCEPTION) 23620
CM0933-II : TRACHEAL RESECTION WITH RECONSTRUCTION 23543
CM0934-II : TRACHEAL RESECTION WITHOUT RECONSTRUCTION 15276
CM0944-II : LARYNGOTRACHEAL/ TRACHEAL STENOSIS - POST CRICO TRACHEAL / POST TRAUMATIC (INTUBATION ) - RESECTION ANASTAMOSIS 17579
CM0945-II : LARYNGOTRACHEAL/ TRACHEAL STENOSIS - POST CRICO TRACHEAL /POST TRAUMATIC (INTUBATION ) - STENTING 20531
CM0947 : SPINAL DEFORMITY STABILISATION/CORRECTION PROCEDURES /VERTERBROPLASTY 44730
CM0948 : SPINAL EPIDURAL ABSCESS/HEMATOMA - LAMINECTOMY / EVACUATION 15796
CM0952 : SURGERY/CHEMOTHERAPY/RADIOTHERAPY FOR ALL LEUKEMIAS 0
CM0952A : All Leukemia ( Chemotheraphy) 0
CM0952A-I : Chronic Myeloid Leukemia (CML) 0
CM0952A-I-i-a : Imatinib 1525
CM0952A-I-i-b : Nilotinib 17800
CM0952A-I-ii : Blast phase-Lymphoid ALL Type Induction + TKI 0
CM0952A-I-ii-a : Induction 12840
CM0952A-I-ii-b : Imatinib 1525
CM0952A-I-ii-c : Nilotinib 17800
CM0952A-I-iii : Blast phase-myeloid AML Type Induction + TKI 0
CM0952A-I-iii-a : Daunorubicin (90mg/m2)+ Cytarabine 12320
CM0952A-I-iii-b : Daunorubicin + Cytarabine + Cladribine 10365
CM0952A-I-iii-c : Daunorubicin + Cytarabine (High Dose) 16725
CM0952A-I-iii-d : Daunorubicin (90mg) + Cytarabine 12320
CM0952A-I-iii-e : Idarubicin + Cytarabine (High Dose) 29600
CM0952A-I-iii-f : Idarubicin + Cytarabine 23240
CM0952A-I-iii-g : mitoxantrone + Cytarabine 10820
CM0952A-I-iii-h : Imatinib 1525
CM0952A-I-iii-i : Nilotinib 17800
CM0952A-I-iii-ii : Other Regimen 10000
CM0952A-I-iii-iii : Other Regimen 10000
CM0952A-II : Acute Myeloid Leukemia (AML) 0
CM0952A-II-a : Daunorubicin + Cytarabine 1 12320
CM0952A-II-b : Idarubicin + Cytarabine 23240
CM0952A-II-c : Daunorubicin + Cytarabine 2 10365
CM0952A-II-d : Daunorubicin + Cytarabine (High Dose) 16725
CM0952A-II-e : Idarubicin + Cytarabine (High Dose) 29600
CM0952A-II-f : Daunorubicin (90mg) + Cytarabine 12320
CM0952A-II-g : idarubicin + Cytarabine 23240
CM0952A-II-h : mitoxantrone + Cytarabine 10280
CM0952A-II-i : Cytarabine 6800
CM0952A-II-j : Decitabine 25000
CM0952A-II-k : azacytidine 77500
CM0952A-II-l : Hydroxyurea 1600
CM0952A-II-m : Cytarabine - High Dose 9720
CM0952A-II-n : Cladribine + Cytarabine + Idarubicin + Gcsf 85150
CM0952A-II-o : Cladribine + Cytarabine + Mitoxantrone + Gcsf 40690
CM0952A-II-p : Fludarabine + Cytarabine + Idarubicin + Gcsf 66710
CM0952A-II-q : Etoposide +Cytarabine+Mitoxantrone 13260
CM0952A-II-r : Cytarabine SC 2800
CM0952A-II-s : azacytidine 77500
CM0952A-II-t : Decitabine 25500
CM0952A-II-u : Other Regimen 10000
CM0952A-III : Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL) 0
CM0952A-III-a-i : Rituximab + chlorambucil Cycle 1 1084
CM0952A-III-a-ii : Rituximab + chlorambucil Cycle 3 25584
CM0952A-III-a-iii : Rituximab + chlorambucil Cycle 4-8 32984
CM0952A-III-a-iv : Maintanance - Rituximab 25500
CM0952A-III-b : Rituximab Day 1, 8, 15, and 22: 100500
CM0952A-III-c : Chlorambucil 2344
CM0952A-III-d-i : Bendamustine + Rituximab (Cycle -1) 36500
CM0952A-III-d-ii : Bendamustine + Rituximab (Cycles 2-6) 37900
CM0952A-III-d-iii : Bendamustine (70mg) (Cycle -1) 12500
CM0952A-III-d-iv : Bendamustine (90 mg) (Cycles 2-6) 6500
CM0952A-III-e : Fludarabine + cyclophosphamide + rituximab (FCR) 31898
CM0952A-III-f : Fludarabine + rituximab (FR) 67930
CM0952A-III-g : Alemtuzumab + rituximab 108950
CM0952A-III-h : Alemtuzumab without rituximab 11450
CM0952A-III-i : High-dose methylprednisolone + rituximab 103955
CM0952A-III-j : High-dose methylprednisolone 6455
CM0952A-III-k : Other Regimen 10000
CM0952A-IV : Acute Lymphoblastic Leukemia (ALL) 0
CM0952A-IV-i : Ph(+) AYA (Age 15-39 years) 0
CM0952A-IV-i-a-1 : Childrens Oncology Group (COG) AALL-0031 INDUCTION PHASE 13340
CM0952A-IV-i-a-2 : Childrens Oncology Group (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 1 17095
CM0952A-IV-i-a-3 : Childrens Oncology Group (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 2 19175
CM0952A-IV-i-a-4 : Childrens Oncology Group (COG) AALL-0031 REINDUCTION 25291
CM0952A-IV-i-a-5 : Childrens Oncology Group (COG) AALL-0031 INTENSIFICATION 41425
CM0952A-IV-i-a-6 : Childrens Oncology Group (COG) AALL-0031 MAINTENANCE Cycles 1-4 (8 weeks) 35621
CM0952A-IV-i-a-7 : Childrens Oncology Group (COG) AALL-0031 MAINTENANCE Cycles 5-12 (8 weeks) 12836
CM0952A-IV-i-b-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) 59429
CM0952A-IV-i-b-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) 62380
CM0952A-IV-i-b-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) 11469
CM0952A-IV-i-b-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) 13420
CM0952A-IV-i-b-5 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction II 15133
CM0952A-IV-i-b-6 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction III 5535
CM0952A-IV-i-b-7 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Maintenance 9923
CM0952A-IV-i-c-1 : Multiagent Chemotherapy + TKIs INDUCTION PHASE 15133
CM0952A-IV-i-c-2 : Multiagent Chemotherapy + TKIs CONSOLIDATION I 8460
CM0952A-IV-i-c-3 : Multiagent Chemotherapy + TKIs CONSOLIDATION II 3700
CM0952A-IV-i-c-4 : Multiagent Chemotherapy + TKIs MAINTENANCE 3410
CM0952A-IV-i-c-5 : Imatinib 1525
CM0952A-IV-i-c-6 : Nilotinib 17800
CM0952A-IV-i-d : Other Regimen 10000
CM0952A-IV-ii : Ph(+) AYA (Age > 40 years) 0
CM0952A-IV-ii-a-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) 59429
CM0952A-IV-ii-a-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) 62380
CM0952A-IV-ii-a-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) 11469
CM0952A-IV-ii-a-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) 13420
CM0952A-IV-ii-a-5 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction II 15133
CM0952A-IV-ii-a-6 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction III 5535
CM0952A-IV-ii-a-7 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Maintenance 9923
CM0952A-IV-ii-b-1 : Multiagent Chemotherapy + TKIs INDUCTION PHASE 15573
CM0952A-IV-ii-b-2 : Multiagent Chemotherapy + TKIs CONSOLIDATION I 12110
CM0952A-IV-ii-b-3 : Multiagent Chemotherapy + TKIs CONSOLIDATION II 3200
CM0952A-IV-ii-b-4 : Multiagent Chemotherapy + TKIs MAINTENANCE 6410
CM0952A-IV-ii-b-5 : Imatinib 1525
CM0952A-IV-ii-b-6 : Nilotinib 17800
CM0952A-IV-ii-c : Corticosteroids + TKIs 9035
CM0952A-IV-ii-d : Other Regimen 10000
CM0952A-IV-iii : Ph(-) AYA (Age 15-39 years) 0
CM0952A-IV-iii-a-1 : GRAALL-2003 INDUCTION 15678
CM0952A-IV-iii-a-2 : GRAALL-2003 SALVAGE 28760
CM0952A-IV-iii-a-3 : GRAALL-2003 CONSOLIDATION 30779
CM0952A-IV-iii-a-4 : GRAALL-2003 Late intensification between consolidation blocks 6 and 7 (for patients in complete remission [CR] after the first induction course) 15495
CM0952A-IV-iii-a-5 : GRAALL-2003 Late intensification between consolidation blocks 6 and 7 (for patients in CR after salvage course) 27210
CM0952A-IV-iii-a-6 : GRAALL-2003 Maintenance 56898
CM0952A-IV-iii-b : CNS Therapy-Treatment of patients with initial CNS involvement: 21155
CM0952A-IV-iii-v : CCG-1961 18310
CM0952A-IV-iii-vi : Other Regimen 10000
CM0952A-IV-iv : Ph(-) AYA (Age > 40 years) 0
CM0952A-IV-iv-a-1 : CALGB 8811 (Larson Regimen) INDUCTION 18038
CM0952A-IV-iv-a-2 : CALGB 8811 (Larson Regimen) CONSOLIDATION 16685
CM0952A-IV-iv-b-1 : Hyper-CVAD with or without Rituximab CYCLE 1,3,5,7 60970
CM0952A-IV-iv-b-2 : Hyper-CVAD with or without Rituximab CYCLE 2,4,6,8 56820
CM0952A-IV-iii-c : Other Regimen 10000
CM0952-ii : Surgery for All Leukemias - Utilise Surgical Oncology Package if unavailable maximum payable 29525
CM0953A : All Lymphoma Chemotheraphy 0
CM0953A-I : Hodgkins Lymphoma 0
CM0953A-I-a : ABVD 4480
CM0953A-I-b : Escalated BEACOPP 7119
CM0953A-I-c : ABVD + Rituximab (cyled every 4 weeks) 28480
CM0953A-I-d-i : ABVD + Rituximab (1 cycle - weekly rituximab 4 doses) followed by ABVD 102480
CM0953A-I-d-ii : ABVD 4480
CM0953A-I-e-i : CHOP + Rituximab 26818
CM0953A-I-e-ii : CHOP 2818
CM0953A-I-f-i : CVP +/- Rituximab 25768
CM0953A-I-f-ii : CVP 1768
CM0953A-I-g : Rituximab 25500
CM0953A-I-h : Other Regimen 10000
CM0953A-II-a : Bortezomib + dexamethasone 68038
CM0953A-II-b : Cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab 26818
CM0953A-II-c : Rituximab 25500
CM0953A-II-d : Rituximab + cyclophosphamide + prednisone 25738
CM0953A-II-e : Rituximab + cyclophosphamide + dexamethasone 25520
CM0953A-II-f-i : Thalidomide with or without rituximab (Weeks 1 and 2) 2540
CM0953A-II-f-ii : Thalidomide with or without rituximab (Weeks 3-50) 6000
CM0953A-II-f-iii : Thalidomide with or without rituximab (Weeks 50-52) 6000
CM0953A-II-f-iv : Thalidomide with or without rituximab Weeks 2-5 and 13-16 24000
CM0953A-II-g-i : Bendamustine with or without rituximab 36500
CM0953A-II-g-ii : Bendamustine - rituximab 12500
CM0953A-II-h-i : Cladribine with or without rituximab 32250
CM0953A-II-h-ii : Cladribine - rituximab 8250
CM0953A-II-i : Bendamustine 12500
CM0953A-II-j : Chlorambucil 1126
CM0953A-II-k : Fludarabine 12030
CM0953A-II-l : Fludarabine + cyclophosphamide + rituximab (FCR) 32398
CM0953A-II-m : Alemtuzumab 2650
CM0953A-II-n : Other Regimen 10000
CM0953A-III : NON HODGKINS LYMPHOMA 0
CM0953A-III-i : BURKITT LYMPHOMA 0
CM0953A-III-i-a -1 : CALGB 10002 Cycle 1: 8967
CM0953A-III-i-a-2 : CALGB 10002 Cycles 2 (beginning Day 8), 4, and 6: 66113
CM0953A-III-i-a-3 : CALGB 10002 Cycles 3, 5, and 7: 33108
CM0953A-III-i-a-4 : CALGB 10002 Cycles 4, and 6: 36413
CM0953A-III-i-b : CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine with intrathecal MTX + cytarabine, followed by systemic MTX and cytarabine) with or without Rituximab 46780
CM0953A-III-i-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1 & 2) 32972
CM0953A-III-i-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) 32572
CM0953A-III-i-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) 59429
CM0953A-III-i-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) 61880
CM0953A-III-i-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) 10969
CM0953A-III-i-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) 12920
CM0953A-III-i-e-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine, plus intrathecal MTX + cytarabine, followed by systemic MTX) alternating with IVAC (ifosfamide + cytarabine + etoposide) and intrathecal MTX with or without Rituximab 46780
CM0953A-III-i-e-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine, plus intrathecal MTX + cytarabine, followed by systemic MTX) alternating with IVAC (ifosfamide + cytarabine + etoposide) and intrathecal MTX with or without Rituximab 42847
CM0953A-III-i-f : RICE (rituximab + ifosfamide + carboplatin + etoposide) 32994
CM0953A-III-i-g : RIVAC (rituximab + ifosfamide + cytarabine + etoposide) 43894
CM0953A-III-i-h : RGDP (rituximab + gemcitabine + dexamethasone + cisplatin) 32255
CM0953A-III-i-i : HDAC + Rituximab 27800
CM0953A-III-i-ii : Other Regimen 10000
CM0953A-III-ii : NON HODGKIN LYMPHOMA -- ADULT T-CELL LEUKEMIA / LYMPHOMA 0
CM0953A-III-ii-a-1 : Zidovudine + alpha-interferon (induction) 4580
CM0953A-III-ii-a-2 : Zidovudine + alpha-interferon (Maintenance Therapy) 2100
CM0953A-III-ii-b : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) 2818
CM0953A-III-ii-c : CHOEP 8640
CM0953A-III-ii-d : Dose-adjusted EPOCH(etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) 6892
CM0953A-III-ii-e : Other Regimen 10000
CM0953A-III-iii : DIFFUSE LARGE B CELL LYMPHOMA 0
CM0953A-III-iii-a : CDE (cyclophosphamide + doxorubicin + etoposide) + rituximab 2500
CM0953A-III-iii-b-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) 46780
CM0953A-III-iii-b-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) 42847
CM0953A-III-iii-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1&2) 32972
CM0953A-III-iii-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) 32572
CM0953A-III-iii-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) 59429
CM0953A-III-iii-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) 61880
CM0953A-III-iii-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) 10969
CM0953A-III-iii-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) 12920
CM0953A-III-iii-e-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) Rituximab 26818
CM0953A-III-iii-e-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) 2818
CM0953A-III-iii-f : Other Regimen 10000
CM0953A-III-iv : AIDS-Related B-Cell Lymphomas 0
CM0953A-III-iv-a : CDE (cyclophosphamide + doxorubicin + etoposide) + rituximab 2500
CM0953A-III-iv-b-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) 46780
CM0953A-III-iv-b-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) 42847
CM0953A-III-iv-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1&2) 32972
CM0953A-III-iv-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) 32572
CM0953A-III-iv-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) 59429
CM0953A-III-iv-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) 61880
CM0953A-III-iv-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) 10969
CM0953A-III-iv-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) 12920
CM0953A-III-iv-e-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab 26818
CM0953A-III-iv-e-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) 2818
CM0953A-III-iv-f : Other Regimen 10000
CM0953A-III-v : Primary Cutaneous Marginal Zone or Follicle Center Lymphoma 0
CM0953A-III-v-a-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab 26818
CM0953A-III-v-a-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) 2818
CM0953A-III-v-b : Rituximab 25500
CM0953A-III-v-c : Other Regimen 10000
CM0953A-III-vi : Follicular Lymphoma (Grade 1-2) 0
CM0953A-III-vi-a-1 : Bendamustine with or without rituximab 36500
CM0953A-III-vi-a-2 : Bendamustine (-) rituximab 12500
CM0953A-III-vi-b-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab 26818
CM0953A-III-vi-b-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) 2818
CM0953A-III-vi-c : Cyclophosphamide + Vincristine + Prednisone + Rituximab (RCVP) 25768
CM0953A-III-vi-d : Rituximab 25500
CM0953A-III-vi-e : Lenalidomide + Rituximab 4940
CM0953A-III-vi-f : Other Regimen 10000
CM0953A-III-vii : Extranodal NK/T-Cell Lymphoma 0
CM0953A-III-vii-a : SMILE 27483
CM0953A-III-vii-b : DeVIC +RT 9163
CM0953A-III-vii-c : VIPID 6619
CM0953A-III-vii-d : Other Regimen 10000
CM0953-ii : Surgery for All Lymphomas - Utilise Surgical Oncology Package if unavailable maximum payable 29525
CM0954 : Myelodysplastic Syndromes Treatment Regimens 0
CM0954-i : Symptomatic Anemia With del(5q) with or without Other Cytogenetic Abnormalities 0
CM0954-i-a : Lenalidomide 2575
CM0954-ii : Symptomatic Anemia Without del(5q) and Serum Erythropoietin =500mU/mL 0
CM0954-ii-a-1 : rHu-Epo with or without G-CSF 26080
CM0954-ii-a-2 : rHu-Epo (-) G-CSF 25750
CM0954-ii-b-1 : Darbepoetin alfa with or without G-CSF 9330
CM0954-ii-b-2 : Darbepoetin alfa (-) G-CSF 9000
CM0954-iii : Symptomatic Anemia Without del(5q), Serum Erythropoietin >500mU/mL, Unlikely to Respond to IST 0
CM0954-iii-a-1 : Decitabine (15mg/m2) 15500
CM0954-iii-a-2 : Decitabine (20mg/m2) 16500
CM0954-iii-b : Lenalidomide 2575
CM0955 : Multiple Myeloma 0
CM0955-a : Lenalidomide (28 days) + Dexamethasone 6817
CM0955-b : Lenalidomide (21 days) + Dexamethasone 5004
CM0955-c : Lenalidomide 2575
CM0955-d : Bendamustine + Lenalidomide + Dexamethasone 13639
CM0955-e : Bendamustine 22000
CM0955-f : Cyclophosphamide + Lenalidomide + Dexamethasone 5136
CM0955-g : Dexamethasone + Cyclophosphamide + Etoposide + Cisplatin (DCEP) 5764
CM0955-h : Dexamethasone + Thalidomide + Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide (DT-PACE) 7724
CM0955-i : High-dose Cyclophosphamide 5140
CM0955-j : VAD / VAMP 6104
CM0955-k : Melphalan 3900
CM0955-l : Melphalan + Prednisolone 1137
CM0955-m : Thalidomide + Dexamethasone 2376
CM0955-n : Melphalan / Prednisolone/Thalidomide(MPT) 2257
CM0956 : ALL LYMPHOMA SALVAGE CHEMO (Package 953 to be utilised) 0
CM0957 : CHILDHOOD B CELL LYMPHOMA VARIABLE REGIMEN (Package 953 to be utilised) 0
CM0970 : SLEEVE RESECTION CA EAR 11515
CM0971 : SLEEVE RESECTION CA LUNG 14290
CM0973 : ENDOSCOPIC PARATHYROIDECTOMY 17715
CM0974-II : IVC FILTER REMOVAL 17921
CM0976A : CT / C-ARM GUIDED DISC OZONE NUCLEOLYSIS (CERVICAL / THORACIC / LUMBAR DISC) 9300
CM0976B : USG GUIDED DISC OZONE NUCLEOLYSIS (CERVICAL / THORACIC / LUMBAR DISC) 5757
CM0978 : C-ARM GUIDED INTRA ARTICULAR INJECTIONS (SHOULDER / ELBOW / WRIST / HIP / KNEE / ANKLE / JOINTS OF FOOT AND HAND 9300
CM0983 : MAXILLECTOMY WITH ORBITAL EXENTERATION 20283
CM0984 : MAXILLECTOMY WITH SKULL BASE RESECTION 22291
CM0986A : POSTERIOR DECOMPRESSION WITHOUT STABILISATION AT ANY LEVEL (2 -3 levels) 14762
CM0986B : POSTERIOR DECOMPRESSION WITH STABILISATION AT ANY LEVEL (2 -3 levels) 26572
FUP0001A : CORONARY BALLOON ANGIOPLASTY (PPCI) - First Qtr 1500
FUP0001B : CORONARY BALLOON ANGIOPLASTY (PPCI) - Next 3 Qtrs 1000
FUP0002A : PTCA WITH STENT - First Qtr 1500
FUP0002B : PTCA WITH STENT - Next 3 Qtrs 1000
FUP0004A : ASD DEVICE CLOSURE - First Qtr 1500
FUP0004B : ASD DEVICE CLOSURE - Next 3 Qtrs 1000
FUP0005A : VSD DEVICE CLOSURE - First Qtr 1500
FUP0005B : VSD DEVICE CLOSURE - Next 3 Qtrs 1000
FUP0006A : PDA STENTING - First Qtr 1500
FUP0006B : PDA STENTING - Next 3 Qtrs 1000
FUP0007A : DEVICE CLOSURE - First Qtr 1500
FUP0007B : DEVICE CLOSURE - Next 3 Qtrs 1000
FUP0008A : SINGLE COIL - First Qtr 1500
FUP0008B : SINGLE COIL - Next 3 Qtrs 1000
FUP0009A : MULTIPLE COILS - First Qtr 1500
FUP0009B : MULTIPLE COILS - Next 3 Qtrs 1000
FUP0010A : BALLOON VALVOTOMY(ALL VALVE) - First Qtr 1300
FUP0010B : BALLOON VALVOTOMY(ALL VALVE) - Next 3 Qtrs 750
FUP0011A : PERMANENT PACEMAKER IMPLANTATION (SINGLE / DUAL CHAMBER) - First Qtr 500
FUP0011B : PERMANENT PACEMAKER IMPLANTATION (SINGLE / DUAL CHAMBER) - Next 3 Qtrs 500
FUP0012A : TEMPORARY PACEMAKER IMPLANTATION - First Qtr 500
FUP0012B : TEMPORARY PACEMAKER IMPLANTATION - Next 3 Qtrs 500
FUP0013A : COARCTATION OF AORTA - WITH STENT - First Qtr 3000
FUP0013B : COARCTATION OF AORTA - WITH STENT - Next 3 Qtrs 1500
FUP0014A : COARCTATION OF AORTA - WITHOUT STENT - First Qtr 3000
FUP0014B : COARCTATION OF AORTA - WITHOUT STENT - Next 3 Qtrs 1500
FUP0016A : CORONARY BYPASS SURGERY - First Qtr 3000
FUP0016B : CORONARY BYPASS SURGERY - Next 3 Qtrs 1500
FUP0017A : CORONARY BYPASS SURGERY-POST ANGIOPLASTY - First Qtr 3000
FUP0017B : CORONARY BYPASS SURGERY-POST ANGIOPLASTY - Next 3 Qtrs 1500
FUP0018A : CABG WITH IABP PUMP - First Qtr 3000
FUP0018B : CABG WITH IABP PUMP - Next 3 Qtrs 1500
FUP0019A : CORONARY BYPASS SURGERY OFF PUMP WITH IABP - First Qtr 3000
FUP0019B : CORONARY BYPASS SURGERY OFF PUMP WITH IABP - Next 3 Qtrs 1500
FUP0020A : CABG OF PUMP WITHOUT IABP - First Qtr 3000
FUP0020B : CABG OF PUMP WITHOUT IABP - Next 3 Qtrs 1500
FUP0021A : CABG WITH ANEURYSMAL REPAIR - First Qtr 1300
FUP0021B : CABG WITH ANEURYSMAL REPAIR - Next 3 Qtrs 750
FUP0022A : CABG WITH VENTRICULAR RUPTURE REPAIR - First Qtr 1300
FUP0022B : CABG WITH VENTRICULAR RUPTURE REPAIR - Next 3 Qtrs 750
FUP0023A : CABG WITH VALVE REPLACEMENT WITH MECHANICAL VALVE - First Qtr 3000
FUP0023B : CABG WITH VALVE REPLACEMENT WITH MECHANICAL VALVE - Next 3 Qtrs 1500
FUP0024A : CABG WITH VALVE REPLACEMENT WITH BIOPROSTHETIC VALVE - First Qtr 3000
FUP0024B : CABG WITH VALVE REPLACEMENT WITH BIOPROSTHETIC VALVE - Next 3 Qtrs 1500
FUP0025A : SINGLE VALVE REPLACEMENT WITH MECHANICAL VALVE - First Qtr 3000
FUP0025B : SINGLE VALVE REPLACEMENT WITH MECHANICAL VALVE - Next 3 Qtrs 1500
FUP0026A : SINGLE VALVE REPLACEMENT WITH BIOPROSTHETIC VALVE - First Qtr 3000
FUP0026B : SINGLE VALVE REPLACEMENT WITH BIOPROSTHETIC VALVE - Next 3 Qtrs 1500
FUP0027A : DOUBLE VALVE REPLACEMENT WITH MECHANICAL VALVE - First Qtr 3000
FUP0027B : DOUBLE VALVE REPLACEMENT WITH MECHANICAL VALVE - Next 3 Qtrs 1500
FUP0028A : DOUBLE VALVE REPLACEMENT WITH BIOPROSTHETIC VALVE - First Qtr 3000
FUP0028B : DOUBLE VALVE REPLACEMENT WITH BIOPROSTHETIC VALVE - Next 3 Qtrs 1500
FUP0029A : TRIPLE VALVE REPLACEMENT WITH MECHANICAL VALVE - First Qtr 3000
FUP0029B : TRIPLE VALVE REPLACEMENT WITH MECHANICAL VALVE - Next 3 Qtrs 1500
FUP0030A : TRIPLE VALVE REPLACEMENT WITH BIOPROSTHETIC VALVE - First Qtr 3000
FUP0030B : TRIPLE VALVE REPLACEMENT WITH BIOPROSTHETIC VALVE - Next 3 Qtrs 1500
FUP0031A : COARCTATION-AORTA REPAIR WITH GRAFT - First Qtr 3000
FUP0031B : COARCTATION-AORTA REPAIR WITH GRAFT - Next 3 Qtrs 1500
FUP0032A : ANEURYSM RESECTION & GRAFTING - First Qtr 3000
FUP0032B : ANEURYSM RESECTION & GRAFTING - Next 3 Qtrs 1500
FUP0033A : INTRATHORACIC ANEURYSM -REQUIRING BYPASS (WITH GRAFT) - First Qtr 3000
FUP0033B : INTRATHORACIC ANEURYSM -REQUIRING BYPASS (WITH GRAFT) - Next 3 Qtrs 1500
FUP0034A : ANNULUS AORTIC ECTASIA WITH VALVED CONDUITS - First Qtr 1300
FUP0034B : ANNULUS AORTIC ECTASIA WITH VALVED CONDUITS - Next 3 Qtrs 750
FUP0035A : ARTERIAL SWITCH - First Qtr 1300
FUP0035B : ARTERIAL SWITCH - Next 3 Qtrs 750
FUP0036A : SENNINGS PROCEDURE - First Qtr 1300
FUP0036B : SENNINGS PROCEDURE - Next 3 Qtrs 750
FUP0037A : TOTAL CORRECTION OF TETRALOGY OF FALLOT - ANY TYPE - First Qtr 1300
FUP0037B : TOTAL CORRECTION OF TETRALOGY OF FALLOT - ANY TYPE - Next 3 Qtrs 750
FUP0038A : WITH SPECIAL CONDUITS - First Qtr 1300
FUP0038B : WITH SPECIAL CONDUITS - Next 3 Qtrs 750
FUP0039A : WITH PROSTHETIC RING - First Qtr 3000
FUP0039B : WITH PROSTHETIC RING - Next 3 Qtrs 1500
FUP0043A : PRIMARY ANGIOPLASTY FOR ACUTE MI +DRUG ELUTING STENT - First Qtr 1500
FUP0043B : PRIMARY ANGIOPLASTY FOR ACUTE MI +DRUG ELUTING STENT - Next 3 Qtrs 1000
FUP0045A : AMPUTATION OF ANY SITE / ANY CAUSE WITH CUSTOM MADE PROSTHESIS - First Qtr 600
FUP0045B : AMPUTATION OF ANY SITE / ANY CAUSE WITH CUSTOM MADE PROSTHESIS - Next 3 Qtrs 500
FUP0046A : OESOPHAGECTOMY WITH TWO FIELD LYMPADENECTOMY / THREE FIELD LYMPADENECTOMY - First Qtr 400
FUP0046B : OESOPHAGECTOMY WITH TWO FIELD LYMPADENECTOMY / THREE FIELD LYMPADENECTOMY - Next 3 Qtrs 400
FUP0047A : ALL - First Qtr 1000
FUP0047B : ALL - Next 3 Qtrs 750
FUP0048A : CML - First Qtr 1000
FUP0048B : CML - Next 3 Qtrs 750
FUP0049A : CLL - First Qtr 1000
FUP0049B : CLL - Next 3 Qtrs 750
FUP0050A : MYELODYSPLASTIC SYNDROME - First Qtr 1000
FUP0050B : MYELODYSPLASTIC SYNDROME - Next 3 Qtrs 750
FUP0051A : LYMPHOMA HODGKIN DISEASE - First Qtr 1000
FUP0051B : LYMPHOMA HODGKIN DISEASE - Next 3 Qtrs 750
FUP0052A : LYMPHOMA NON HODGKINS DISEASES - First Qtr 1000
FUP0052B : LYMPHOMA NON HODGKINS DISEASES - Next 3 Qtrs 750
FUP0053A : SPECIALIZED RADIATION THERAPY - 3DCRT PACKAGE ADJUVANT PACKAGE 28-33 FRACTIONS(INCLUDES AQUAPLAST MOULD, PLANNINGCT, COUNTOURING, RT PLANNING & EXECUTION) - First Qtr 2000
FUP0053B : SPECIALIZED RADIATION THERAPY - 3DCRT PACKAGE ADJUVANT PACKAGE 28-33 FRACTIONS(INCLUDES AQUAPLAST MOULD, PLANNINGCT, COUNTOURING, RT PLANNING & EXECUTION) - Next 3 Qtrs 1000
FUP0054A : SPECIALIZED RADIATION THERAPY 3D CRT- RADICAL PACKAGE 34-37 FRACTIONS - First Qtr 2000
FUP0054B : SPECIALIZED RADIATION THERAPY 3D CRT- RADICAL PACKAGE 34-37 FRACTIONS - Next 3 Qtrs 1000
FUP0055A : SPECIALIZED RADIATION THERAPY - IMRT ADJUVANT PACKAGE 28-33 FRACTIONS (INCLUDES AQUAPLAST MOULD,PLANNING CT FOR IMRT, CONTOURING, RT PLANNING, QA, EXECUTION) - First Qtr 2000
FUP0055B : SPECIALIZED RADIATION THERAPY - IMRT ADJUVANT PACKAGE 28-33 FRACTIONS (INCLUDES AQUAPLAST MOULD,PLANNING CT FOR IMRT, CONTOURING, RT PLANNING, QA, EXECUTION) - Next 3 Qtrs 1000
FUP0056A : SPECIALIZED RADIATION THERAPY - IMRT - RADICAL PACKAGE 34-40 FRACTIONS - First Qtr 2000
FUP0056B : SPECIALIZED RADIATION THERAPY - IMRT - RADICAL PACKAGE 34-40 FRACTIONS - Next 3 Qtrs 1000
FUP0057A : SPECIALIZED RADIATION THERAPY - IMRT WITH IGRT - First Qtr 2000
FUP0057B : SPECIALIZED RADIATION THERAPY - IMRT WITH IGRT - Next 3 Qtrs 1000
FUP0058A : SPECIALIZED RADIATION THERAPY - RAPID ARC THERAPY - First Qtr 2000
FUP0058B : SPECIALIZED RADIATION THERAPY - RAPID ARC THERAPY - Next 3 Qtrs 1000
FUP0059A : TOTAL BODY RADIATION - First Qtr 2000
FUP0059B : TOTAL BODY RADIATION - Next 3 Qtrs 1000
FUP0060A : UPTO-60% WITH SCALDS (CONSERVATIVE) - First Qtr 750
FUP0060B : UPTO-60% WITH SCALDS (CONSERVATIVE) - Next 3 Qtrs 500
FUP0061A : UP TO-60% MIXED BURNS (WITH SURGERIES) - First Qtr 750
FUP0061B : UP TO-60% MIXED BURNS (WITH SURGERIES) - Next 3 Qtrs 500
FUP0062A : ABOVE 60% MIXED BURNS (WITH SURGERIES) - First Qtr 750
FUP0062B : ABOVE 60% MIXED BURNS (WITH SURGERIES) - Next 3 Qtrs 500
FUP0063A : TOTAL ELBOW REPLACEMENT - First Qtr 500
FUP0063B : TOTAL ELBOW REPLACEMENT - Next 3 Qtrs 500
FUP0064A : SHOULDER REPLACEMENT - First Qtr 500
FUP0064B : SHOULDER REPLACEMENT - Next 3 Qtrs 500
FUP0065A : TOTAL HIP REPLACEMENT - First Qtr 500
FUP0065B : TOTAL HIP REPLACEMENT - Next 3 Qtrs 500
FUP0066A : REVISION HIP REPLACEMENT SURGERY (ONLY WITH SPECIFIC APPROVAL) - First Qtr 500
FUP0066B : REVISION HIP REPLACEMENT SURGERY (ONLY WITH SPECIFIC APPROVAL) - Next 3 Qtrs 500
FUP0067A : REVISION KNEE REPLACEMENT SURGERY ( ONLY WITH SPECIFIC APPROVAL) - First Qtr 500
FUP0067B : REVISION KNEE REPLACEMENT SURGERY ( ONLY WITH SPECIFIC APPROVAL) - Next 3 Qtrs 500
FUP0068A : TOTAL KNEE REPLACEMENT - First Qtr 500
FUP0068B : TOTAL KNEE REPLACEMENT - Next 3 Qtrs 500
FUP0069A : INBORN ERROR OF METABOLISM - First Qtr 3000
FUP0069B : INBORN ERROR OF METABOLISM - Next 3 Qtrs 1500
FUP0070A : PRIMARY IMMUNO DEFICIENCY DISORDERS - First Qtr 1500
FUP0070B : PRIMARY IMMUNO DEFICIENCY DISORDERS - Next 3 Qtrs 1000
FUP0071A : HYPOPLASTIC/APLASTIC ANEMIA (FANCONI ANEMIA) - First Qtr 900
FUP0071B : HYPOPLASTIC/APLASTIC ANEMIA (FANCONI ANEMIA) - Next 3 Qtrs 500
FUP0072A : PRETERM BABY RDS WITH OR WITHOUT SURFACTANT WITH MECHANICAL VENTILATION/CPAP - First Qtr 1250
FUP0072B : PRETERM BABY RDS WITH OR WITHOUT SURFACTANT WITH MECHANICAL VENTILATION/CPAP - Next 3 Qtrs 750
FUP0073A : TERM BABY-CONGENITAL HEART DISEASE / CONGESTIVE CARDIAC FAILURE/ WITH VENTILATION - First Qtr 1250
FUP0073B : TERM BABY-CONGENITAL HEART DISEASE / CONGESTIVE CARDIAC FAILURE/ WITH VENTILATION - Next 3 Qtrs 750
FUP0074A : TERM BABY - CONGENITAL HEART DISEASE / CONGESTIVE CARDIAC FAILURE/ WITHOUT VENTILATION - First Qtr 1250
FUP0074B : TERM BABY - CONGENITAL HEART DISEASE / CONGESTIVE CARDIAC FAILURE/ WITHOUT VENTILATION - Next 3 Qtrs 750
FUP0075A : ECMO-EXTRACORPOREAL MEMBRANE OXYGENATION - First Qtr 3000
FUP0075B : ECMO-EXTRACORPOREAL MEMBRANE OXYGENATION - Next 3 Qtrs 1500
FUP0076A : MULTI SYSTEM ORGAN FAILURE- WITH OR WITHOUT /ARDS/DIC(BLOOD PRODUCTS) - First Qtr 1800
FUP0076B : MULTI SYSTEM ORGAN FAILURE- WITH OR WITHOUT /ARDS/DIC(BLOOD PRODUCTS) - Next 3 Qtrs 1000
FUP0077A : MULTI SYSTEM ORGAN FAILURE- WITH OR WITHOUT /ARDS/DIC(BLOOD PRODUCTS) - First Qtr 1800
FUP0077B : MULTI SYSTEM ORGAN FAILURE- WITH OR WITHOUT /ARDS/DIC(BLOOD PRODUCTS) - Next 3 Qtrs 1000
FUP0078A : TUMORS (NEONATES/PAEDIATRIC) - First Qtr 500
FUP0078B : TUMORS (NEONATES/PAEDIATRIC) - Next 3 Qtrs 500
FUP0079A : CONGENITAL LUNG LESIONS (CLE, CCAM) - First Qtr 2000
FUP0079B : CONGENITAL LUNG LESIONS (CLE, CCAM) - Next 3 Qtrs 1000
FUP0080A : EXCISION OF BRAIN TUMORS - [PRIMARY /BENIGN ) (BOTH INTRA AXIAL AND EXTRA AXIAL -INCLUDESSUBTENTORIAL- CP ANGLE BRAINSTEM/CEREBELLAR/ SUPRATENTORIAL- FRONTAL/TEMPORAL /PARIETAL SELLAR/SUPRASELLAR/CRANIOPHARYNGIOMA) - First Qtr 2000
FUP0080B : EXCISION OF BRAIN TUMORS - [PRIMARY /BENIGN ) (BOTH INTRA AXIAL AND EXTRA AXIAL -INCLUDESSUBTENTORIAL- CP ANGLE BRAINSTEM/CEREBELLAR/ SUPRATENTORIAL- FRONTAL/TEMPORAL /PARIETAL SELLAR/SUPRASELLAR/CRANIOPHARYNGIOMA) - Next 3 Qtrs 1000
FUP0081A : EXCISION OF BRAIN TUMORS - [MALIGNANT ) (BOTH INTRA AXIAL AND EXTRA AXIAL -INCLUDESSUBTENTORIAL- CP ANGLE BRAINSTEM/CEREBELLAR/ SUPRATENTORIAL- FRONTAL/TEMPORAL /PARIETAL SELLAR/SUPRASELLAR/CRANIOPHARYNGIOMA) - First Qtr 2000
FUP0081B : EXCISION OF BRAIN TUMORS - [MALIGNANT ) (BOTH INTRA AXIAL AND EXTRA AXIAL -INCLUDESSUBTENTORIAL- CP ANGLE BRAINSTEM/CEREBELLAR/ SUPRATENTORIAL- FRONTAL/TEMPORAL /PARIETAL SELLAR/SUPRASELLAR/CRANIOPHARYNGIOMA) - Next 3 Qtrs 1000
FUP0082A : EXCISION OF BRAIN TUMORS - [SECONDARIES ) (BOTH INTRA AXIAL AND EXTRA AXIAL -INCLUDESSUBTENTORIAL- CP ANGLE BRAINSTEM/CEREBELLAR/ SUPRATENTORIAL- FRONTAL/TEMPORAL /PARIETAL SELLAR/SUPRASELLAR/CRANIOPHARYNGIOMA) - First Qtr 2000
FUP0082B : EXCISION OF BRAIN TUMORS - [SECONDARIES ) (BOTH INTRA AXIAL AND EXTRA AXIAL -INCLUDESSUBTENTORIAL- CP ANGLE BRAINSTEM/CEREBELLAR/ SUPRATENTORIAL- FRONTAL/TEMPORAL /PARIETAL SELLAR/SUPRASELLAR/CRANIOPHARYNGIOMA) - Next 3 Qtrs 1000
FUP0083A : ANEURYSM CLIPPING - First Qtr 2000
FUP0083B : ANEURYSM CLIPPING - Next 3 Qtrs 1000
FUP0084A : STEREOTACTIC PROCEDURES- SURGICAL PROCEDURE - First Qtr 2000
FUP0084B : STEREOTACTIC PROCEDURES- SURGICAL PROCEDURE - Next 3 Qtrs 1000
FUP0085A : TRANS SPHENOIDAL SURGERY (SELLAR/SUPRASELLAR/SKULL BASAL LESION) - First Qtr 2000
FUP0085B : TRANS SPHENOIDAL SURGERY (SELLAR/SUPRASELLAR/SKULL BASAL LESION) - Next 3 Qtrs 1000
FUP0086A : TRANS ORAL SURGERY - First Qtr 2000
FUP0086B : TRANS ORAL SURGERY - Next 3 Qtrs 1000
FUP0087A : PROSTHETIC VALVE THROMBOSIS- THROMBOLYSIS - First Qtr 1500
FUP0087B : PROSTHETIC VALVE THROMBOSIS- THROMBOLYSIS - Next 3 Qtrs 1000
FUP0088A : CORPECTOMY (ANTERIOR /ANTEROLATERAL) AT ALL SPINAL LEVELS - First Qtr 2000
FUP0088B : CORPECTOMY (ANTERIOR /ANTEROLATERAL) AT ALL SPINAL LEVELS - Next 3 Qtrs 1000
FUP0089A : SPINAL FIXATION RODS ,SCREWS,PLATES, ARTIFICIAL DISCS - First Qtr 2000
FUP0089B : SPINAL FIXATION RODS ,SCREWS,PLATES, ARTIFICIAL DISCS - Next 3 Qtrs 1000
FUP0090A : EMBOLISATION OF ANEURYSM/ ANEURYSM COILING BALLOON ASSISTED - First Qtr 2500
FUP0090B : EMBOLISATION OF ANEURYSM/ ANEURYSM COILING BALLOON ASSISTED - Next 3 Qtrs 1500
FUP0091A : DEEP BRAIN STIMULATION - First Qtr 3000
FUP0091B : DEEP BRAIN STIMULATION - Next 3 Qtrs 1500
FUP0092A : D V T - IVC FILTER - First Qtr 3500
FUP0092B : D V T - IVC FILTER - Next 3 Qtrs 1500
FUP0093A : AORTO-BIILIAC-BIFEOMRAL BYPASS WITH VEIN / SYNTHETIC GRAFT - First Qtr 3500
FUP0093B : AORTO-BIILIAC-BIFEOMRAL BYPASS WITH VEIN / SYNTHETIC GRAFT - Next 3 Qtrs 1500
FUP0094A : AXILLO BIFEMORAL BYPASS WITH SYNTHETIC GRAFT - First Qtr 3500
FUP0094B : AXILLO BIFEMORAL BYPASS WITH SYNTHETIC GRAFT - Next 3 Qtrs 1500
FUP0095A : CAROTID ARTERY BYPASS WITH SYNTHETIC GRAFT - First Qtr 3500
FUP0095B : CAROTID ARTERY BYPASS WITH SYNTHETIC GRAFT - Next 3 Qtrs 1500
FUP0096A : NECK VASCULAR INJURY - CAROTID VESSELS - First Qtr 3500
FUP0096B : NECK VASCULAR INJURY - CAROTID VESSELS - Next 3 Qtrs 1500
FUP0097A : ABDOMINAL VASCULAR INJURIES - AORTA, ILLAC ARTERIES, IVC, ILIAC VEINS - First Qtr 3500
FUP0097B : ABDOMINAL VASCULAR INJURIES - AORTA, ILLAC ARTERIES, IVC, ILIAC VEINS - Next 3 Qtrs 1500
FUP0098A : THORACIC VASCULAR INJURIES - First Qtr 3500
FUP0098B : THORACIC VASCULAR INJURIES - Next 3 Qtrs 1500
FUP0101A : PPH SURGICAL MANAGEMENT - HYSTERECTOMY/LIGATION/ EMBOLIZATION - First Qtr 1000
FUP0101B : PPH SURGICAL MANAGEMENT - HYSTERECTOMY/LIGATION/ EMBOLIZATION - Next 3 Qtrs 500
FUP0102A : PPH SURGICAL MANAGEMENT - HYSTERECTOMY/LIGATION/ EMBOLIZATION - First Qtr 2500
FUP0102B : PPH SURGICAL MANAGEMENT - HYSTERECTOMY/LIGATION/ EMBOLIZATION - Next 3 Qtrs 1000
FUP0103A : THALASSEMIA MAJOR/HAEMOGLOBINOPATHIES/ CHELATION THERAPY/SICKLE CELL ANAEMIA - First Qtr 2500
FUP0103B : THALASSEMIA MAJOR/HAEMOGLOBINOPATHIES/ CHELATION THERAPY/SICKLE CELL ANAEMIA - Next 3 Qtrs 2500
FUP0105A : ACUTE RESPIRATORY FAILURE (WITH VENTILATOR - FOR MINIMUM 5 DAYS ) - First Qtr 2500
FUP0105B : ACUTE RESPIRATORY FAILURE (WITH VENTILATOR - FOR MINIMUM 5 DAYS ) - Next 3 Qtrs 1000
FUP0106A : ACUTE PANCREATITIS - CONSERVATIVE MANAGEMENT / MILD / MODERATE / SEVERE MEDICAL / IMAGE GUIDED DRAINAGE OF PANCREATIC COLLECTIONS - First Qtr 2500
FUP0106B : ACUTE PANCREATITIS - CONSERVATIVE MANAGEMENT / MILD / MODERATE / SEVERE MEDICAL / IMAGE GUIDED DRAINAGE OF PANCREATIC COLLECTIONS - Next 3 Qtrs 1500
FUP0107A : ACUTE MI REQUIRING IABP PUMP - First Qtr 4000
FUP0107B : ACUTE MI REQUIRING IABP PUMP - Next 3 Qtrs 2000
FUP0108A : IMMUNOGLOBULIN THERAPY - HEREDITARY MOTOR SENSORY NEUROPATHIES/HEREDITARY SENSORY AND AUTONOMIC NEUROPATHY/PLEXOPATHY (LUMBOSACRAL/ BRACHIAL)/PERIPHERAL NEUROPATHY (WITH NERVE BIOPSY) (HANSEN, NUTRITIONAL, TOXIC, INFECTIVE, IMMUNE)/CARPAL TUNNEL SYNDROME/ACUTE ENTRAPMENT/ COMPRESSIVE NEUROPATHY / GBS/DOG BITE CATEGORY III/OTHERS - First Qtr 4000
FUP0108B : IMMUNOGLOBULIN THERAPY - HEREDITARY MOTOR SENSORY NEUROPATHIES/HEREDITARY SENSORY AND AUTONOMIC NEUROPATHY/PLEXOPATHY (LUMBOSACRAL/ BRACHIAL)/PERIPHERAL NEUROPATHY (WITH NERVE BIOPSY) (HANSEN, NUTRITIONAL, TOXIC, INFECTIVE, IMMUNE)/CARPAL TUNNEL SYNDROME/ACUTE ENTRAPMENT/ COMPRESSIVE NEUROPATHY / GBS/DOG BITE CATEGORY III/OTHERS - Next 3 Qtrs 2000
FUP0109A : GROWTH HORMONE FOR HYPOPITUTARISM - First Qtr 3500
FUP0109B : GROWTH HORMONE FOR HYPOPITUTARISM - Next 3 Qtrs 1500
FUP0110A : LIVER TRANSPLANTATION - First Qtr 45000
FUP0110B : LIVER TRANSPLANTATION - Next 3 Qtrs 35000
FUP0111A : RT. HEPATECTOMY/NON ANATOMICAL RESECTION OF LIVER - First Qtr 2200
FUP0111B : RT. HEPATECTOMY/NON ANATOMICAL RESECTION OF LIVER - Next 3 Qtrs 1200
FUP0112A : LT. HEPATECTOMY/NON ANATOMICAL RESECTION OF LIVER - First Qtr 2200
FUP0112B : LT. HEPATECTOMY/NON ANATOMICAL RESECTION OF LIVER - Next 3 Qtrs 1200
FUP0113A : PORTOCAVAL ANASTOMOSIS - First Qtr 4000
FUP0113B : PORTOCAVAL ANASTOMOSIS - Next 3 Qtrs 2000
FUP0114A : SLEEVE GASTRECTOMY FOR MORBID OBESITY - First Qtr 2500
FUP0114B : SLEEVE GASTRECTOMY FOR MORBID OBESITY - Next 3 Qtrs 1500
FUP0115A : ROUXEN Y GASTRIC BYPASS FOR MORBID OBESITY - First Qtr 2500
FUP0115B : ROUXEN Y GASTRIC BYPASS FOR MORBID OBESITY - Next 3 Qtrs 1500
FUP0116A : DEVASCULARISATION WITH OESOPHAGEAL TRANSECTION - First Qtr 5000
FUP0116B : DEVASCULARISATION WITH OESOPHAGEAL TRANSECTION - Next 3 Qtrs 1500
FUP0118A : THORACO ABDOMINAL ANEURYSM REPAIR WITH RENO / MESENTRIC REVASCULARISATION - First Qtr 2200
FUP0118B : THORACO ABDOMINAL ANEURYSM REPAIR WITH RENO / MESENTRIC REVASCULARISATION - Next 3 Qtrs 1000
FUP0119A : RENAL TRANSPLANTATION SURGERY INCLUDES --POST RENAL TRANSPLANT REJECTION A.STEROID RESISTANT B.STEROID SENSITIVE/ POST RENAL TRANSPLANT INFECTION - LIFE TREATENING TREATMENT FOR FUNGAL INFECTIONS ( LIPOSOMAL AMP -B OR EICHNOCANDINS) , - First Qtr 40000
FUP0119B : RENAL TRANSPLANTATION SURGERY INCLUDES --POST RENAL TRANSPLANT REJECTION A.STEROID RESISTANT B.STEROID SENSITIVE/ POST RENAL TRANSPLANT INFECTION - LIFE TREATENING TREATMENT FOR FUNGAL INFECTIONS ( LIPOSOMAL AMP -B OR EICHNOCANDINS) , - Next 3 Qtrs 33300
FUP0120A : INVESTIGATION AND MANAGEMENT CHRONIC HEPATITIS B / C - First Qtr 1500
FUP0120B : INVESTIGATION AND MANAGEMENT CHRONIC HEPATITIS B / C - Next 3 Qtrs 1500
FUP0121A : INFERIOR VENA CAVA STENTING SINGLE STENT - First Qtr 2000
FUP0121B : INFERIOR VENA CAVA STENTING SINGLE STENT - Next 3 Qtrs 1000
FUP0122A : ACUTE STROKE THROMBOLYSIS (R TPA ) - First Qtr 2000
FUP0122B : ACUTE STROKE THROMBOLYSIS (R TPA ) - Next 3 Qtrs 1000
FUP0123A : RENAL ARTERY EMBOLIZATION WITH MULTIPLE COILS AND MICRO CATHETER - First Qtr 2500
FUP0123B : RENAL ARTERY EMBOLIZATION WITH MULTIPLE COILS AND MICRO CATHETER - Next 3 Qtrs 1000
FUP0124A : CORTICAL VENOUS SINUS THROMBOLYSIS - First Qtr 2500
FUP0124B : CORTICAL VENOUS SINUS THROMBOLYSIS - Next 3 Qtrs 1000
FUP0125A : INFERIOR VENA CAVA FILTER PLACEMENT - First Qtr 3000
FUP0125B : INFERIOR VENA CAVA FILTER PLACEMENT - Next 3 Qtrs 1500
FUP0126A : SUBCLAVIAN, ILIAC, SUPERFICIAL FEMORAL ARTERY STENTING EACH WITH ONE STENT - First Qtr 2500
FUP0126B : SUBCLAVIAN, ILIAC, SUPERFICIAL FEMORAL ARTERY STENTING EACH WITH ONE STENT - Next 3 Qtrs 1200
FUP0127A : TIBIAL ANGIOPLASTY IN CRITICAL LIMB ISCHEMIA - First Qtr 2500
FUP0127B : TIBIAL ANGIOPLASTY IN CRITICAL LIMB ISCHEMIA - Next 3 Qtrs 1200
FUP0128A : MESENTERIC ARTERY ANGIOPLASTY & STENTING IN ACUTE & CHRONIC MESENTERIC ISCHEMIA - SINGLE STENT - First Qtr 2500
FUP0128B : MESENTERIC ARTERY ANGIOPLASTY & STENTING IN ACUTE & CHRONIC MESENTERIC ISCHEMIA - SINGLE STENT - Next 3 Qtrs 1200
FUP0129A : BILIARY DRAINAGE PROCEDURES/ERCP - EXTERNAL DRAINAGE AND STENT PLACEMENT - METALLIC BILIARY STENT / POST OP BILIARY STRICTURE/LEAK/CHOLANGITIS/BILIARY PANCREATITIS/CHOLEDOCHAL CYST/BILE DUCT STONES - First Qtr 2000
FUP0129B : BILIARY DRAINAGE PROCEDURES/ERCP - EXTERNAL DRAINAGE AND STENT PLACEMENT - METALLIC BILIARY STENT / POST OP BILIARY STRICTURE/LEAK/CHOLANGITIS/BILIARY PANCREATITIS/CHOLEDOCHAL CYST/BILE DUCT STONES - Next 3 Qtrs 1000
FUP0130A : INTRA-ARTERIAL THROMBOLYSIS FOR ACUTE ISCHEMIC LIMBS - First Qtr 2000
FUP0130B : INTRA-ARTERIAL THROMBOLYSIS FOR ACUTE ISCHEMIC LIMBS - Next 3 Qtrs 1000
FUP0131A : CENTRAL VENOUS STENTING FOR CENTRAL VENOUS OCCLUSION (BRACHIOCEPHALIC, SUBCLAVIAN VEIN AND SUP VENA CAVA) SINGLE METALLIC STENT - First Qtr 2500
FUP0131B : CENTRAL VENOUS STENTING FOR CENTRAL VENOUS OCCLUSION (BRACHIOCEPHALIC, SUBCLAVIAN VEIN AND SUP VENA CAVA) SINGLE METALLIC STENT - Next 3 Qtrs 1200
FUP0132A : ENDOVASCULAR INTERVENTION FOR SALVAGING HEMODIALYSIS AV FISTULA - First Qtr 2000
FUP0132B : ENDOVASCULAR INTERVENTION FOR SALVAGING HEMODIALYSIS AV FISTULA - Next 3 Qtrs 1000
FUP0133A : BALLOON RETROGRADE TRANSVENOUS OBLITERATION OF BLEEDING GASTRIC VARICES (BRTO) - First Qtr 3500
FUP0133B : BALLOON RETROGRADE TRANSVENOUS OBLITERATION OF BLEEDING GASTRIC VARICES (BRTO) - Next 3 Qtrs 1500
FUP0134A : PREOPERATIVE PORTAL VEIN EMBOLIZATION FOR LIVER TUMORS - First Qtr 2000
FUP0134B : PREOPERATIVE PORTAL VEIN EMBOLIZATION FOR LIVER TUMORS - Next 3 Qtrs 1000
FUP0135A : CHEMO EMBOLIZATION FOR LIVER TUMORS USING DRUG AND PVA OR DC BEADS - First Qtr 2000
FUP0135B : CHEMO EMBOLIZATION FOR LIVER TUMORS USING DRUG AND PVA OR DC BEADS - Next 3 Qtrs 1000
FUP0136A : TRANS JUGULAR INTRAHEPATIC PORTO SYSTEMIC SHUNT (TIPSS) - First Qtr 3500
FUP0136B : TRANS JUGULAR INTRAHEPATIC PORTO SYSTEMIC SHUNT (TIPSS) - Next 3 Qtrs 1500
FUP0137A : EMBOLIZATION OF PULMONARY AV MALFORMATION - First Qtr 2500
FUP0137B : EMBOLIZATION OF PULMONARY AV MALFORMATION - Next 3 Qtrs 1000
FUP0138A : PREOPERATIVE PROPHYLACTIC TUMOR EMBOLISATION - First Qtr 2000
FUP0138B : PREOPERATIVE PROPHYLACTIC TUMOR EMBOLISATION - Next 3 Qtrs 1000
FUP0139A : EMBOLIZATION OF AV MALFORMATION OF BRAIN PER SITTING WITH ONYX - First Qtr 6000
FUP0139B : EMBOLIZATION OF AV MALFORMATION OF BRAIN PER SITTING WITH ONYX - Next 3 Qtrs 1000
FUP0140A : CAROTID STENTING SINGLE STENT WITH EMBOLIC PROTECTION DEVICE - First Qtr 2000
FUP0140B : CAROTID STENTING SINGLE STENT WITH EMBOLIC PROTECTION DEVICE - Next 3 Qtrs 1000
FUP0141A : INTRACRANIAL VENOUS STENTING - First Qtr 6000
FUP0141B : INTRACRANIAL VENOUS STENTING - Next 3 Qtrs 1000
FUP0142A : INTRACRANIAL ARTERIAL STENTING - First Qtr 6000
FUP0142B : INTRACRANIAL ARTERIAL STENTING - Next 3 Qtrs 1000
FUP0143A : PERIPHERAL STENT GRAFT FOR PERIPHERAL ANEURYSMS AND AV FISTULA - First Qtr 2500
FUP0143B : PERIPHERAL STENT GRAFT FOR PERIPHERAL ANEURYSMS AND AV FISTULA - Next 3 Qtrs 1200
FUP0144A : EMBOLIZATION OF CARATICO-CAVERNOUS FISTULA - First Qtr 6000
FUP0144B : EMBOLIZATION OF CARATICO-CAVERNOUS FISTULA - Next 3 Qtrs 1000
FUP0145A : PLAIN SIMPLE COILING OF ANEURYSM - First Qtr 2500
FUP0145B : PLAIN SIMPLE COILING OF ANEURYSM - Next 3 Qtrs 1500
FUP0146A : ILIAC / IVC STENTING / HIGH END VASCULAR REVASCULARISATION PROCEDURE - First Qtr 2500
FUP0146B : ILIAC / IVC STENTING / HIGH END VASCULAR REVASCULARISATION PROCEDURE - Next 3 Qtrs 1200
FUP0147A : VENOUS / POLY TETRA FLUORO ETHYLENE PATCH ANGIOPLASTY - First Qtr 2500
FUP0147B : VENOUS / POLY TETRA FLUORO ETHYLENE PATCH ANGIOPLASTY - Next 3 Qtrs 1200
FUP0148A : HEPATIC VEIN ANGIOPLASTY AND STENTING - First Qtr 3000
FUP0148B : HEPATIC VEIN ANGIOPLASTY AND STENTING - Next 3 Qtrs 1500
FUP0149A : MINIMAL ACCESS SURGERY- VALVE REPLACEMENT - First Qtr 3500
FUP0149B : MINIMAL ACCESS SURGERY- VALVE REPLACEMENT - Next 3 Qtrs 2500
FUP0150A : MINIMAL ACCESS SURGERY- CABG - First Qtr 2000
FUP0150B : MINIMAL ACCESS SURGERY- CABG - Next 3 Qtrs 1000
FUP0151A : MULTI ORGAN RESECTION FOR ANY GI CANCERS - First Qtr 1500
FUP0151B : MULTI ORGAN RESECTION FOR ANY GI CANCERS - Next 3 Qtrs 1000
FUP0152A : VISCERAL ARTERY ANEURSYM REPAIR / RENAL ARTERY ANEURYSM REPAIR - First Qtr 2500
FUP0152B : VISCERAL ARTERY ANEURSYM REPAIR / RENAL ARTERY ANEURYSM REPAIR - Next 3 Qtrs 1500
FUP0153A : HYBRID / OPEN INCLUDING COVERED STENT PLACEMENT - UNILATERAL - First Qtr 2500
FUP0153B : HYBRID / OPEN INCLUDING COVERED STENT PLACEMENT - UNILATERAL - Next 3 Qtrs 1200
FUP0154A : HYBRID / OPEN INCLUDING COVERED STENT PLACEMENT - BILATERAL - First Qtr 2000
FUP0154B : HYBRID / OPEN INCLUDING COVERED STENT PLACEMENT - BILATERAL - Next 3 Qtrs 2000
CM0494A : ARRYTHMIAS (SUPRAVENTRICULLAR / VENTRICULAR) - INVASIVE MANAGEMENT (without 3D mapping) 49500
CM0100-N : BREAST CANCER - TAMOXIFEN 100
CM0100-O : BREAST CANCER - AROMATASE INHIBITORS 1000
CM0100-P : BREAST CANCER - Zoledronic Acid for skeletal metastasis 2700
CM0124-c : PROSTATE CANCER - Zoledronic Acid for skeletal metastasis 2700
CM0955-O : Multiple Myeloma - Zoledronic Acid 2700
CM0100-a-III : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 175mg/m2) Repeat cycle - every 21 days for 4 cycles 7000
CM0100-a-IV : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 80mg/m2) Repeat cycle - weekly for 12 cycles 3500
CM0101-a-IV : BLADDER CANCER - Radiosensitizing - Cisplatinc + 5-FU ; Days 1, 2, 3, 15, 16, and 17: IV hydration at a rate of 500mL/hour; followed by 5-FU 400mg/m2 IV push; followed by cisplatin 15mg/m2 IV over 1 hour as induction and consolidation therapy 9800
CM0101-a-V : BLADDER CANCER -Radiosensitizing - Cisplatin + paclitaxel ; Days 1, 8, and 15: Paclitaxel 50mg/m2 ; Day 1-3, 8-10, 15-17: Cisplatin 15mg/m2; followed by twice-daily radiotherapy for 8 days 18400
CM0101-a-VI : BLADDER CANCER -Radiosensitizing - 5-FU + mitomycin32 ; Day 1 of radiotherapy: Mitomycin 12mg/m2 IV bolus, plus ; Week 1 (fractions 1-5) and Week 4 (fractions 16-20) of radiotherapy: 5-FU 500mg/m2 continuous IV infusion (10 days total) 15100
CM0101-c : BLADDER CANCER - Concurrent Cisplatin; Cisplatin 40mg/m2 IV once weekly for up to 5 cycles 1800
CM0103 : OESOPHAGEAL CANCER 0
CM0103-v: ESOPHAGEAL CANCER - Concurrent Cisplatin; Cisplatin 40mg/m2 IV once weekly for up to 5 cycles 1800
CM0105 : COLORECTAL CANCER 0
CM0106 : OSTEOSARCOMA/ BONE TUMORS 0
CM0106-vi : Other bone tumors - Mesenchymal Chordosarcoma VIDE (vincristine + ifosfamide + doxorubicin + etoposide) ; Day 1: Vincristine 1.4mg/m2 (max 2mg), ; Days 1-3: Doxorubicin 20mg/m2 IV + ifosfamide 3mg/m2 IV + mesna 3g/m2 + etoposide 150mg/m2 IV. ; Repeat cycle every 3 weeks for up to 6 cycles. 9200
CM0110 : Neuroblastoma ALL STAGES 0
CM0114-i-b-1 : EWINGS SARCOMA - Induction Treatment - VAC/IE - VAC ; Day 1: Vincristine 2mg/m2 (max 2mg) IV, doxorubicin 75mg/m2 IV bolus, cyclophosphamide 1,200mg/m2 IV, mesna. ; Dactinomycin 1.25mg/m2 IV can be substituted for doxorubicin when a total doxorubicin dose of 375mg/m2 is reached. 4600
CM0114-i-b-2 : EWINGS SARCOMA - Induction Treatment - VAC/IE - IE ; IE cycles ; Days 1-5: Ifosfamide 1,800mg/m2 IV + mesna + etoposide 100mg/m2 IV. ; Repeat each cycle every 3 weeks for 17 cycles. 6000
CM0114-i-e : EWINGS SARCOMA - Induction Treatment - VACA ; Day 1: Vincristine 1.5mg/m2 IV + cyclophosphamide 1,200mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 21 days for 10 cycles. 4600
CM0117-e : VULVAL CANCER - Cisplatin + 5FU ; Days 1 and 29: Cisplatin 50mg/m2 IV ; Days 2-5, and 30-33: 5-FU 1,000mg/m2 IV 11100
CM0128-ii-c-1 : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide ; Daily oral temozolomide (75mg/m2/day, 7 days per week from the first to the last day of radiotherapy) 7200
CM0128-ii-c-2 : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - adjuvant temozolomide - preceeded by Concurrent Temozolomide (with RT) ; Temozolomide 150-200mg/m2/day for 5 days. ; Repeat cycle every 28 days for 6 cycles 2100
CM0130 I a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Pazopanib ; Pazopanib 800mg orally once daily 19250
CM0130 I b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off. 29250
CM0130 I c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Bevacizumab + IFN-alpha ; Bevacizumab 10mg/kg IV every 2 weeks + IFN-alpha. 66750
CM0130 I d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Sorafenib ; Sorafenib 400mg orally twice daily 3650
CM0130 II a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Everolimus ; Everolimus 10mg orally once daily 37250
CM0130 II b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Pazopanib ; Pazopanib 800mg orally once daily 19250
CM0130 II c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Sorafenib ; Sorafenib 400mg orally twice daily 3650
CM0130 II d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off. 29250
CM0130 II e : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Bevacizumab ; Bevacizumab 10mg/kg IV every 2 weeks. 66250
CM0130 III a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off. 29250
CM0130 III b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Bevacizumab ; Bevacizumab 10mg/kg IV every 2 weeks. 66250
CM0130 III c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Everolimus ; Everolimus 10mg orally once daily 37250
CM0130 III d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Erlotinib ; Erlotinib 150mg orally once daily 3400
CM0130 III e : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Pazopanib ; Pazopanib 800mg orally once daily 19250
CM0130 III f : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Sorafenib ; Sorafenib 400mg orally twice daily 3650
CM0130 IV: RENAL CELL CARCINOMARENAL CELL CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0131-i-g : UNKNOWN PRIMARY - Adenocarcinoma - mFOLFOX ; Day 1: Oxaliplatin 85mg/m2 IV over 2 hours + leucovorin 400mg/m2 IV over 2 hours + 5-FU 400mg/m2 IV bolus then ; Days 1 and 2: 5-FU 1200mg/m2 (total 2400mg/m2 over 46-48 hours) IV continuous infusion. ; Repeat cycle every 2 weeks for 24 cycles 8000
CM0131-i-h : UNKNOWN PRIMARY - Adenocarcinoma - CapeOX ; Day 1: Oxaliplatin 130mg/m2 IV over 2 hours ; Day 1-14: Capecitabine 850-1000mg/m2 orally twice daily. ; Repeat cycle every 3 weeks for 16 cycles. 6500
CM0131-i-i : UNKNOWN PRIMARY - Adenocarcinoma - Irinotecan + carboplatin ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Days 1, 8, and 15: Irinotecan 60mg/m2 IV. ; Repeat cycle every 4 weeks for up to 6 cycles 7700
CM0131-ii-c : UNKNOWN PRIMARY - Squamous cell carcinoma -Paclitaxel + carboplatin ; Day 1: Carboplatin AUC 6mg per min/mL IV over 30 minutes + paclitaxel 200mg/m2 IV over 3 hours. ; Repeat cycle every 3 weeks for 8 cycles in responding patients and for 6 cycles maximum in patients with stable disease 7200
CM0131-ii-d : UNKNOWN PRIMARY - Squamous cell carcinoma -Cisplatin + gemcitabine ; Day 1: Cisplatin 100mg/m2 IV ; Day 1 and 8: Gemcitabine 1250mg/m2 IV. ; Repeat every 3 weeks for 4 cycles. 5250
CM0131-ii-e : UNKNOWN PRIMARY - Squamous cell carcinoma -mFOLFOX ; Day 1: Oxaliplatin 85mg/m2 IV over 2 hours + leucovorin 400mg/m2 IV over 2 hours + 5-FU 400mg/m2 IV bolus then ; Days 1 and 2: 5-FU 1200mg/m2 (total 2400mg/m2 over 46-48 hours) IV continuous infusion. ; Repeat cycle every 2 weeks for 24 cycles. 8000
CM0131-ii-f : UNKNOWN PRIMARY - Squamous cell carcinoma -Paclitaxel + cisplatin ; Day 1: Paclitaxel 175mg/m2 IV + cisplatin 60mg/m2 IV. ; Repeat cycle every 3 weeks. 6450
CM0131-ii-g : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + carboplatin ; Day 1: Docetaxel 75mg/m2 IV over 30 minutes + carboplatin AUC 5mg per min/mL IV over 30 minutes. ; Repeat cycle every 3 weeks for 8 cycles 8700
CM0131-ii-h : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + cisplatin ; Day 1: Docetaxel 60mg/m2 IV + cisplatin 80mg/m2 IV. ; Repeat cycle every 3 weeks for 2 cycles and an additional 4 cycles until disease progression is demonstrated 5040
CM0131-ii-i : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + cisplatin ; Day 1: Docetaxel 75mg/m2 IV + cisplatin 75mg/m2 IV. ; Repeat cycle every 3 weeks for up to 6 cycles. 3820
CM0131-ii-j : UNKNOWN PRIMARY - Squamous cell carcinoma -Cisplatin + fluorouracil ; Days 1-5: Cisplatin 20mg/m2 IV ; Days 1-5: Fluorouracil 700mg/m2/day IV via continuous infusion over 24 hours. ; Repeat cycle every 4 weeks for 3 cycles. 7050
CM0879-I-a :LAPAROSCOPIC - ECTOPIC RESECTION 12607
CM0629-II-a : OBSCURE BLEED - Conservative management including Capsule endoscopy 17715
CM0629-II-b : OBSCURE BLEED - Conservative 5905
CM0629-II-c : NON VARICEAL BLEED - CLIPPING 17715
CM0629-II-d : NON VARICEAL BLEED - ARGON PLASMA COAGULATION 27252
CM0629-II-e : NON VARICEAL BLEED - CONSERVATIVE 5905
CM0774 A : LAPROSCOPIC ASSISTED VAGINAL HYSTERECTOMY 11839
CM0820-I-A : Amputation of AK / BK 17715
CM0820-I-B : Amputation of AE / BE 14763
CM0820-I-C : Amputation of Fore-Foot 8858
CM0820-I-E : Amputation of Toes 4134
CM0820-I-F : Amputation of Fingers 5905
CM0820-I-G : Trans Meta-Tarsal Amputation 8858
CM0879-I-b :LAPROTOMY - ECTOPIC RESECTION 7086
CM0898 A : COLONIC PULL THROW 29525
CM0898 B : COLOPLASTY 17715
CM0898 C : ABDOMINAL RESECTION 23620
CM0905-IA : CYST EXCISION WITH HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE 26573
CM0905-IB : CYST EXCISION WITHOUT HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE 20668
CM0774 B : LAPROSCOPIC ASSISTED VAGINAL HYSTERECTOMY 11839
CM0952A-I-iii-j : Chronic Myeloid Leukemia (CML) - Other Regimen 10000
CM0952A-II-z : Acute Myeloid Leukemia (AML) - Other Regimen 10000
CM0183a : Neck/ Shaft Of Femur ORIF 13139
CM0183b : IM Nailing 8858
CM0183c : Shaft of Other Long Bones (Humerus) 10039
CM0183d : Tibia 8858
CM0183e : Radius, Fibula, Ulna (ORIF) 8858
CM0183f : Clavicle ( CRIF) (Displaced) 4724
CM0183g : Clavicel (ORIF) (Displaced) 7086
CM0183h : Both Bones of Forearm, Both Bones of Leg (Fixation of both bones) 13139
CM0183i : Bimalleolar Fracture 8858
CM0183j : Closed Reduction and Proximal Femoral nailing / Screw Fixation 8858
CM0183k : Closed Reduction and Pinning / Tens Nail 7086
CM0183l : Closed Reduction and Internal Fixation with K wire 3543
CM0183m : Tension Band wiring 7086
CM0184a : Neck/ Shaft Of Femur ORIF 13139
CM0184b : IM Nailing 8858
CM0184c : Shaft of Other Long Bones (Humerus) 10039
CM0184d : Tibia 8858
CM0184e : Radius, Fibula, Ulna (ORIF) 8858
CM0184f : Clavicle ( CRIF) (Displaced) 4724
CM0184g : Clavicel (ORIF) (Displaced) 7086
CM0184h : Both Bones of Forearm, Both Bones of Leg (Fixation of both bones) 13139
CM0184i : Bimalleolar Fracture 8858
CM0184j : Closed Reduction and Proximal Femoral nailing / Screw Fixation 8858
CM0184k : Closed Reduction and Pinning / Tens Nail 7086
CM0184l : Closed Reduction and Internal Fixation with K wire 3543
CM0184m : Tension Band wiring 7086
CM0186A-i : IMPLANT EXIT- K-WIRES - Single 886
CM0186A-ii : IMPLANT EXIT- K-WIRES - Multiple 1477
CM0186A-iii : IMPLANT EXIT- SCREWS - single (Open) 2362
CM0186A-iv : IMPLANT EXIT- SCREWS - Multiple (Open) 4429
CM0186A-v : IMPLANT EXIT- SCREWS - single (Closed) 1181
CM0186A-vi : IMPLANT EXIT- SCREWS - Multiple (Closed) 1772
CM0186A-vii : IMPLANT EXIT- OTHER MINOR IMPLANTS (TENS, TBW, etc) - Solitary 2953
CM0186A-viii : IMPLANT EXIT- OTHER MINOR IMPLANTS (Pins / TENS, TBW, etc) - Multiple 4577
CM0186B-i : IMPLANT EXIT- PLATES (Open) 7382
CM0186B-ii : IMPLANT EXIT- Femoral Screws / IM Nails / Rush Nail (Open) 5905
CM0186B-iii : IMPLANT EXIT- SPINE IMPLANTS - upto 2 levels(complete exit) (eg- L2-L3, L3-L4) 10334
CM0186B-iv : IMPLANT EXIT- SPINE IMPLANTS - upto 2 levels(partial exit) (eg- L2-L3, L3-L4) 8858
CM0186B-v : IMPLANT EXIT- SPINE IMPLANTS - > 2 levels(complete exit) (eg- L2-L3, L3-L4, L4-L5) 12106
CM0186B-vi : IMPLANT EXIT- SPINE IMPLANTS - > 2 levels(partial exit) (eg- L2-L3, L3-L4, L4-L5) 10334
CM0186B-vii : IMPLANT EXIT- Bipolar, etc 8858
CM0186B-viii : IMPLANT EXIT - Other Major implants 7382
CM0187a : ARTHRODESIS OF JOINTS - HIP 15944
CM0187b : ARTHRODESIS OF JOINTS - SHOULDER / KNEE 11810
CM0187c : ARTHRODESIS OF JOINTS - ELBOW/ ANKLE / WRIST 8858
CM0187d : ARTHRODESIS OF JOINTS - ANKLE - Triple Arthrodesis 9448
CM0187e : ARTHRODESIS OF JOINTS - HAND / FOOT 5905
CM0192-A : ILIZAROV RING FIXATOR APPLICATION-FEMUR - DEFORMITY CORRECTION / LIMB LENGTHENING 14763
CM0192-B : ILIZAROV RING FIXATOR APPLICATION- TIBIA - DEFORMITY CORRECTION / LIMB LENGTHENING 10629
CM0192-C : PLATING/EXTERNAL FIXATOR/K WIRES - to choose either CM0183 /CM0184 / CM0191 / CM0202 0
CM0193-A : SURGERY FOR NEGLECTED CTEV/RECURRENT CTEV/RESISTANT CTEV BY JESS FIXATION 26425
CM0195-A : KNEE LIGAMENT RECONSTRUCTION-ACL RECONSTRUCTION/PCL RECONSTRUCTION 17715
CM0195-B : KNEE LIGAMENT RECONSTRUCTION-MPFL RECONSTRUCTION 14763
CM0204- b : ACETABULAR FRACTURES 17420
CM0204-a : CORRECTION SACRO ILLIAC JOINT 11810
CM0625-II A : AMPUTATIONS - FORE QUARTER 23620
CM0625-II B : AMPUTATIONS - HIND QUARTER / Internal Hemipelvectomy 23620
CM0625-II C : AMPUTATIONS - HIND QUARTER / External Hemipelvectomy 23620
CM0722-II-A : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MAXILLA 5920
CM0722-II-B : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MANDIBLE 5920
CM0722-II-C : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MANDIBLE, MAXILLA- INTERDENTAL WIRING 2953
CM0807-a - I : Cementing (only as Addon) 2953
CM0807-a : BONE RESECTION 14763
CM0807-b - I : Cementing (only as Add on) 2953
CM0807-b : BONE Curettage 8858
CM0820-II-A : Amputation of AK / BK 17715
CM0820-II-B : Amputation of AE / BE 14763
CM0820-II-C : Amputation of Fore-Foot 8858
CM0820-II-E : Amputation of Toes 4134
CM0820-II-F : Amputation of Fingers 5905
CM0820-II-G : Trans Meta-Tarsal Amputation 8858
CM0820-III-a : Amputation of great toe 4134
CM0820-III-b : Amputation toe- single 2953
CM0820-III-c : Amputation toe- Multiple 4134
CM0820-III-d : Amputation of Finger - single 4134
CM0820-III-e : Amputation of Finger - Multiple 5905
CM0820-III-f : Transmetatarsal Amputation 5905
CM0861-II-A : POSTERIOR DISCECTOMY WITH SPACER/IMPLANT/VERTEBROPLASTY (open) 25392
CM0861-II-B : POSTERIOR DISCECTOMY WITH BONE GRAFT 19487
CM0861-II-C : POSTERIOR DISCECTOMY WITHOUT BONE GRAFT/SPACER/IMPLANT/VERTEBROPLASTY 14763
CM0250-A : BILIARY ATRESIA 20668
CM0250-B : CHOLEDOCHAL CYST 20668
CM0255A : CONGENITAL HYDRONEPHROSIS (IF ANTENATALLY DETECTED & AGE 11810
CM0255B : CONGENITAL HYDRONEPHROSIS (IFAGE >1YR AND NO EVIDENCE AS PER ANTENATAL USG) 17715
CM0256- B : EXSTROPHY BLADDER - STAGE 2 17715
CM0256-A : EXSTROPHY BLADDER - STAGE 1 23620
CM0260A : HAMARTOMA EXCISION<5CM 8858
CM0260B : HAMARTOMA EXCISION >5CM 11810
CM0273A : CONGENITAL UROGENITAL ANOMALY STAGED CORRECTION Stage 1 26573
CM0273B : CONGENITAL UROGENITAL ANOMALY STAGED CORRECTION Stage 2 26573
CM0276A : Lobectectomy 30913
CM0276B :Cyst excision 59049
CM0277A : SURGICAL CORRECTION FOR ANY CONGENITAL ANOMALY (Complex - Single stage) 29525
CM0277B : SURGICAL CORRECTION FOR ANY CONGENITAL ANOMALY (simple - Single stage) 17715
CM0277C : SURGICAL CORRECTION FOR ANY CONGENITAL ANOMALY - Two Stage - per stage - upto 14763
CM0277D : SURGICAL CORRECTION FOR ANY CONGENITAL ANOMALY - Three Stage - per stage - upto 10039
CM0280-A : RECTAL POLYP - POLYPECTOMY- OPEN 17715
CM0280-B : RECTAL POLYP - POLYPECTOMY- LAP 20668
CM0861-I-A : POSTERIOR DISCECTOMY WITH SPACER/IMPLANT/VERTEBROPLASTY (open) 25392
CM0861-I-B : POSTERIOR DISCECTOMY WITH BONE GRAFT 19487
CM0861-I-C : POSTERIOR DISCECTOMY WITHOUT BONE GRAFT/SPACER/IMPLANT/VERTEBROPLASTY 14763
CM0862A : ANTERIOR DISCECTOMY WITHOUT IMPLANTS 17715
CM0862B : ANTERIOR DISCECTOMY WITH IMPLANTS 25480
CM0947 A : SPINAL DEFORMITY STABILISATION/CORRECTION PROCEDURES ( MORE THAN 4 LEVELS) 44287
CM0947 B : SPINAL DEFORMITY STABILISATION/CORRECTION PROCEDURES LESS THAN 4 LEVELS) 29525
CM0947C : SPINAL DEFORMITY STABILISATION/CORRECTION PROCEDURES WITH VERTERBROPLASTY 26573
CM0629-I-a : OBSCURE BLEED - Conservative management including Capsule endoscopy 17715
CM0629-I-b : OBSCURE BLEED - Conservative 5905
CM0629-I-c : NON VARICEAL BLEED - CLIPPING 17715
CM0629-I-d : NON VARICEAL BLEED - ARGON PLASMA COAGULATION 27252
CM0629-I-e : NON VARICEAL BLEED - CONSERVATIVE 5905
CM0694-I-a : BILIARY DRAINAGE PROCEDURES - T- Tube 11810
CM0694-I-b : BILIARY DRAINAGE PROCEDURES - Choledocojejunostomy 20668
CM0694-I-c : BILIARY DRAINAGE PROCEDURES - Hepaticojejunostomy 26573
CM0694-I-d : ERCP and Stent (plastic) 14763
CM0694-I-e : ERCP and Stent (SEMS) 32477
CM0694-I-f : POST OP BILIARY STRICTURE 20668
CM0905-IBI : CYST EXCISION WITHOUT HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE 20668
CM0905-IIA : CYST EXCISION WITH HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE 26573
CM0775-I-a : SALPINGO OOPHORECTOMY B/L- FOR CA 14969
CM0775-I-b : SALPINGO OOPHORECTOMY U/L FOR CA 10629
CM0625-I A : AMPUTATIONS - FORE QUARTER 23620
CM0625-I B : AMPUTATIONS - HIND QUARTER / Internal Hemipelvectomy 23620
CM0625-I C : AMPUTATIONS - HIND QUARTER / External Hemipelvectomy 23620
CM0765A : GLOSSECTOMY (HEMI/PARTIAL) WITH RECONSTRUCTION- FOR CANCER 17715
CM0765B : GLOSSECTOMY (TOTAL) WITH RECONSTRUCTION- FOR CANCER 23532
CM0338-A : EXCISION OF ARTERIO VENOUS MALFORMATION - SMALL (Limbs) < 3 sq CM Surface Area 8858
CM0338-B : EXCISION OF ARTERIO VENOUS MALFORMATION - SMALL (Limbs) 3 to 6 CM 11810
CM0338-C : EXCISION OF ARTERIO VENOUS MALFORMATION - SMALL (Others) < 3 CM 14763
CM0338-D : EXCISION OF ARTERIO VENOUS MALFORMATION - SMALL (Others) 3 to 6 CM 17715
CM0338-E : EXCISION OF ARTERIO VENOUS MALFORMATION - SMALL (Brain) < 6 CM 23472
CM0339-A : EXCISION OF ARTERIO VENOUS MALFORMATION - LARGE (Brain) > 6 CM 43697
CM0339-B : EXCISION OF ARTERIO VENOUS MALFORMATION - LARGE (Limbs) > 6 CM 14763
CM0339-C : EXCISION OF ARTERIO VENOUS MALFORMATION - LARGE (Others) > 6 CM 23620
CM0343-A : MEDIUM SIZE ARTERIAL ANEURYSMS (eg. Radial, cephalic, brachial, etc) - Repair 20668
CM0343-B : MEDIUM SIZE ARTERIAL ANEURYSMS (eg. Carotid, Jugular, Femoral, etc) - Repair 27458
CM0344-A : MEDIUM SIZE ARTERIAL ANEURYSMS WITH SYNTHETIC GRAFT (eg. Radial, cephalic, brachial, etc) 35430
CM0344-B : MEDIUM SIZE ARTERIAL ANEURYSMS WITH SYNTHETIC GRAFT(eg. Carotid, Jugular, Femoral, etc) 43402
CM0347 : AORTO - BILLIAC - BIFEMORAL BYPASS WITH VEIN 0
CM0347A-i : AORTO - ILLIAC BYPASS WITH VEIN 29525
CM0347A-ii : AORTO - FEMORAL BYPASS WITH VEIN 35430
CM0347B-i : AORTO - BILLIAC BYPASS WITH VEIN 41335
CM0347B-ii : AORTO - BIFEMORAL BYPASS WITH VEIN 46797
CM0347C : AORTO - BILLIAC - BIFEMORAL BYPASS WITH SYNTHETIC GRAFT 0
CM0347C-i : AORTO - ILLIAC BYPASS WITH SYNTHETIC GRAFT 41335
CM0347C-ii : AORTO - FEMORAL BYPASS WITH SYNTHETIC GRAFT 47240
CM0347D : AORTO - BILLIAC - BIFEMORAL BYPASS WITH SYNTHETIC GRAFT 0
CM0347D-i : AORTO - BILLIAC BYPASS WITH VEIN WITH SYNTHETIC GRAFT 48125
CM0347D-ii : AORTO - BIFEMORAL BYPASS WITH VEIN WITH SYNTHETIC GRAFT 54768
CM0367-A : VASCULAR INJURY IN UPPER LIMBS - AXILLARY REPAIR WITH VEIN GRAFT 20077
CM0367-B : VASCULAR INJURY IN UPPER LIMBS - BRACHIAL - REPAIR WITH VEIN GRAFT 14763
CM0367-C : VASCULAR INJURY IN UPPER LIMBS - RADIAL AND ULNAR - REPAIR WITH VEIN GRAFT 11810
CM0368A : MAJOR VASCULAR INJURY -REPAIR (Femoral) 24653
CM0368B : MAJOR VASCULAR INJURY -REPAIR (Tibial) 20668
CM0369A : MINOR VASCULAR INJURY REPAIR -LOWER LIMBS (Fibular, Popliteal) 10777
CM0369B : MINOR VASCULAR INJURY REPAIR -LOWER LIMBS (Foot) 7086
CM0369C : MINOR VASCULAR INJURY REPAIR -LOWER LIMBS (Digits) 4724
CM0373A : ABDOMINAL VASCULAR INJURIES - AORTA, ILLAC ARTERIES, IVC, ILIAC VEINS - Vein Graft 41335
CM0373B : ABDOMINAL VASCULAR INJURIES - AORTA, ILLAC ARTERIES, IVC, ILIAC VEINS - Synthetic Graft 53587
CM0375A : VARICOSE VEINS RFA FOR U/L 10334
CM0377C : THROMBOLYSIS FOR DEEP VEIN THROMBOSIS (Systemic) - STK 5905
CM0377D : THROMBOLYSIS FOR DEEP VEIN THROMBOSIS (Systemic) - RTPA 17715
CM0384A : PSEUDOANEURYSM LIGATION - Small vessels (eg. Radial, cephalic, brachial, etc) 8858
CM0384B : PSEUDOANEURYSM LIGATION - Medium vessels (eg. Carotid, Jugular, Femoral, etc) 17715
CM0384C : PSEUDOANEURYSM LIGATION - Large vessels (eg. Aorta, Iliac, IVC, etc) 20520
CM0384D : PSEUDOANEURYSM LIGATION -Post AV Fistula 8100
CM0395A : GRAFT THROMBECTOMY BYPASS 12548
CM0395B : AV ACCESS SURGERY (not for Dialysis) 8858
CM0674-II-a : TIBIAL ANGIOPLASTY IN CRITICAL LIMB ISCHEMIA - Balloon plasty 34397
CM0674-II-b : TIBIAL ANGIOPLASTY IN CRITICAL LIMB ISCHEMIA - Stenting 55064
CM0692-II-A : ACUTE STROKE THROMBOLYSIS (R TPA ) (Cathter Directed) 44435
CM0692-II-B : ACUTE STROKE THROMBOLYSIS (R TPA ) (IV - Thrombolysis) 0
CM0814-I-a : VASCULAR MALFORMATIONS- Sclerotherapy 7677
CM0814-I-b : VASCULAR MALFORMATIONS- Sclerotherapy and Excision 15501
CM1038 : Drainage of Subdiaphramatic Abscess 5905
CM1046 : Excision Benign Tumor -Small intestine 8857
CM1067 : IlieoSigmoidostomy 10038
CM1076 : Repair of Common Bile Duct 8857
CM1083 : Pharyngectomy& Reconstruction - Total 11810
CM1084 : Tracheoplasty (Throat) 8857
CM1088 : Estlander Operation (lip) 4133
CM1093 : Operation for carcinoma lip- cheek advancement 7086
CM1096 : Resection Enucleation of Adenoma (lung) 5905
CM1099 : Thoracoplasty 11810
CM1100 : Thoracoscopic Segmental Resection 14762
CM1101 : Thoracoscopic Sympathectomy 8857
CM1191 : Abdominal Perineal neo construction Cx + Uteria + Vagina 11810
CM1198 : Brust abdomen repair 8267
CM1212 : Intrauterine transfusions 5905
CM1220 : Fixator with Joint Arthrolysis 11810
CM1223 : Pelvic Osteotomy with fixation with plaster 17715
CM1313 : Operations for Congenital Arteriovenous Fistula 13500
CM1316 : Fecal Fistula Closure 14762
CM1317 : GI Tumor Excision 17715
CM1318 : Hirschsprungs Disease - Retal Biopsy-Punch 5905
CM1319 : Hirschsprungs Disease - Retal Biopsy -Open 5905
CM1320 : Intussusception - Non -Operative Reduction in infants 11810
CM1321 : Congenital Lobar Emphysema 14762
CM1322 : Exomphalos/gastroschisis 14762
CM1323 : Microvascular reconstruction 26572
CM1325 : Axillary dissection 8857
CM1326 : Enucleation of pancreatic neoplasm 14762
CM1419 A : Acute lymphoblastic leukemia: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN 20000
CM1420 A : Acute myeloid leukemia: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage 30000
CM1421 A : Hodgkin Lymphoma (Favorable group): Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN 15000
CM1422 A : Hodgkin Lymphoma (unfavorable group): Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN 25000
CM1423 A : Non-Hodgkin Lymphoma: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN 50000
CM1429 A : Chronic Myeloid Leukemia : supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN 20000
CM1430 A : Terminally Ill - Pain management (Opioid therapy / Neural Blocks / epidural or Intrathecal infusions / Antero-lateral spinal cordotomy (tractotomy) by RFA) / TPN - Per month 3000
CM0692-II-B-i : ACUTE STROKE THROMBOLYSIS (R TPA ) (IV - Thrombolysis - 50 mg) 30300
CM0692-II-B-ii : ACUTE STROKE THROMBOLYSIS (R TPA ) (IV - Thrombolysis - 70mg) 48300